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Introduction 
This thesis describes non-Hodgkin's lymphoma (NHL) care in the Netherlands, the 
identification of barriers and facilitators for optimal NHL care and the effect of a tailored 
strategy on the care delivered to NHL patients. All research is done in context of the PEARL 
study: imfrovement of patiEnts' hospitAl caf!e for non-hodgkin's bymphoma. 
This introductory chapter starts with a description of non-Hodgkin's lymphomas, including 
information about incidence of NHL, subtypes, diagnosis, treatment, prognosis and 
survival. Next, information is provided about quality of care, describing guidelines, quality 
indicators and steps to improve NHL care. Finally, the main objectives and outline of this 
thesis are explained. 
Non-Hodgkin's lymphomas 
Incidence and subtypes 
Malignant lymphomas represent a heterogeneous group of malignant lymphocyte 
proliferations, which can be classified as either Hodgkin's lymphomas (HL) or non-
Hodgkin's lymphomas (NHL). NHLs are the sixth most common malignant neoplasm in the 
United States1 and the most common hematologic neoplasm in adults worldwide. 2 The 
estimated number of new cases was almost 71,000 for the United States in 20141 and over 
93,000 for Europe in 2012.3 NHLs constitute of more than 40 disease entities. The most 
prevalent are diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal 
zone cell lymphoma, small lymphocytic lymphoma and mantle cell lymphoma, together 
accounting for 80% of all NHLs (see Figure 1).4 NHLs occur more often in males and the 
median age of onset is approximately 60 years. 
Figure 1. Subtypes of non-Hodgkin's lymphoma 
• Diffuse IJrge B-ccl lymphomJ 
• Foll1cu lar lymphomJ 
• Marg111JI Lone lymphom<:J 
• Small lymphocytic B-celllymphoma 
• Pt•nferJI T-ee! lymphoma 
• Mantle ccl lymphomJ 
Others 
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NHLs can roughly be divided into two large groups; indolent and aggressive NHLs. Indolent 
lymphomas, such ase FL, are in general defined as slowly progressive, which is why they 
often present at a late stage of disease. Aggressive lymphomas, such as DLBCL, present 
often with rapidly growing lymph nodes and B-symptoms. These symptoms include 
unexplained weight loss, fever, night sweats, and fatigue. 
Diagnosis 
The recommended method to diagnose NHL is a histological lymph node biopsy. Histology 
and immunophenotype of the lymph node are reviewed and classified using the World 
Health Organization (WHO) classification system. 5 Additionally, blood examination, CT-or 
PET-scans (computed/positron emission tomography scans) and a bone marrow aspirate 
and biopsy are performed to determine the stage of the disease. The Ann Arbor criteria 
are used for classification of the disease into four stages (see Figure 2): 
I. The disease is limited to one region (lymph node or lymphatic organ) 
II. The disease has spread to more than one region (lymph nodes and/or lymphatic 
organs), but is limited to one side of the diaphragm. 
Ill. The disease has spread to lymph nodes and/or lymphatic organs on both sides of 
the diaphragm. 
IV. The disease has spread through the whole body, also to extra-lymphatic organs 
(e.g. liver, bone marrow, lungs). 
Figure Z. Ann Arbor staging (stage I to IV) 
In addition to the four Ann Arbor stages, the presence of B-symptoms and extranodal 
involvement can be specified : 
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"A" is added to the stage if B-symptoms are absence, "B" if they are present. 
"E" is added to the stage if extra lymphatic tissue is involved on one side of the 
diaphragm. 
"S' is added to the stage if the spleen is involved. 
Determining the stage of the disease is essential for selecting the most optimal treatment. 
In addition, the patients' prognostic profile is important. The international prognostic 
index {IPI score)6 is developed to categorize aggressive NHLs based on clinical features, 
including age, stage, LDH level, number of extranodal disease sites and overall 
performance status. 
Treatment 
The different types of NHL all have their own optimal treatment method. Which treatment 
is chosen is dependent of several other factors, such as stage and primary location of the 
tumor, prognostic profile of the patients and the presence of other diseases. The goal of 
treatment can be curative or palliative, dependent on the factors described above. The 
most common regimes for initial NHL treatment include radiation-, chemo- and 
immunotherapy. Since DLBCL and FLare the most common subtypes of NHL, the focus will 
be on these lymphomas. 
For asymptomatic and stable {indolent) Fls treatment is not directly induced. Watch-and-
wait {close observation of the tumor) is a common strategy of choice for these 
lymphomas. If treatment is indicated, radiation- or chemotherapy is mostly performed 
and remission can often be achieved. However, relapses are very common in FL patients. 
For DLBCL with a limited stage, chemotherapy combined with radiation therapy is 
commonly used. The most common treatment for advanced stage DLBCL is systemic R-
CHOP {chemotherapy {CHOP) combined with immunotherapy {Rituximab)). Progression-
free survival and even potentially cure can be achieved in DLBCL patients. In patients with 
relapsed DLBCL, stem ·t:ell t ransplantation {SCT), combined with high-dose chemotherapy, 
can be considered . 
Prognosis and survival 
The prognosis for patients with NHL is largely dependent on subtype and stage of their 
NHL. The stage of the disease is combined in the IPI score together with age, LDH, 
performance status and the presence of extranodal disease sites. Modified IPI scores have 
been developed for several subtypes of NHL {e.g. FLIPI {follicular) and MIPI {mantle cell)). 
The overall relative 5-year survival rate for patients with NHL is estimated on 69%.7 
However, overall relative 5-year survival for DLBCL patients is much lower than for FL 
patient {55% and 87%, respectively) .8 On the other hand, in FL patients relapses are very 
common whereas in approximately SO% of the DLBCL patients cure can be achieved. 
Quality of care 
Guidelines 
Evidence-based guidelines on diagnosis, treatment, and follow-up of patients with NHL 
have been developed during the past years and provide recommendations for optimal 
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NHL care.9. 15 These national and international guidelines support professionals as well as 
patients in their decisions about diagnosis, therapy, and follow-up. In general, publication 
and distribution of these guidelines is not sufficient to maximize their effect on the quality 
of care, 16 hence active implementation is needed. 
Quality indicators 
Guideline adherence can be assessed by means of quality indicators: "measurable 
elements of practice performance for which there is evidence or consensus that they can 
be used to assess the quality of care" .17 Different aspects of care, such as diagnosis, 
staging, treatment, follow-up and organization of care, should be represented in these 
quality indicators. In this way, improvement needs in the total care process can be 
identified. 
Quality indicators typically consist of a numerator and denominator. They represent the 
patients who actually receive the care as recommended divided by the patients to whom 
the care should be applied to. An example is shown in Table 1. 
Table 1. Example of a quality indicator 
Numerator 
Denominator 
lndisator score 
Number of NHL patients who are staged following the Ann Arbor 240 
classification 
Number of NHL patients eligible for Ann Arbor classification 400 
60% 
Quality of NHL care 
It is important to gain insight into the care that is actually provided to NHL patients and 
what the barriers to and facilitators for optimal NHL care are. The definition of quality of 
care used in this thesis is the extent of agreement between the desired, evidence-based 
care and the care as delivered in daily practice . If necessary, tailored interventions can be 
developed to improve the quality of care. Most theories on implementation of evidence in 
healthcare emphasize assessment of influencing factors first, in order to acquire a tailored 
improvement strategy.18' 19 The model of Grol et al./9 describes six steps to develop, test, 
and evaluate an innovation {see Figure 3). These steps will be described for NHL care 
below. 
Step 1. Description of NHL guideline adherence 
With respect to adherence to NHL guideline recommendations, Wennekes et a/.20 showed 
that NHL care was not yet optimal in 2007. Guideline adherence was assessed by means of 
quality indicators. These quality indicators were selected by a multidisciplinary expert 
panel from available evidence-based NHL guidelines. We believe that better guideline 
adherence can lead to higher quality of care. 
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I Guidelines, new evidence, reviews I I Perceived problems, best practices I 
~ .! .n 
Step 1 
Describe innovation that needs to be implemented 
• Step2 
Analyze current healthcare situation 
• Step3 
Identify influencing factors in current healthcare 
• Step 4 
Develop tailored improvement strategy 
• StepS 
Test tailored improvement strategy 
t 
Step 6 
Evaluate improvement strategy and adapt 
strategy if necessary 
I 
Figure 3. Implementation model, Grol et aL 
Step 2. Assessing current NHl. care 
Before starting implementation, it is necessary to gain insight into current NHL care. 
Several studies already demonstrated suboptimal care for patients with NHL.20-22 They 
described large gaps between daily practice and NHL care as recommended in the 
guideline. This lack of guideline adherence concerned, among others, diagnostics, therapy, 
and prognostic parameters. For example, in 22 Dutch hospitals, adherence was lowest for 
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IPI score assessment, documentation of indicator lesions found on CT-scans during 
diagnostics and after therapy, adequate pathology reporting, and discussing patients 
during multidisciplinary team consultations (MTCs).20 The clinical relevance of guideline 
adherence is shown in several cancer studies.23-27 These studies showed that better 
adherence to guidelines is associated with better overall survival or progression-free 
survival. 
Step 3. Identification of barriers and facilitators 
Every step in a process is influenced by surrounding factors . It is important to explore 
what experienced barriers and facilitators concerning delivered NHL care exist among 
patients and professionals involved in NHL care. These factors can be used in the 
development of a tailored implementation strategy. 
Several models have shown to be effective in structuring the experienced barriers and 
facilitators .28-30 These models include features of the guidelines itself; features of 
professionals and patients, features of the guideline, and of the social and organizational 
context. 
Step 4-6. Improving quality of NHL care 
In step 2 and 3, it becomes clear to what extend professionals adhere to the NHL guideline 
and what factors determine the performances of the different professionals involved in 
NHL care. Insight into these barriers and facilitators is of great importance to know what 
kind of activities should be developed to prevent inadequate diagnostics/staging, 
treatment and follow-up and improve survival by implementing the evidence-based 
multidisciplinary NHL guideline. 
Many potentially effective strategies for implementing clinical guidelines are available, but 
none are superior in all aspects.31 Therefore, improvement strategies are developed based 
on the results from step 2 and 3 concerning current NHL care. 
Thesis outline 
"2015 will be the year of transparency in health care", this is what the Dutch Minister of 
Health Edith Schippers stated after Prinsjesdag 2014. In this thesis, where a systematic 
approach is used to improve the quality of hospital care for patients diagnosed with a non-
Hodgkin's lymphoma (NHL), transparency plays an important role. In summary, this thesis 
contains the results of the PEARL study, which includes insight into current NHL care and 
barriers and facilitators of optimal NHL care. Next to this, it describes the development 
and evaluation of improvement strategies directed to a more optimal NHL care. The 
dissemination of these results contributes to a more transparent overview of NHL care in 
the Netherlands. 
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Main objectives for this thesis, assessed in the PEARL study, are: 
1. To gain insight into the current NHL care based on previously developed quality 
indicators. 
2. To explore barriers and facilitators according to patients and professionals, that 
influence optimal NHL care as described in evidence based NHL guidelines. 
3. To develop and test the improvement strategies, tailored to the barriers and 
facilitators found, and evaluate these on feasibility, effectiveness and costs. 
Current NHL care 
In chapter 2, we gained insight into the current NHL care and compared these results to 
the care measurements of Wennekes et a/. 2° Current care is assessed by retrospective 
searches in medical records by Netherlands Comprehensive Cancer Organisation (IKNL). In 
19 hospitals, approximately 22 newly diagnosed NHL patients are selected for data 
collection regarding adherence to the quality indicators. 
Chapter 3 describes the determinants of variation in guideline adherence, measured in 19 
Dutch hospitals. We asked the question to which extent differences in patient, tumor, 
professional and hospital characteristics are associated with hospital variation in guideline 
adherence and indirect with the quality NHL care. 
Problem analysis 
In chapter 4 barriers and facilitators for delivering optimal care are investigated at 
different levels. A framework including features of guidelines, professionals and patients, 
and features of the social context (e.g., colleagues of the involved professionals and 
geographic distance to hospital), and the organizational context, is used. 28 30 To detect 
possible influencing factors regarding optimal NHL care, a literature study is performed, 
followed by a qualitative study consisting of interviews among professionals involved in 
NHL care and with NHL patients. Finally, a survey is performed to quantify the features 
identified in the interviews. 
Cluster-randomized controlled trial 
Based on the results presented in chapter 2, 3 and 4, tailored interventions are developed 
in order to increase guideline adherence. One of these interventions is directed to the 
patient: an educational e-tool to help patients with non-Hodgkin's lymphoma manage 
their personal care pathway. The development and evaluation of this tool is described in a 
feasibility study in chapter 5. 
In chapter 6, we examined the effect of the tailored interventions on guideline adherence 
and quality of NHL care. The interventions are tested in a cluster-randomized controlled 
trial (c-RCT) in 19 Dutch hospitals. The hospitals are the level of randomization which 
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includes two arms: centers rece1vmg a standard strategy of audit and feedback, and 
centers receiving the standard strategy followed by an strategy tailored to the barriers and 
facilitators found. Next to the effect of the interventions, we evaluated the processes of 
this c-RCT. 
Finally, the main findings of this thesis will be discussed and implications for future 
research and clinical practice will be outlined in Chapter 7. 
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Chapter 2 
Trends in quaUty of non-Hodgkinos lymphomY~a 
teare: is it getfth'og ~etter? 
J.J.C. Stienen, P.B. Ottevanger, L. Wennekes, S.A.M. van de Schans, 
H.M . Dekker, R.W.M. van der Maazen, J.H.J.M. van Krieken, 
N.M.A. Blijlevens, R.P.M.G. Hermens. On behalf of the PEARL study group 
Annals of Hematology 2015; 94(7}:1195-203. 
Abstract 
Background: This study outlines trends in quality of delivered non-Hodgkin's lymphoma 
(NHL) care in the Netherlands between 2007 and 2011 and to what extend this was 
influenced by the national Visible Care program, which aimed at increasing transparency 
by providing insight into the quality of healthcare. 
Methods: We analyzed data collected from medical records in two observational studies, 
combined into 20 validated quality indicators (Qis) of which 6 were included in the 
national program. A random sample of 771 patients, diagnosed with NHL in 26 Dutch 
hospitals, was examined. Multilevel regression analyses were used to assess differences in 
quality of NHL care and to provide insight into the effect of the national program. 
Results: We reported improved adherence to only 3 out of 6 Qls involved in the national 
program and none of the other 14 validated Qls. Improvement was shown for 
performance of all recommended staging techniques (from 26 to 43%), assessment of 
International Prognostic Index (from 21 to 43%), and multidisciplinary discussion of 
patients (from 23 to 41%). 
Conclusion: We found limited improvement in quality of NHL care between 2007 and 
2011; improvement potential (<80% adherence) was still present for 13 Qls. The national 
program seems to have a small positive effect, but has not influenced all 20 indicators 
which represent the most important, measurable parts in quality of NHL care. These 
results illustrate the need for tailored implementation and quality improvement 
initiatives. 
Keywords: non-Hodgkin's lymphoma, quality of health care, guidelines, oncology, 
hematology, transparency, trends. 
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Introduction 
Non-Hodgkin's lymphoma (NHL) affects over 300,000 people worldwide each year.1 NHL is 
listed in the top 10 of most common cancers, with an estimated number of 69,000 new 
cases in the USA in 20132 and responsible for 3% of all cancer deaths in the USA.3 In the 
Netherlands, the incidence of NHL is as high as 4000 newly diagnosed patients per year. 
With an expanding and ageing population, these figures are expected to increase. Well 
organized and well carried out diagnostics and treatments are essential to help patients in 
the best possible way. Treatment of NHL is highly dependent on the subtype, stage and 
aggressiveness of the tumor. For the most common subtypes, diffuse large B-cell 
lymphoma (DLBCL) and follicular lymphoma (FL), chemotherapy combined with 
immunotherapy (i.e. monoclonal antibody rituximab) has improved patient outcomes 
remarkably.4' 5 Despite these improvements, the five-year relative survival rate for these 
patients is only 50-75%. 6 
To deliver high quality care to patients diagnosed with NHL, multidisciplinary evidence-
based guidelines are developed to help professionals in their choices about diagnostics 
and therapy.7-10 Quality of care can be measured using quality indicators, which are 
"measurable elements of practice performance for which there is evidence or consensus 
that they can be used to assess the quality of care". 11 From previous research, it is known 
that discrepancies exist between NHL care delivered in daily practice and the (quality of) 
care recommended in guidelines.12-14 Gaining insight into quality of delivered care is an 
upcoming phenomenon in healthcare; hospitals and other healthcare facilities are 
exposed to (external) auditing and benchmarking, often using quality indicators. 15-17 
Especially healthcare insurances, policy makers (government) and patient organizations 
are important actors. The USA and UK have both introduced public reporting as a tool to 
improve the quality of care. National institutes as the National Quality Forum and the Dr 
Foster Health focus on delivering healthcare information to the public, for example, by 
providing a hospital guide to the public including information on waiting times, length of 
stay and mortality rates for several surgical procedures.18 
In the Netherlands, a national initiative of transparency in hospital care started in 2008, 
raised and funded by the government (Visible Care program) . The aim of this initiative was 
to increase transparency by providing insight into the quality of healthcare and enabling 
healthcare providers to report on actually applied diagnostics and delivered therapy and 
follow-up. Quality indicators were developed and measured for over 100 disease entities, 
including malignant lymphoma. 
This study outlines the differences in quality of delivered NHL care in the Netherlands 
between 2007 and 2011 and to what extend this was influenced by the Visible Care 
program. 
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Methods 
Study design and population 
Data from two observational studies were used to investigate the natural course of 
delivered quality of NHL care and the influence of the Visible Care program. First, 
Wennekes et a/. developed quality indicators and measured their performance in 22 
Dutch hospitals by including 348 patients diagnosed with NHL between 2006 and 2007.14 
The quality indicators were derived from evidence-based guidelines and developed by an 
expert panel using the systematic RAND-modified Delphi method.19 The main goal was to 
provide insight into guideline adherence for the most important processes and structures 
of NHL care. Second, baseline measurements of the PEARL study/0 a cluster-randomized 
controlled trial (c-RCT), also assessed indicator performance in 19 Dutch hospitals and 
randomly included 423 patients diagnosed with NHL between 2010 and 2011. Patients 
eligible for both studies were defined as patients diagnosed with a mature B-, T-or NK-cell 
neoplasm and older than 18 years at diagnosis. Patients with multiple myeloma or 
cutaneous lymphoma or presenting with chronic leukemia were excluded. 
Data collection 
For the PEARL study, trained registration employees collected data from medical records 
for the quality indicators. A digital registration form was accomplished in collaboration 
with the Netherlands Comprehensive Cancer Organisation (IKNL). Selection of patients 
took place using the cancer registry, which is part of IKNL. IKNL used the cancer registry to 
make a list of potentially eligible patients in the participating hospitals. Patients were 
randomly listed, after which the first 30 patients were selected and data was collected for 
20-25 patients per hospital. This cancer registry is based on the pathology coding system 
of the World Health Organization (WHO) and patients with mature B-, T- and NK-cell 
neoplasms were selected for inclusion. 
Patient characteristics (gender, age, hospital region, patient preferences, comorbidities) 
and tumor-specific information (morphology, stage, extra nodal disease, previous 
malignancies, and lactate dehydrogenase (LD) values) were collected. Furthermore, dates 
and data about diagnosis (pathology, imaging techniques, blood counts), treatment of NHL 
(type of therapy, response) and multidisciplinary team consultation (MTC) were assessed. 
This information was used to determine the indicator performance scores: the percentage 
of patients who received care as recommended in the guidelines. If the indicator scores 
where <90%, improvement potential was considered to be present.21' 22 Quality indicators 
for the domain diagnosis and staging, treatment and follow-up and organization and 
coordination were included in the indicator set (see Table 2). The data collection method 
for the PEARL study (2011 dataset) is in line with the method described by Wennekes et 
a/.14 (2007 dataset). 
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The national transparency initiative 
In the context of the Visible Care program, a national transparency initiative to provide 
insight into the quality of hospital care, quality indicators for malignant lymphoma were 
developed in 2010.23 The purpose was to develop quality indicators which represent the 
most important parts of NHL care and could be easily measured by the hospitals 
themselves. All disciplines involved in NHL care were asked to provide delegates to 
participate in the development of the indicator set. The final indicator set included 
indicators about Ann Arbor staging and International Prognostic Index (IPI) scoring, 
performing all required staging techniques such as bone marrow biopsy and CT scans, 
assessing therapy response, arranging MTCs and providing all diagnostic results within 4 
weeks. The indicator set as developed by Wennekes et a/.14 was used as one of the 
references during the development of this Visible Care indicator set. The implementation 
of the quality indicators was mandatory, since the program was part of new national 
policy. Each year, hospitals were asked to provide the malignant lymphoma indicator 
results about the previous year. Yearly feedback was given to the hospitals by providing 
anonymous results of all hospitals outlined by the hospitals' own results. All anonymous 
results were made publically available through the website www.zichtbarezorg.nl, with 
the intention that these feedback methods would lead to higher quality of overall NHL 
care. It was the hospitals' own responsibility In which way the yearly audit was performed 
and the feedback was processed. 
Wennekes et a/.14 collected data of hospital care before the introduction of the Visible 
Care program and we repeated this assessment after the first two years of the program. In 
this way, it was possible to provide insight into the proposed positive effect of the national 
transparency initiative on quality of delivered medical care. 
Statistical analyses 
Descriptive statistics were performed to get insight into the patient characteristics of the 
two study populations. Quality indicator scores were assessed for both datasets (2007 and 
2011) and expressed in percentages to describe current practice. Univariate analyses (.i 
tests) were used to test whether differences in patient characteristics and quality indicator 
scores were present between 2007 and 2011. 
The relation between patient and tumor characteristics (e.g. gender, previous 
malignancies and LD-value) and differences in quality indicator scores between 2007 and 
2011 was studied using univariate logistic regression analyses (P<O.OS). Factors often 
mentioned as reasons for non-adherence were also included: Charlson index, 
performance status, Ann Arbor stage, patient preferences and type of lymphoma. Clinical 
relevant determinants that influenced quality indicator scores in a univariate setting were 
tested as a group using multivariate, multilevel logistic regression analyses (odds ratios). In 
case of intercorrelations between characteristics (>0.4), only one of the two was included 
in multivariate analyses. A multilevel model was used to account for the nested structure 
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of the data, with individual patients nested within hospitals. The intraclass correlation 
coefficient (ICC) was calculated for each quality indicator to get insight into the cluster 
effect of the hospitals. ICC values between 0 and 0.40 are found in other secondary care 
research. 24 
Reliability of the data collection was assessed with a duplicate registration of 30 records 
by two registration employees in three hospitals. The reliability of the indicator scores was 
calculated with a kappa value, a statistical measure for inter-observer agreement 
corrected for chance.25 A missing values analysis (t-test) was performed to explore if more 
than 5% of the data was missing and if missing values were missing completely at random 
(Little's test). 
All statistical analyses, except multilevel analyses, were performed using IBM SPSS 
Statistics for Windows, version 20.0 (1MB Corp, Armonk, NY, USA). Multilevel analyses 
were performed using SAS software system for Windows, version 9.2 (SAS Institute Inc, 
Cary, NC, USA). 
Result s 
Study population 
Table 1 shows the characteristics of 348 patients of the 2007 dataset and 423 patients of 
the 2011 dataset. There were no significant differences in gender, age, prevalence of NHL 
subtypes, aggressiveness of the tumor, Charlson index, patient preferences and hospital 
region between the two study populations. In 2011, more patients were included with 
previous malignancies, Ann Arbor stage III-IV and normal LD values, compared to 2007. 
Table 1. Patient characteristics in 2007 and 2011. 
Characteristics 2007 (N::348) 2011 (N::423) 
% 95%0 % 95%0 
Gender 
Male 56 51-61 
I 
57 52-62 
Female 44 39-49 43 38-48 
Missing N=13 
Mean age (yearsJ 66+/-14 66 +/-13 
Charlson index# 
High risk 47 42-52 46 41-51 
Low risk 53 48-58 ! 54 49-59 
Missing N=1 
NHltype 
OLBCL 42 37-47 46 41-51 
Follicwlar lymphoma 23 19-27 18 14-22 
Mantle-cell lymphoma 9 6-12 5 3-7 
Marginal zone B-celllymphoma 8 5-11 11 8-14 
Other classification 18 14-22 .20 16-24 
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Table 1. continued. 
t.haracterislliGS 
Tumor type 
Aggressive 
Indolent 
Ann Arbor stage* 
lorll 
til or IV 
Un'f<,nown 
Not ajaplicable 
Extra nodal disease 
Yes 
No 
Missing 
Previous malignancies* 
No (NHL is first malignancy) 
Yes 
Missing 
Normal LD value* 
Yes 
No 
Missing 
Patient's preferences 
Objections 
No objections 
Missing 
Hospital region 
North 
East 
South 
I 
' 
I 
! 
l 
¥ 
i 
I 
' 
2007(N=343) 2011 (N, 4:UJ 
% 95% Cl % 95S'Ci 
61 56-66 60 55-65 
39 34-44 40 35-45 
44 38-50 32 27-37 
56 50-62 68 63-73 
N=2 N=14 
N=39 N=l4 
58 52-64 61 56-66 
42 36-48 39 34-44 
N=42 N=1 
91 88-94 83 79-87 
9 6-12 17 13-21 
N=1 
20 16-24 56 51-61 
80 76-84 44 39-49 
N=32 
6 4-8 6 4-8 
94 92-96 94 92-96 
i\1=1 N""l 
53 48-58 45 40-50 
25 20-30 27 23-31 
22 18-26 28 24-32 
Abbreviations: DLBCL, diffuse large B-cell lymphoma; LD, lactatedehydrogenase 
#weighted co-morbidity index combined with age 
* patient characteristic significantly different (P<0.05) between 2007 and 2011 
Quality indicator scores 
Table 2 describes the 20 quality indicator scores, corrected for case-mix (i.e. gender, Ann 
Arbor stage, aggressiveness, previous malignancies, LD value, Charlson index and hospital 
region) and the nested structure of the data (multilevel analysis). The quality indicators 
were divided into three domains: diagnosis and staging, treatment and follow-up, and 
organization and coordination of care. 
Diagnosis and staging. In this domain, improvement is seen for two of the seven quality 
indicators. Indicator scores for execution of all recommended staging techniques (Q14) 
improved from 26 to 43% (OR=l.902 (1.268-2.852)) and assessment of the International 
Prognostic Index (QI5) improved from 21 to 43% (OR=2.883 (1.675-4.961)). Two indicators 
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scored significantly lower in 2011 compared to 2007: diagnosis based on morphology and 
immune phenotype decreased from 99 to 96% {QI3: OR=0.190 {0.049-0.744)) and 
examination of blood counts decreased from 90 to 82% {QI7: OR=0.576 {0.340-0.976)). 
Treatment and follow-up. No significant differences are seen for the six quality indicators 
in this domain. 
Organization and coordination of care. In this domain, only one of the seven quality 
indicator scores significantly improved {QI17): more patients {41%) were discussed in 
MTCs in 2011 compared to 2007 {23%) {OR=3.360 {2.007-5.624)). 
Influence of the national transparency initiative 
The six quality indicators used as initial concept for the Visible Care quality indicators are 
underlined in Table 2. Significant increased quality indicator scores were found for three 
of the six indicators incorporated in the transparency initiative: the use of all staging 
techniques increased from 26 to 43%, the assessment of the IPI from 21 to 43% and 
patients discussed in MTCs from 23 to 41% {QI4, Ql5 and Ql17, respectively). 
The other three quality indicators included in the transparency initiative did not change 
significantly: 80% of the patients was staged according to the Ann Arbor classification 
{QI2), 60% had a correct evaluation after chemotherapy {QI11) and the maximum 
diagnostic period of 4 weeks was realized in about half of the patients {QI19). Two of the 
14 quality indicators that were not included in the Visible Care program, showed 
significantly decreased scores {QI3 and Ql7). 
Statistics 
The mean ICC was 0.14 {range 0.005-0.33), which was calculated for all quality indicators 
to account for clustering. The reproducibility of the data collected for the indicator scores 
in 2011 was good: the average kappa value was 0.8 {range 0.4-1.0; 87% ;::0.6). This 
indicates an overall good agreement between the registration employees. For the 2007 
dataset, reproducibility was also good.14 Missing value analysis showed overall less than 
5% missing data in the overall dataset {2007 and 2011). The factor 'performance status' 
was excluded from analysis because it was missing for most of the cases {80%). Quality 
indicator 13 had 10% missing values, however these were missing completely at random 
{MCAR, P=0.771). 
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Table 2. Indicator scores for quality of delivered NHL care in 2007 and 2011. 
Quality Indicator %2007 N Missing Excluded %2011 N Missing Exclude.d OR Year (95% Cl) y 
DI~M.; is and stO<jlng 
Ql1 Diagnosis based on histological examination and on an 82 212 93 43 79 369 21 33 0.840 (0.494-1.428) 
excision or wide incision biopsy 
A. Histological examination 97 305 0 43 97 389 1 33 
B. Excision or wide incision biopsy# 82 212 93 43 80 369 21 33 
QJ.1 Patients stagced according to the Ann Aroor classification 80 305 0 43 81 390 0 33 1.102 (.0. 705·1.724) 
Ql 3 Diagnosis for NHL based on morphology and immune 99 283 23 43 96 376 14 33 I o.190 (0.049-0.744) 
phenotype 
A. Morphology 100 287 18 43 100 378 12 33 
B. Immune phenotype 99 291 16 43 97 378 12 33 
C. No molecular clonality (or only supplementary) 100 284 21 43 99 376 14 33 
QL1 Staging technJques should iflclude CT scans of rteck, 
tnorax, and abdomen, bone marrow aspirate, and bone 2S 347 1 0 43 421 2 0 i 1.902 (1.268-2.852) 
marrow blo.psy 
A. CT scan of the neck 41 34g 0 0 46 421 2 0 
B. CT scan of the t horax 84 348 0 0 75 421 2 0 
C. CT scan of the abdomen 84 348 0 0 77 421 2 0 
D. Bon~ marrow aspirate 68 348 0 0 66 421 2 0 
E. Bone marrow biopsy ('crista) 85 347 1 0 78 421 2 0 
9.!.2 Assessment of International Prognostic Index (I PI) for 21 213 0 135 43 250 4 169 ! 2.883 (1.675-4.961) patients with aggressive NHL l 
Ql 6 Assessment of lactate dehydrogenase vaJue 93 347 1 0 92 423 0 0 I 0.99$ (0,534·1.855) 
Ql 7 Examination of blood counts 90 348 0 0 82 422 1 0 i 0.576 (0.340-0.976) 
A. Leukocyte count 99 348 0 0 98 422 1 0 
B. Leukocyte differentiation 91 348 0 0 83 422 1 0 
C. Thrombocyte count 99 348 0 0 97 422 1 0 
D. Haemoglobin level 99 348 0 0 98 423 0 0 
N 
-...J 
N 
00 
Table 2. Continued. 
Quality Indicator l % 2007 N Missing Excluded ,. % 2011 N Missing Excluded t OR Year (95% Cl) y 
Trtcttment ond {o!iow·<-IP i ------·----------- --------···--·----~ 
Ql 8 Reporting of response to therapy using complete 
remission, partial remission, stable disease, progression, 
recurrence 
Ql 9 Alii targ·et lesions document~d in radiology report before 
therapy 
A. location of lesions reported 
B. Size of lesions reported 
C. Siz·e of lesions reported in mm 
Ql10 All target lesions documented in radiology report after 
therapy 
A. location of lesions reported 
B. Size of lesions reported 
C. Size of lesions reported in mm 
0:111 Evaluatiorcl after chemotherapy with CT scans (or PET}, 
and f-or stage IV patients a•fso with a bone marrow aspirate and 
biopsy 
A. CT scan before therapy 
B. CT/Pet scan after thera•py 
C. Bone marrow asplrate eva•luatlon * 
D. Bone marrow biopsy eva+uation * 
Ql 12 Patients with DlBCl received chemotherapy with RCHOP 
Ql13 Dose of RCHOP was not reduced or reason for reduction 
was reported 
65 
64 
99 
74 
64 
67 
98 
68 
68 
61 
94 
77 
46 
37 
77 
81 
231 
227 
228 
227 
227 
82 
84 
82 
83 
176 
2-03 
185 
68 
68 
144 
$0 
25 
3 
2 
3 
3 
3 
1 
3 
2 
12 
0 
13 
2 
2 
1 
31 
92 
113 
118 
118 
118 
263 
263 
263 
263 
160 
145 
150 
278 
278 
203 
237 
70 
67 
100 
77 
67 
58 
98 
70 
58 
62 
97 
89 
39 
45 
78 
82 
318 
344 
344 
344 
344 
114 
116 
115 
114 
246 
269 
250 
122 
122 
194 
111 
1 
3 
3 
3 
3 
3 
1 
2 
3 
5 
2 
4 
0 
0 
0 
42 
104 
76 
76 
76 
76 
306 
306 
306 
306 
172 
152 
169 
301 
301 
229 
270 
1.318 (0.840-2.068) 
0.917 (0.587·1.432) 
0.589 (0.275-1.264) 
1.583 (0.939·2.668) 
1.223 (0.663-2.258) 
0.998 (0.378-2.631) 
Table 2. Continued. 
Quality Indicator %2007 
Or~anizat!on and coordil!.atia" 
Ql14 Sending and receiving of unfixed biopsy materia l 
Ql15 Integrated reporting of pathology techniques 
Ql 16 Pathology report should be complete 
A. Origin of tissue 
B. Tissue characteristics 
C. Biopsy method 
D. Receipt of material 
E. Frozen tissue 
.Q.L1Z Patients &iscussed in multidisciplinary tearn 
COI}SUitaUons 
Ql 18 Results of pathology known before the start of 
! treatment (incl. bone marrow) 
Q;!_J! Diagnostic period of 4 weeks after the f4rst visit to the 
hospital 
Ql 20 Start of therapy within 2 weeks after diagnostic period 
y Reference year= 2007, Odds Ratios corrected for case-mix and ICC 
#Excluding fine needle aspiration (FNA) 
* Only applicable to stage IV patients 
41 
88 
12 
91 
56 
77 
41 
27 
23 
73 
56 
55 
N Missing 
285 20 
284 21 
279 26 
285 20 
286 19 
305 0 
284 20 
284 21 
346 2 
256 0 
343 5 
234 22 
The underlined quality indicator numbers (QI) are included in the Visible Care program. 
N 
l.D 
Excluded %2011 N Missing Excluded , OR Vear (95% Cl) , 
j 
43 I 41 321 69 33 ! 0.657 (0.419-1.032) ! 
43 I 89 365 25 33 1.389 {'0.752·2.564) 
43 14 378 12 33 1.379 (0.792-2.403) 
43 98 378 12 33 
43 52 378 12 33 
43 91 378 12 33 
43 34 378 12 33 
43 21 378 12 33 
0 41 422 1 0 3.360 (2.007-5.624) 
92 83 317 2 104 1.384 (0.866-2.210) 
0 49 420 3 0 0.857 ~0.!>99-1.227) 
92 54 313 6 104 1.263 (0.822-1 .941) 
Discussion 
In this study, we provided insight into the differences in quality of delivered NHL care in 
the Netherlands between 2007 and 2011, taking into account the Visible Care program. 
The data indicated that quality of delivered NHL care improved at a few points, but also 
showed a greater need for improvement for several quality indicators. Indicator scores 
that decreased significantly included assessment of immune phenotype for diagnosis and 
full examination of blood counts. However, significant improvement was shown for 
execution of all recommended staging techniques, assessment of the IPI and 
multidisciplinary discussion of patients. 
Quality indicators included in the Visible Care program concerning malignant lymphoma 
were developed and published in 2010. The main goal of this program was to increase 
transparency of the Dutch hospital care, for which publically available data were required. 
This could have been a major incentive for hospitals to meet the quality indicators and 
thus improve their NHL care (if necessary). It is noticeable that the quality indicators with 
increased scores (QI4, QIS and Ql17) between 2007 and 2011 were all included in the 
national initiative, which implies a positive effect of the program. However, other (local) 
initiatives or international study results were not taken into account in our analysis. For 
example, the added value of discussing all oncology patients during MTCs has been an 
increasing point of interest the past years, which could have influenced our results. 
Quality indicator scores that significantly decreased between the two measurements, 
induded items about pathology diagnosis based on immune phenotype (Qi3) and 
examination of leukocyte differentiation during blood analyses (QI7). Despite these 
decreases, the scores were still between 80% and 100%, which indicates good 
performance and only a small improvement potential. Improvement potential is often 
assigned to indicator scores below 90%, 21' 22 since higher scores might not be feasible due 
to case-mix factors as high age, many comorbidities and patient preferences. It can 
therefore be argued if the significantly decreased scores seen for the two quality 
indicators are clinically relevant. 
Between 2007 and 2011, there were no large changes in guideline recommendations for 
NHL care in the Netherlands, besides the addition of a recommendation to use 
fluorideoxyglucose positron emission tomography (FOG-PET) scans for determining 
therapy response. 26'27 Using CT scanning, location and size in millimeters should be 
documented, which is not necessary when a FOG-PET scan is done, since it is based on 
color intensity instead of size. This could possibly explain the decreasing trend observed in 
the quality indicator concerning lesions documented in radiology reports after therapy 
(QI10: 67 to 58%, not significant). Based on our datasets, we determined that FOG-PET 
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(CT-)scans were used more often for evaluation after chemotherapy in 2011 (63%) 
compared to 2007 (29%, P<O.OOl). 
Another decreasing trend was seen providing all diagnostic results within 4 weeks after 
the first visit to the hospital (QI19: 56 to 49%, not significant). A factor that may play a role 
is referral of patients between and within hospitals, which increased from 51% in 2007 to 
64% in 2011 (P<O.OOl). A possible explanation for this might be the increasing burden on 
the healthcare system, caused by the growing needs of patients. Although this decreasing 
trend is not significant, and therefore subject to chance, providing all diagnostic results 
within four weeks might be worth arguing because of its clinical importance concerning 
prognosis and start of treatment for patients diagnosed with NHL We believe that longer 
waiting times could result into poorer prognosis for patients, which is already known for 
patients with head and neck cancer.28 Furthermore, short waiting times are valuable for 
the level of patient centeredness of hospitals, of which the importance has grown 
considerably. 
To our knowledge, this is the first study that focused on providing insight into the 
differences in time in quality of delivered NHL care, and evaluated the effect of a national 
transparency initiative. Besides the present study and Wennekes et al.'s14, only a few 
other studies conducted research on quality of NHL care, focusing on parts of the care 
process such as staging and treatment, 12'13' 29 or follow-up care.30 In line with our study, 
they showed that the quality of NHL care is not yet optimal, compared to the 
recommended care as described in evidence-based guidelines. 
Much research has been conducted concerning public reporting, with widely varying 
results. However, the effect of performance data on improvement of quality of care is less 
often studied, and if so, mostly focuses on mortality rates.31 A study by Lamb et a/. 32 
explored the 5-year impact of voluntary public reporting on professional groups and 
showed improvement for ambulatory care measures. Our results are in accordance with 
these studies, however, we were able to provide insight into the quality of care for several 
measures not included in the public reporting as well. This provided the unique 
opportunity to examine the effect of public reporting, as done within the Visible Care 
program, on total quality of NHL care. 
Data collection for observational studies included was performed by independent, trained 
registration employees. In daily practice or public reporting programs, professionals 
themselves are often responsible for the data collection, which might introduce bias as 
they are involved as stakeholders. Our data collection showed also high reproducibility 
between the registration employees, indicating good competency and reliable data 
collection. 
There are also some limitations to this study. Firstly, the hospitals included for data 
collection in 2011 are not completely identical to those included in 2007: 15 hospitals 
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participated in both measurements, 11 hospitals either in 2007 or 2011. However, no 
distinct differences were found in indicator scores when the non-overlapping hospitals 
were left out of the analyses. Together with a relatively large study population (N=771), 
we believe that both datasets are representative for hospitals in the Netherlands. 
Secondly, we did not have insight into possible local improvement initiatives of the 
participating hospitals between 2007 and 2011, which makes it difficult to link the Visible 
Care program as direct and only attribute to the changes seen in some quality indicators 
of NHL care. One influencing factor could be that high room for improvement rates were 
seen for four of the six quality indicators included in this program (<30% scores, 2007 
dataset). It can be argued that, in general, quality indicators with low scores are easier to 
improve than those with higher scores. Hospitals, participated in the 2007 study, received 
general feedback on their performance as a group and as hospital region, which might 
have triggered some local improvement initiatives. However, improving NHL care was not 
the aim of the 2007 study and no concrete improvement initiatives are known based on 
the provided feedback. This result is supported by a Cochrane review, which showed that 
the effect of audit and feedback on improvement is usually small.33 
In summary, during the 4-year period between 2007 and 2011, we found little 
improvement in overall quality of NHL care. Improvement potential as found in 2007 
remained for all quality indicators in 2011, unless some significant increased indicator 
scores. Based on our results, we can conclude that a national initiative as the Visible Care 
program might not have enough power to improve hospital care for NHL in general, but 
might provide a first step towards a more improvement-oriented hospital care. 
Improvement strategies tailored to the suboptimal quality of NHL care might be a rational 
step to develop and test in a randomized setting. 
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Chapter 3 
Variation in guideline adherence in 
non-Hodgkin's lymphoma care: 
impact of patient and hospital characteristics 
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BMC Cancer 2015; 15:578. 
Abstract 
Background: The objective of this observational study was to assess the influence of 
patient, tumor, professional and hospital related characteristics on hospital variation 
concerning guideline adherence in non-Hodgkin's lymphoma (NHL) care. 
Methods: Validated, guideline-based quality indicators (Qis) were used as a tool to assess 
guideline adherence for NHL care. Multilevel logistic regression analyses were used to 
calculate variation between hospitals and to identify characteristics explaining this 
variation. Data for the Qls regarding diagnostics, therapy, follow-up and organization of 
care, together with patient, tumor and professional related characteristics were 
retrospectively collected from medical records; hospital characteristics were derived from 
questionnaires and publically available data. 
Results: Data of 423 patients diagnosed with NHL between October 2010 and December 
2011 were analyzed. Guideline adherence, as measured with the Qls, varied considerably 
between the 19 hospitals: >20% variation was identified in all 20 Qls and high variation 
between the hospitals (>50%) was seen in 12 Qls, most frequently in the treatment and 
follow-up domain. 
Hospital variation in NHL care was associated more than once with the characteristics age, 
extra nodal involvement, multidisciplinary consultation, tumor type, tumor aggressiveness, 
LDH level, therapy used, hospital region and availability of a PET-scanner. 
Conclusion: Fifteen characteristics identified at the patient level and at the hospital level 
could partly explain hospital variation in guideline adherence for NHL care. Particularly age 
was an important determinant: elderly were less likely to receive care as measured in the 
Qls. The identification of determinants can be used to improve the quality of NHL care, for 
example, for standardizing multidisciplinary consultations in daily practice. 
Keywords: non-Hodgkin's lymphoma, hematology, guidelines, determinants, hospital 
variation, oncology. 
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Introduction 
Non-Hodgkin's lymphoma (NHL) is the most common hematologic neoplasm worldwide, 
and affects over 300,000 people each year. 1 In the United States, NHL is the sixth most 
common cancer with an estimated number of almost 70,000 new cases in 2013.2 This 
heterogeneous group of malignant proliferations of lymphocytes consists of more than 40 
disease entities. Approximately 50% of the cases comprises the types diffuse large B-cell 
lymphoma (DLBCL) and follicular lymphoma.3 
Treatment of NHL is highly dependent on the type and stage of the tumor. Primary 
therapy options include chemotherapy, radiation therapy, immunotherapy and wait-and-
see policy. More effective therapy options are emerging, partly due to many randomized 
controlled trials in this field. Despite these improvements, the five-year relative survival 
rate is still rather low for DLBCL patients (55-60%), and for patients diagnosed with 
follicular lymphoma this is 74-86%.4' 5 
The emerging diagnostic and therapy options require evidence-based guidelines to assist 
professionals and patients in their decision-making process for NHL care. These guidelines 
should be in line with the description of care of the Institute of Medicine (IOM): care 
should be safe, effective, patient-centered, timely, efficient and equitable.6 However, 
previous studies showed variation in care for NHL patients based on discrepancies 
between daily practice and recommendations in guidelines.7•9 Actual guideline adherence 
was assessed with quality indicators, defined as 'measurable elements of practice 
performance for which there is evidence or consensus that they can assess the quality of 
the care provided' .10 The suboptimal adherence to guidelines in NHL patient management 
can be an indication of suboptimal quality of care and therefore may require tailored 
interventions, since quality of care does not improve by itself. In order to develop tailored 
improvement strategies, it is important to gain more insight into factors that influence 
guideline adherence in daily practice on patient and hospital level. In previous studies, 
determinants of NHL care focused on patient and tumor characteristics, such as age, 
tumor stage and co-morbidity score.7.9' 11'12 However, little is known about the possible 
influence of hospital factors. In other healthcare settings, patients' age and diagnosis are 
often associated with guideline adherence,13-15 however, hospital factors (e.g. hospital 
size) seem important to consider as well. 13'16-19 
In the current study, we assessed hospital variation in guideline adherence in NHL care 
and to what extent these variations can be explained by differences on patient and 
hospital level. This report builds upon previous work where quality indicators were 
developed and measured to provide insight into guideline adherence for NHL care.9' 20 
Together with insight into variation in guideline adherence and accompanying 
determinants, tailored strategies to improve NHL care can be designed. 
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Methods 
Study design and population 
This observational study was performed using baseline measurements of the PEARL study, 
a cluster-randomized controlled trial (c-RCT) to test and evaluate tailored strategies to 
improve hospital care for patients with NHL (registered at ClinicaiTrial.gov: 
NCT01562509).21 
The extent of hospital variation was assessed in 19 hospitals across three regions of the 
Netherlands (north, east and south), including university, teaching and non-teaching 
hospitals. Patients eligible for this study were defined as patients diagnosed with a mature 
B-, T-or NK-cell neoplasm between October 2010 and December 2011, and older than 18 
years at diagnosis. Patients with cutaneous lymphomas or leukemia-type neoplasms were 
excluded. The Dutch cancer registry was used by the Netherlands Comprehensive Cancer 
Organisation (IKNL) to make a list of potentially eligible patients in the participating 
hospitals. For each hospital a random sample of 25-30 patients was selected for data 
collection. 
Data collection 
Quality indicators 
Data were assessed using systematically developed and validated quality indicators (Qis), 
based on (inter)national evidence-based guidelines.9 This set of 20 Qls was developed by 
professionals involved in NHL care and covers important processes and structures in 
management of NHL care in the domains diagnosis and staging, treatment and follow-up, 
and organization and coordination of care. In short, the Qls reflect quality of NHL care as 
described in guidelines. Trained registration employees, from IKNL, collected data from 
medical records for the Qls using predefined registration forms. Room for improvement 
was defined if quality indicator scores were less than 90%.9' 22-24 
Patient, tumor, professional and hospital related characteristics 
The characteristics were selected because of their potential association with guideline 
adherence and quality of NHL care, based on prior research findings.9' 11'12' 25 Potentially 
relevant patient and tumor related characteristics were age (continuous), gender 
(male/female), co-morbidities (yes/no), performance status (good/bad, good indicating a 
WHO score <2 or Karnofsky score ;?:60), patients' preferences (yes/no objections), previous 
malignancies (yes/no), tumor aggressiveness (yes/no), extranodal involvement (yes/no, 
this term is used if the disease is not in the lymph nodes (extra nodal) or has spread from 
lymph nodes to extranodal sites), Ann Arbor disease stage (1/11 or III/IV), tumor type 
(yes/no DLBCL), International Prognostic Index (IPI) score (low/intermediate/high), lactate-
dehydrogenase level (LDH, yes/no high level (>250 u/L)) and hemoglobin level (Hb, yes/no 
aberrant level (<7.5/8.5 or >10/11, females/males)). Factors related to professionals 
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{dichotomous, yes/no) included multidisciplinary team consultation {MTC), discussion in 
pathology panel, in-hospital referral and therapy used (watch-and-wait was defined as 'no 
therapy used'). Patient, tumor and professional related factors were all collected from 
medical records at patient level. 
The hospital characteristics include type of hospital (yes/no teaching hospital), region of 
hospital (north/east/south), availability of an in-hospital pathology laboratory (yes/no) 
and PET-scanner (yes/no) and availability of professionals specialized in hematology, 
including a specialized oncology nurse (yes/no). Hospital characteristics were collected for 
each hospital from publically available data as well as from a short, digital questionnaire 
(multiple choice questions) sent to the contact person (oncologist or hematologist) at each 
hospital. 
Statistical analysis 
Quality indicator scores and hospital variation were calculated to provide insight into 
guideline adherence in NHL care, which gives an indication of the quality of care as 
delivered to NHL patients. Patient, tumor, professional and hospital related characteristics 
were described by calculating frequencies and means. Univariate analyses (K-test and t-
test) were performed to study correlations between the Ql scores (dependent variables) 
and the selected characteristics (independent variables) . Single correlations were only 
tested for Qls and characteristics if the link between the two factors is clinically explicable 
(e.g. radiology related Qls were not tested for pathology related characteristics, since 
these processes are independently performed from each other). 
Multivariate logistic regression was performed to study correlations for those 
characteristics with P<0.20 in univariate analyses. Correlations between the independent 
variables were also tested. If a correlation {>0.8) was detected, only one variable was 
included in the multivariate analyses. 
Finally, multilevel logistic regression analysis was used to determine to what extent the Ql 
scores were influenced by the characteristics.26 Multivariate backwards regression models, 
including random coefficients, were constructed for each quality indicator. The reason for 
using this analysis was the hierarchical nature of the characteristics, as patients (level 1) 
were nested in hospitals (level 2). We considered P<O.OS as statistically significant and 
calculated the explained variance (R2) per multilevel model with the Glimmix procedure 
using SAS software (SAS12.0 for Windows; SAS Institute, Cary, North Carolina, USA). Odds 
ratios {OR) were used to describe the association between the characteristics and quality 
indicator. An OR >1 indicates a positive association with the quality indicator (greater 
relative chance of guideline adherence if the determinant is present) . 
Ethics 
On behalf of the research ethics committee {CMO) of the Radboud university medical 
center, we hereby let you know that the current study has been carried out in accordance 
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with the applicable rules concerning the review of research ethics committees and 
informed consent (registration number 2011/560). 
IKNL has contracts with each Dutch Hospital about the Cancer Registry that all patients are 
informed about the registration and are registered unless the patient has objected to be 
registered. The Netherlands Cancer Registry is obliged to work according to the law about 
protection of privacy data and the law "Geneeskundige BehandeiOvereenkomst". All 
procedures to privacy of doctors and patients is fixed in regulations. An independent 
Committee of Privacy reassures that the Netherlands Cancer Registry works is compliant 
to these regulations. Based on this, consent of the patients for this specific study was not 
applicable; according to the Dutch law all cancer patients are included in the Netherlands 
Cancer Registry as maintained by IKNL, unless the patient has objected to be registered. 
Results 
Patient, tumor and professional related characteristics 
Table 1 shows the patient, tumor and professional related characteristics included in this 
study, measured at patient level. In total, data were collected for 423 patients diagnosed 
with NHL between 2010-2011 across 19 Dutch hospitals. The mean age ofthe patients was 
66 years (range 22-94), 57% was male and 61% had at least one co-morbidity. Tumor 
related characteristics showed that 61% had extranodal involvement, 60% was diagnosed 
with an aggressive tumor and Ann Arbor stage Ill of IV was observed in 68% of the 
patients. 
Professional related factors as discussion in a pathology panel and an MTC were 
performed in 33 and 41% of the patients, respectively. Of the 423 patients in this study, 
75% received therapy, either chemotherapy, radiotherapy or a combination of these two, 
as initial treatment. Three factors were excluded from further analyses: performance 
status and IPI score because of too many missing values (respectively, 83 and 58% 
missings) and patient preferences because of <10% variation (only 6% had objections 
concerning diagnostics or therapy). 
Hospital characteristics 
Table 2 outlines the characteristics of the participating hospitals, measured at hospital 
level. Of the 19 hospitals, 47% was situated in the Northern region and 53% comprised 
teaching hospitals. An in-hospital pathology laboratory was present in 47% of the hospitals 
and 42% had the availability of an in-hospital PET-scanner. Most hospitals (87%) had a 
specialized pathologist, whereas 78% had a specialized oncologist or hematologist and 
47% a specialized radiologist/nuclear physician. In 68% of the hospitals a specialized 
oncology nurse was available. Two factors were excluded from further analyses because 
of high correlation with at least one other hospital characteristic: trial participation and 
hospital size. 
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Table 1. Patient related characteristics 
·Characteristics 
Patient factors 
Male sex 
Mean age, years (range) 
Co-morbidities (H) 
Objections (patient preferences)• 
Good performance statusb 
Tumor related factors 
P·revious maJ1gna,.,.cies 
Extranodal involvement 
High LDH Ievett 
Aberrant Hb leveld 
Ann Arbor stage 111/IV 
Aggressive tumor 
DUKL t umor typee 
IPI score (intermediate-)highb 
Professional related factors 
Patients 
N 
242 
423 
256 
25 
67 
71 
258 
171 
173 
268 
254 
194 
49 
iNroTAt-=4?31 
% 
57 
66 (22-94) 
61 
6 
94 
17 
61 
44 
42 
68 
60 
46 
38 
In-hospital referral 270 64 
Multidisciplinary team consultation 172 41 
Discussed in pathology panel 137 33 
Therapy used1 319 75 
Abbreviations: LDH, lactate-dehydrogenase; Hb, Hemoglobin; DLBCL, diffuse large B-cell lymphoma; 
IPI, International Prognostic Index. 
a Excluded from further analyses due to <10% variation. 
b Exciuded from further analyses due to >50% missings, based on WHO and Karnofsky scores. 
c High LDH level is defined as >250 U/1. 
d Aberrant Hb level is defined as <8.5 or >11 mmol/1 for males and <7.5 or >10 mmol/1 for females. 
e Non-DLBCL tumor types include follicular lymphoma (18%), marginal zone B-cell lymphoma (11%), 
mantle-cell lymphoma (5%). lympho(plasma)cytic lymphoma (10%), and miscellaneous (9%) . 
1 The watch-and-wait management was coded as 'no therapy used' . 
Quality indicators 
Guideline adherence in NHL care was measured with a set of 20 Qls, presented in Table 3. 
Room for improvement (<90% adherence) was seen in 18 out of 20 Qls. Regarding 
diagnosis and staging, the indicator with the lowest score was performance of all staging 
techniques (QI4, 48%) and the indicator with the highest score was diagnosis based on 
morphology and immune phenotype (QI3, 96%). Indicators for treatment and follow-up 
showed a range of 62-82%, including complete evaluation after chemotherapy (Qill) as 
lowest score and reporting dose reduction for chemotherapy RCHOP (QI13) as highest 
score. In the domain of organization and coordination, the lowest score was for complete 
pathology reports (QI16, 14%) and the highest score for integrated reporting of pathology 
techniques (QilS, 89%). 
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In all three domains, Ql scores differed considerably between the 19 participating 
hospitals; variation in guideline adherence (>20%) among the hospitals was noted in all 20 
Qls. The lowest hospital variation was seen for Qls concerning diagnosis of NHL based on 
morphology and immune phenotype (QI3) and assessment of LDH level (QI6), respectively 
26% (range 74-100) and 30% (range 70-100). High variation (>SO%) between the hospitals 
was seen in 12 of the 20 Qls, most frequently (N=S) in the treatment and follow-up 
domain. 
Table 2. Hospital characteristics 
Characteristics 
Hospital region 
North 
East 
South 
Teaching hospital 
In-hospital pathology laboratory 
In-hospital PET-scanner 
Specializecl oncologist or hematologist 
Specialized radiologist/nuclear physician 
Specialized pathologist 
Specialized oncology nurse 
Trial participation" 
Hospital size( no. of beds)• 
Small(<350) 
Medium(350-650) 
Large(>650) 
Hospitals (NwrAL=19) 
fiJ % 
9 47 
5 26 
5 26 
10 53 
9 47 
8 42 
14 78 
9 47 
16 87 
13 68 
12 63 
8 42 
5 26 
6 32 
a Excluded from further analyses due to high correlation with other 
hospital characteristics. 
Determinants of guideline adherence in NHL care 
Table 3 displays, per quality indicator, the determinants that significantly influence 
hospital variation concerning guideline adherence for NHL care. In multilevel modeling, 15 
of the 22 characteristics were involved with variation in guideline adherence: 13 at patient 
level and 2 at hospital level. Several characteristics influenced hospital variation in only 1 
quality indicator, including gender, co-morbidities, previous malignancies, referral to 
another specialist, presence of a pathology panel and PET-scanner. 
Determinants associated with 2 to 5 quality indicators were extra nodal involvement, MTC, 
DLBCL tumor type, tumor aggressiveness, LDH and Hb level, therapy used and hospital 
region. Of these 8 determinants, only therapy showed a clear direction of effect: patients 
receiving therapy were more likely to receive care as described in the guidelines, including 
Ann Arbor classification (QI2), performing all staging techniques (QI4) and assessment of 
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IPI (QI5) and LDH level (QI6). The other determinants were both negatively (OR<l) and 
positively (OR>l) linked to guideline adherence. For example, patients discussed in an 
MTC were less likely to receive an LDH level assessment (QI6), whereas they were more 
likely to receive all staging techniques(QI4). 
The main patient characteristic associated with guideline adherence was age (5 out of 20 
quality indicators). In particular, older people were less likely to receive care as measured 
by the Qls, including correct diagnostic biopsy performance (Qil), Ann Arbor staging (QI2), 
performing all staging techniques (QI4), assessment of IPI risk factor (QIS), and receiving R-
CHOP chemotherapy (QI12), compared to younger patients. 
Hospital characteristics associated with Ql scores in this dataset included hospital region 
and an in-hospital PET-scanner. Hospitals in region 2 showed more documentation of 
target lesions in radiology reports after therapy (QilO) and more complete reports therapy 
evaluations (Qill), whereas they showed less complete reports for pathology (QI16), 
compared to the other two regions. The availability of an in-hospital PET-scanner was 
positively associated with a multidisciplinary discussion of patients (QI17). Participation in 
trials and hospital size were not included in multivariate analysis, because of the high 
correlation with hospital type, and availability of an in-hospital pathology laboratory and 
PET-scanner. 
Table 3 also shows the explained variance of the determinants included in the final 
multilevel model. A substantial part of the variation in guideline adherence can be 
explained by patient and/or hospital characteristics: ten Qls showed that determinants 
could explain the variation for at least 10%. Variation regarding Ann Arbor staging (QI2), 
evaluation with CT-scans after therapy (Qill) and R-CHOP chemotherapy for DLBCL 
patients (QI12) showed relatively large explained variances of, respectively, 35, 30 and 
26%. 
Discussion 
This study demonstrated substantial hospital variation in guideline adherence for NHL 
care . Fifteen characteristics at the patient level could partly explain this variation, such as 
extranodal involvement, MTC, tumor type, therapy used and hospital region. Hospital 
characteristics contributed less to the variation in adherence than patient, tumor and 
professional related characteristics. Patients' age was involved most frequently as 
determinant, illustrating that older people are less likely to receive NHL care as described 
in the guidelines. 
Our study showed large gaps between daily practice performance and care as described in 
the evidence-based guidelines. Large variation in guideline adherence between hospitals is 
often associated with lower quality of care, since guidelines aim to assist professionals to 
deliver the most optimal care. However, less adherence does not always indicate lower 
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Table 3. Indicator scores and determinants for guideline adherence concerning NHL care. 
Quality Indicator Indicator 
DiC:Qf/0$/s aru! r;tcrging score (%) 
Ql1 Diagnosis based on histological examination or an excision or wide 369 79 
incision biopsy 
Older age 
Ql2 Patients staged according to Ann Arbor classification 
Older ag.e 
Therapy used 
Ql3 Diagnosis based on morphology and immune phenotype 
390 
376 
Ql4 Staging techniques include CT-scans, bone marrow aspirate, and bone 421 
hio;psy 
Olderag•e 
Extranodal involvement 
Discussed i11 MTC 
Aberrant Hb level 
Therapy used 
Ql5 Assessment of International Prognostic Index for patients with 250 
aggressive NHL 
Older age 
DLBCL tumor type 
Therapy used 
QIG Assessment of LDf1 level 423 
Discussed in MTC 
Therapy used 
Ql7 Examination of blood counts 422 
81 
96 
48 
43 
92 
82 
59-100 
74-100 
0-74 
0-81 
70-lOO 
14-100 
OR {!S%0 ) 
0.97 (0.95-0.99) 
0.93 t0.90-0.9S) 
7.55 {4.04-14.00) 
0.98 (0.96-0.99) 
0.52 (0.33-0.84) 
1.88 (1.10·3.20) 
0.54 (0.34-0.86) 
3.08 (1.76-5 .3·9) 
0.97 (0.95-0.99) 
2.85 (1.07-4.82) 
8.70 (1.82-41.50) 
0.42 (0.19·0.94) 
2.92 (1.36-6.27) 
p. Explaintd 
value varl.a!'lce {% •. 
5 
<0.01 
35 
<0.01 
<0.01 
n.a. 
14 
0.02 
<0.01 
0.02 
0.01 
<0.01 
17 
0.01 
0.03 
<0.01 
9 
0.03 
<0.01 
n.a. 
Table 3 Continued. 
Quality Indicator 
rr~u;;tm6l!l t and follow·llp 
Ql8 Reporting of response to therapy using predefined terminology 
High LDH level 
Ql9 Lesions docu,mented in radiology report I:Je.fore therapy 
Ql10 Lesions documented in radiology report after therapy 
DLBCL tumor type 
Co-moroidities(~1) 
Hospital region R1 
R2 
R3 
Qlll Evatuatfo'lil after chemotherapy with (PET)CT-scans, bone marrow 
aspirate, and bone biopsy 
Extranoda,J il'lvotvement 
Hosp,itaf re,gi·on R1 
R2 
Rl 
Ql12 Patients with DLBCL received RCHOP chemotherapy 
Older age 
Qt13 Dose of RCHOP was not reduced or reason for reduction was 
reported 
~ 
V'1 
Extranodal involvement 
N 
304 
344 
114 
246 
! 
t 
194 
111 
Indicator Range In 19 OR (95% Cl) P- Explained 
score(%) hospitals (%). value variance (~ 
73 53-100 2 
1.79 {1.03-3 .11) 0.04 
67 22-90 n.a. 
58 0-100 24 
0.34 (0.15-0.79) 0.01 
0.34 (0.15-0.81) 0.02 
1.08 {0.38-3.07) 
4.10 (1.48-11.40) 
Ref. 0.02 
62 29·100 30 
0.18 t0.09-0 .34) <0.01 
0.93 (0 .47-1.84) 
4.54 (1.88-10.96) 
Ref. <0.01 
78 44-100 26 
0.92 (0.88-0.95) <0.01 
82 40-100 8 
0.31 ('0.:1.0-0.99? 0.05 
+>-
0'\ 
Table 3 Continued . 
Quality Indicator N Indicator Range in 19 ()R {9S-" Cl ) P- fxplained 
Or ·attizotion ond coordination o care , core (%) hospital$ (~} value variance f)! 
Ql14 Sending of unfixed biopsy material 321 41 0-91 n.a. 
Ql15 h'ltegrated reporting of patnology techniques 365 89 35-100 11 
Extranodal invo:lvement 2.46 (1.10-5.50) 
Discussed in pathology panel 5.25 (1.75-15.74) 
Ql16 Pathology report describes all necessary, predefined characteristics 378 14 0-47 
Discussed in MTC 
Hospital region R1 
R2 
R3 
Q117 Patients discussed in multidisciplinary team consultations 
Ava.llabillty of PET-s:canner 
Ql18 Results of bone marrow pathology known before start of treatment 
Aggressive tumor 
Aberrant Hb level 
Ql19 Dfagnosth: period of 4weeks afte.r first visit to the hospital 
Previous mat.ignandes 
Extral'lOda·t involvement 
tn-hospltal referral 
Hi.gh LDH ~evel 
Ql20 Start of therapy within 2weeks after diagnostic period 
Male gender 
Aggressive tumor 
High LDH level 
' 422 41 4-96 
317 83 43-100 
420 47 22-70 
313 58 37-79 
2.46 (1.10-5.51) 
2.73 (0.62-12.04) 
0.17 (0.02-1.31) 
Ref. 
4.22 (1.01·17.56) 
0.30 (0 .13-0.70) 
0.38 (0 .20-0.72) 
0.52 {0.29-0.95) 
1.72 (1 .11-2.66) 
0.52 (0 .34-0.81) 
1.9 2(1.27-3.03} 
1.69 (1.03-2. 76) 
1.99 (1.17-3.41) 
1.92 (1.16-3.19) 
Abbreviations: MTC, multidisciplinary team consultation; DLBCL, diffuse large B-cell lymphoma; LDH, lactate-dehydrogenase; Hb, 
ritixumab-involved chemotherapy. 
0.03 
<0.01 
23 
0.03 
0.04 
9 
0.05 
11 
<0.01 
<0.01 
10 
0.03 
0.02 
<0.01 
<0.01 
9 
0.04 
0.01 
O.Ql 
Hemoglobin; RCHOP, 
quality of care: complying with patient preferences or performing less diagnostics due to a 
low performance status can also point towards patient-centered, safe and deliberately 
delivered care. It is believed that variation due to deliberately deviate from guidelines is 
reflected in the upper 10% of Ql scores (90-100%). Therefore, many studies indicate room 
for improvement if guideline adherence, as measured by indicators, is below 90%.9' 22-24 In 
our study, 18 out of 20 Qls showed room for improvement, of which 12 Qls demonstrated 
high hospital variation (>50%), indicating other factors than patient preferences or 
performance status might play a role. Similar to our study, Weeks et a/. 27 found high 
variation in NHL management decisions, for example in performing a PET-scan (range 38-
95%) or a bone marrow biopsy (range 21-99%). Studies concerning other tumor types also 
showed variation in delivered care between hospitals.18' 28-31 
While this is the first study to investigate determinants at patient as well as hospital level 
for guideline adherence, and indirectly for the quality of care for NHL patients, other 
studies examining multilevel determinants have been carried out in several areas, 
including lung, prostate and (colo)rectal cancer. 18'29'32-34 Schroeck et a/. 33 provided insight 
into adherence to Qls for prostate cancer and its regional variation. Most measures 
showed low adherence rates and high regional variation, for example 72% variation in 
follow-up with radiation oncologists (range 14-86%). They showed that characteristics 
such as age, clinical stage and number of urologists explained the differences for 5-20%. 
Etzioni et a/. 32 showed that characteristics as higher-volume surgeons and teaching 
hospitals contributed to long-term survival in rectal cancer patients, whereas Sacerdote et 
a/. 34 found several social, clinical and hospital characteristics to be associated with the 
treatment of colorectal cancer, for example, age, gender, hospital volume and an in-
hospital radiotherapy service. Mathoulin et a/. 29 investigated the quality of colorectal 
cancer surgery and found several associations with patient, tumor and hospital related 
factors, such as age, disease stage and hospital type. Finally, Ouwens et a/. 18 found patient 
characteristics to have a greater influence on quality of integrated care than professional 
or hospital characteristics for patients with non-small cell lung cancer. 
Several determinants of guideline adherence and NHL care were found in our study as 
well. Regarding patient factors, especially patients' age appeared to influence variation in 
guideline adherence for NHL care most. For older patients, it can be argued that 
suboptimal diagnostics and suboptimal but better tolerated therapies sometimes are the 
best achievable care. However, the reasons for deviation from the guideline should be 
well thought out and documented by the professionals, which may be influenced by 
available information for decision making, professionals' choice or patient preferences. 
Unfortunately, we were not able to include arguments to deliberately deviate from 
guideline recommendations, since these are frequently not documented (in a 
standardized way) in medical records. 
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Previous studies found patients' age as an important factor for delivered NHL care: they 
studied elderly DLBCL patients, defined as patients aged over 60 or 75 years. 11' 12'25 
Younger age and better performance status were associated with receiving CHOP-like 
chemotherapy. Van de Schans et a/.12 showed age as the only factor associated with 
receiving less than six cycles of CHOP-like chemotherapy (adjusted for variables as gender 
and co-morbidity). Concerning overall survival, all three studies concluded that optimal 
therapy for elderly was associated with better outcomes, after case-mix corrections. 11' 12'25 
After multivariate analyses, Trebouet et a/.35 found also a relation between treatment 
administration and improved survival in patients over 90 years of age with aggressive NHL. 
An important drawback of intensive chemotherapy is treatment related toxicity. The 
elderly are more susceptible to complications, which makes it even more important to 
accurately select patients for therapy. 11 They stated that elderly are more susceptible to 
develop complications, which makes it even more important to accurately select patients 
for therapy. The judgment of professionals must be underscored in this selection process. 
A possible option to optimize outcomes was proposed by Lin et at. 25; they opted 
implementation of tailored interventions to improve the performance status of patients 
before the start of therapy. In addition, in other fields of oncology lower guideline 
adherence was seen for elderly as well.34' 36 Suggested reasons for the lower rates were 
that elderly patients receive less diagnostics and/or therapy for medical reasons, such as 
higher burden of co-morbidities34, or diagnosis of advanced disease stages36, which was 
initially seen in our dataset as well (data not explicitly shown). However, co-morbidities 
and disease stage were included in our analyses and age remained a determinant in the 
final models. 
Besides age, several other tumor and patient related determinants were involved in 
explaining hospital variation, including previous malignancies, LDH and Hb level, gender, 
co-morbidity, extra nodal involvement, tumor type and tumor aggressiveness. Most of 
these aspects are common factors measured in NHL research concerning prognostic 
factors and survival analyses.11'12' 25'35 Unfortunately, this literature shows involvement of 
the factors with survival in univariate analyses, but not in multivariate analyses. Tumor 
type and aggressiveness are often not assessed, since studies regularly select only DLBCL 
or aggressive tumors as subjects of interest.11'25' 37 Kuper-Hommel et a/.37' 38 investigated 
differences in therapy and outcome between patients with nodal and extranodal 
lymphomas in two large population-based studies. They showed that patients with 
extra nodal lymphomas were less often optimally treated but did not find clear differences 
in overall survival. In our study, patients with extranodal involvement received less often 
all required staging techniques and showed more often dose reductions during R-CHOP 
chemotherapy or reductions without reporting the reason. 
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Not all determinants found seem directly relevant for clinical practice, such as the 
influence of the Hb level on Ql18: pathology results have to be known before the start of 
treatment. A possible explanation could be that the urge of starting therapy is higher for 
patients with a aberrant Hb level and an aggressive tumor. It seems valuable to explore 
these determinants in other NHL populations. 
Of the professional and hospital related determinants for hospital variation in NHL care, 
treatment is an important factor in relation to better survival, as discussed above. Factors 
as MTC, hospital region, in-hospital referral, PET-scanner and discussion in a pathology 
panel are often not taken into account in survival analyses. The possible relation of these 
factors with overall survival is an interesting issue to address in future research. Hospital 
region will probably be one of the most challenging determinants, since hospitals cannot 
move to another geographical region and regional collaborations are embedded, which 
might be tough to effect change upon. Nevertheless, guideline adherence and quality of 
care described per region can give valuable insight into regional differences concerning 
interpretation and rating of the guideline recommendations and provide possible points of 
interest for improving quality of care. 
Strengths of this study are the large study sample (N=423} derived from a population-
based cancer registry and the validated guideline-based Qls used for the assessment of 
variation in guideline adherence for NHL care. These factors contribute to the reliability of 
our results. Another factor contributing to a reliable dataset is that trained registration 
employees of IKNL collected the data independently of the project team. An additional 
strength of our study is that 2 levels of potential determinants were included, namely 
patient and hospital level. Multilevel analyses made it possible to include these factors in 
one regression model per quality indicator. 
There are also some limitations that need to be addressed. First, characteristics at the 
level of professionals were not taken into account, since NHL care is provided by a 
multidisciplinary team of a hematologist and/or (radiation)oncologist, radiologist, nuclear 
physician, pathologist and oncology nurse. It was not possible to relate one professional to 
one patient, which is necessary for inclusion of characteristics at professional level. 
However, some professional related factors measured at patients level were included in 
our study, such as patients discussed in MTC and therapy used. Second, only two of eight 
hospital characteristics included for analyses were found to have significant impact in the 
final multilevel models. This can be caused by the limited sample size of 19 hospitals, 
indicating more hospitals may be needed for possible future research. Third, no hospitals 
from the Western part of the Netherlands were included in our study, which might have 
introduced some selection bias. However, we did include 19 of the 91 Dutch hospitals, 
including three different regions, representing 21% of the Dutch hospital population. Last, 
a significant amount (>50%} of data was missing for the parameters performance status 
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and IPI score. One of the reasons for this could be that only official WHO scores and 
Karnofsky scores were collected, excluding general terms as 'healthy man' or 'vital 
women'. Arguments for not calculating the IPI score included that therapy choices do not 
change for most patients based on the IPI score, except for patients participating in clinical 
trials. 
Conclusion 
In conclusion, this study showed considerable hospital variation in guideline adherence, as 
an indication for quality of delivered NHL care, including the domains diagnosis and 
staging, treatment and follow-up and organization and coordination of care. Our study 
demonstrated that patient characteristics appear to have more influence on guideline 
adherence than hospital characteristics, especially patients' age. Tailored strategies to 
optimize NHL care should take into account the determinants identified in this study. 
Especially for older patients, reasons for not performing all necessary diagnostics and 
staging techniques should be a topic of interest, taking into account safe and patient-
centered care as well. 
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Chapter 4 
Delivering high quality care to patients 
with a non-Hodgkin's lymphonrna: 
barriers perceived by patients and professionals 
J.J.C. Stienen, P.B. Ottevanger, L. Wennekes, S.A.M. van de Schans, 
H.M. Dekker, N.M.A. Blijlevens, R.W.M. van der Maazen, 
J.H.J.M. van Krieken, R.P.M.G. Hermens. 
Netherlands Journal of Medicine 2014; 72(1):41-8. 
Abstract 
Background: Despite the presence of non-Hodgkin's lymphoma (NHL) guidelines, there are 
still gaps between best evidence as described in guidelines and quality of care in daily 
practice. Little is known about factors that affect this discrepancy. We aim to identify 
barriers that influence the delivery of care and to explore differences between patients' 
and professionals' experiences, as well as between the different disciplines involved. 
Methods: Patients and professionals involved in NHL care were interviewed about their 
experiences with NHL care. The barriers identified in these interviews were quantified in a 
web-based survey. Differences were tested using Chi-square tests. 
Results: Barriers frequently perceived by patients concerned lack of patient information 
and emphatic contact {12-43%}, long waiting times {19-35%} and lack of guidance and 
support (39%}. Most mentioned barriers by professionals concerned the unavailability of 
the guideline {32%}, lack of an up-to-date guideline (66%}, lack of standardized forms for 
diagnostics {56-70%} and of multidisciplinary team consultations {56%). Perceived barriers 
concerning the guideline and standardized forms significantly varied between the 
disciplines involved {range 14-84%, P<0.05). 
Conclusion: Patients and professionals experienced different barriers for high quality NHL 
care. A tailored strategy to optimize guideline adherence and daily NHL care, based on 
these barriers, has to be developed and tested. 
Keywords: barriers, implementation, non-Hodgkin's lymphoma, qualitative analyses, 
quality of care, quantitative analyses. 
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Introduction 
The incidence of malignant lymphoma has increased significantly over the past years.1' 2 
Malignant lymphoma's can be classified into Hodgkin's lymphoma {HL) and non-Hodgkin's 
lymphoma {NHL). The latter is the most common hematologic neoplasm in adults 
worldwide.3 Multidisciplinary evidence-based guidelines for NHL have been developed, 
both national and international, to assist professionals and patients in their decisions 
regarding appropriate diagnostics, treatment and follow-up.4-7 
Unfortunately, just the publication and dissemination of guidelines is often not enough to 
close the existing gap between guidelines and daily practice.8 We believe that better 
guideline adherence can lead to higher quality of care. Therefore, the first step in 
improving quality of care is getting insight into current daily practice and the factors that 
influence the delivery of high quality of care.9 
For NHL care, several studies have demonstrated that care for patients is suboptimal.10-12 
Wennekes et a/.12, for example, described lack of guideline adherence concern ing 
diagnostics, therapy and follow-up. However, less is known about barriers that influence 
delivery of high quality NHL care experienced by patients and professionals. The aim of 
this study is to identify the most important barriers that influence daily NHL care as 
perceived by patients and professionals.13 
Methods 
Study design 
We qualitatively explored barriers of delivering NHL care by performing semi-structured 
interviews among patients and professionals. In order to assess the importance of the 
barriers found, we quantified the barriers in a web-based survey. 
Participants and recruitment 
Patients 
Patients were recruited for the interviews through the website of the Dutch Lymphoma 
Organization {patient association {LVN)), or by their attending physician . For the surveys, 
Twitter and the online forum of the LVN were used for recruitment. Patients diagnosed 
before 2008 were excluded to ensure information on current quality of care {2008 to 
2011). Patients were reminded to complete the survey by an updated news item on the 
LVN website and by another tweet. Consent for the interview and survey was presumed if 
patients positively responded. 
Professionals 
Professionals involved in NHL care, including haemato-oncologists, pathologists, radiation 
oncologists, radiologists and nuclear medicine physicians were included in the study. For 
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the interviews, professionals from 22 hospitals involved in an NHL study in 2006 12 were 
invited to participate. Additionally, professionals involved in the Lymphoma Working Party 
of the Haemato-Oncology Foundation for adults in the Netherlands (HOVON) were invited 
by e-mail. For the surveys, the Dutch Societies of Internal medicine (NIV), Pathology 
(NVvP), Radiology (NVvR), Nuclear medicine (NVNG), and Radiation oncology (NVRO) were 
consulted for contact information. Based here on, professionals were contacted either via 
a call in the newsletter (NVvP, NVvR), by email (NVNG, NVRO), or by post (NIV). Since no 
additional registration exists for professionals specialized in NHL, all members of the 
Dutch Societies were contacted. A reminder was sent to all, two to four weeks after the 
initial mailing. The surveys were independently tested by two project members before 
fielding the questionnaires. Consent for the surveys was presumed if the questionnaire 
was completed. 
Instrument development and content 
Interviews 
The interviews were scheduled according to the participants' preferences concerning date 
and setting (face-to-face or by telephone). Participants were asked about their 
experiences with clinical practice regarding NHL care. The structure of the interviews was 
based on previously developed quality indicators12 and two theoretical models.14' 15 These 
models facilitate description of potential barriers using 5 domains: factors related to the 
guideline (1), to professionals (II) and patients {Ill) and factors concerning the 
organizational (IV) and social (V) context. Data collection was finished when no new 
influencing factors were found and saturation was reached. All interviews were audio 
taped and transcribed verbatim for analysis with Atlas.ti" (version 6.2.23, Atlas.ti Scientific 
Software Development GmbH; Berlin, Germany). The results of the interviews were used 
for the surveys. 
Surveys 
Because patients and professionals have different perspectives in NHL care, two different 
surveys were developed. The surveys were converted into a web-based survey using 
LimeSurvey (version 1.91, Boston, MA). The online survey did not accept unanswered 
questions and adaptive questioning was used. A modified version of the 'Consumer 
Quality Index (CQI) for cancer patients' was used.16 The CQI, based on the American 
CAHPS instrument, is a standardized method to measure experiences of patients 
concerning quality of care. Permission to use this survey was obtained. 
The patients were asked about their experiences regarding the organization of NHL care, 
competence of professionals, information provision and communication, collaboration in 
NHL care, guidance and support, and after care. Questions were scored using closed 
questions with four answer possibilities, including never (1), sometimes (2), most of the 
time (3) and always (4). When relevant, 'I don't know' or 'not applicable' were included. 
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The first part of the survey contained 11 questions about characteristics of the patients, 
including age, gender and type of NHL. 
The surveys developed for professionals consisted of 85 questions for haemato-
oncologists, 52 for pathologists, 63 for radiologists and nuclear medicine physicians, and 
59 for radiation oncologists. The first part of the survey contained 8 questions about 
characteristics of the professionals and their clinical setting, including age, gender and the 
type of hospital. The surveys were divided into the same 5 domains as the interviews, 14' 15 
and concerned statements about the Dutch NHL guideline and local protocols, working 
according to the recommendations, the organization of NHL care and the social context. 
The statements were scored on a 5-point Likert scale (1=strongly agree, 5=strongly 
disagree). 
Data analysis 
Interviews 
The interview transcripts were analyzed using qualitative content analyses, taking into 
account the direct as well as the underlying meaning of the text.17 Potential barriers were 
identified independently by two members of the project team. Any discrepancies were 
discussed until consensus was attained . Two other members of the project team randomly 
choose two transcripts to verify the qualitative analyses. After extraction, the established 
barriers were categorized into the above-mentioned domains and their frequency was 
scored. 
Surveys 
SPSS (version 16.0, Chicago, IL) was used for the analyses of the survey results. The answer 
possibilities of the patients' survey were dichotomized as disagreement (score 1 or 2) and 
agreement (score 3 or 4) . For professionals, the Likert scores were classified as agreement 
(score 1 or 2), neutral (score 3) and disagreement (4 and 5). Differences between patients 
and professionals were descriptively reported. Chi-square tests (statistical significance set 
at two-sided p<0.05) were performed to get insight into differences in perceived barriers 
between the four disciplines involved in NHL care. 
Results 
Participants and recruitment 
Seventeen patients and 33 professionals from hospitals spread over the Netherlands were 
interviewed. Table 1 shows the characteristics of 28 patients and 132 professionals, who 
filled in the survey. Patients and professionals from all age groups were represented and 
the two sexes were equally divided in both patients and professionals. Most patients (19 
out of 28) in our study population had a diffuse large B-cell lymphoma or follicular 
lymphoma. 
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Barriers perceived by patients and professionals 
The interviews resulted in barriers in all five predefined domains. In total, during the 
interviews 62 unique barriers were identified by patients (24 barriers) and professionals 
(47 barriers). They mainly indicated barriers in the professional (24 barriers) and 
organizational domain (15 barriers). Professionals also mentioned 13 barriers concerning 
the guideline. Eight unique barriers in the social context and 2 barriers related to the 
patient were identified. See Supplement S1 for the most frequently mentioned barriers 
per domain. 
In Table 2a and 2b, the most important barriers perceived according to patients and 
professionals, as quantified by the surveys, are summarized. Barriers are included if at 
least 15% of the responders classified that item as a barrier and if ~15 responders 
answered the question concerned. Barriers among patients, professionals, and differences 
between them are described below. Some illustrative quotations from the interviews are 
included in Figure 1. 
Table 1. Characteristics of patients and professionals who filled out the survey 
Characteristics Patients Characteristic!• 
N (28}% 
Gender Gender 
Male 14 50 Male 
Female 14 50 Female 
Age groups Age groups 
25-44 8 29 25-44 
45-64 I 18 64 45-64 it65 2 7 it 65 
NHL classification Discipline 
Follicular lymphoma 9 32 Hematology/oncology 
D!.BCL 10 36 Pathology 
Marginal zone B-cell 2 7 Radiation oncology 
lymphoma 7 25 Radiology/nuclear medicine 
Other classification 
Region of hospital Region of hospital,. 
North 3 12 North 
East 2 8 East 
South 3 12 South 
West 18 69 West 
Abroad 
Type of hospitalb Type of hospital 
University 10 38 University 
Non-university 21 81 Non-university 
LeveJ of education Years of experience 
Low 13 4S O-S year 
Middle 10 37 6-15 year 
Mllh 4 15 16-25 year 
I Professionals N (132) % 
72 55 
60 45 
62 47 
67 52 
! 2 2 
so 38 
31 24 
36 27 
15 11 
14 11 
25 19 
7 5 
82 62 
4 3 
45 34 
87 66 
49 37 
' 
49 37 
26 20 
>25 year 8 6 
Abbreviation: DLBCL, diffuse large B-celllymphoma. a Professionals were asked in which region they 
were trained; b Five patients were under treatment in more than one hospital. 
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(I) Guideline-related barriers 
#J staffed wotklng here 1.5 years ago as an onoolagist altd everyone~'iJS . 
tsfking .about the gulaetioo. Unfotturuttely, I oottfdll 't lt2y my hamts on a 
fJliJPM or oniirJ2 versi&n" 
(II) Physician-related barriers 
•Looking back, it wctlld haw beoo bettwr to 
get all infvrmation about possible side effects 
in a fotaer or booklet. Now I heard everything 
tram ather NHL pst16.'7ts duting m!J 
ahamoth~ sessi&ns~ 
(Ill) Patient-related barriers 
----
'There are .a fqt of differ-. s 
m our reports. T'hePilffmit, a 
f·tlinfit1 smruJafd wbeft! all 
ifrtpr:ntant items am il'1tJluded 
~;l'.oufd be develope\!" 
(----~-"'. dtodcasehc. oifm8mand ~ get some ofioler things cl3ne for school, whifJJJ is 
why t~ was~ for two l'Wfll;fts" 
----~ 
(IV) Organization-related barriers 
~~ could go to my physfoian ar his secretary with qvesti&ns, but t/Je 
secretary couldn't answer any of my ~stions. I think ft was a missed 
L--.... -·-·~~ 
(V) Social-related barriers 
- "A muitid.iscf!Jiim. rt meeting is.' org.:ar..tzcd t"'·iee.·. a month~· 
Unforlun;ately, radiation oncologists ana nuclear medici~e J 
pfrlysicians Bfa not involved in thssa meetings yet• --------·---
---- . -
Figure 1. Illustrative quotations from patients and professionals concerning perceived barriers 
of quality of NHL care delivered. 
(/) Guideline-related barriers 
No barriers related to the guideline (developed for and by professionals) were mentioned 
by the patients. Professionals pointed out barriers mainly regarding the lack of availability 
of local NHL protocols (47%) and lack of an up-to-date version of the NHL guideline (66%). 
They agreed about the need to have an up-to-date, online version of the guideline (66% 
and 83%, respectively) and an online version of the local NHL protocol (63%). Of note, 24% 
of the professionals were not familiar with the guideline. 
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{II) Professional-related barriers 
The most frequently mentioned barrier by patients concerned professionals providing 
insufficient information about patient associations {44%), the lack of attention for coping 
of the patients' relatives (35%) and not showing personal interest in a patient (28%). 
Insufficient written information provided by professionals was mentioned frequently 
during the interviews and 22% agreed on this in the survey. 
Professionals did not mention barriers regarding information provision and 
communication, but mainly focused on the lack of standardized forms for diagnostic 
requests and reports (ranging from 56 to 70%) and the not routinely used Cheson 
response criteria {40%). 
{II!} Patient-related barriers 
Concerning patient self-reflection, some patients mentioned a lack of participation in 
decision making (13%); professionals did not mention barriers in this domain. In the 
interviews, a few patients and professionals mentioned patients' preferences concerning 
postponement of diagnostics or treatment as impeding factor. 
{IV} Organization-related barriers 
Patients pointed out waiting times as a barrier, with hospital appointments not planned 
on one day (50%) being the most common issue. Professionals mentioned the lack of 
compulsory training days for NHL care (32%) and the absence of a specialized oncology 
nurse (24%) as a barrier. The latter one was also mentioned frequently during the 
interviews. 
{V) Social-related barriers 
Barriers perceived by patients included items on teamwork and guidance & support; for 
example, the lack of help offered after breaking bad news (39%). Professionals pointed 
out barriers concerning structural multidisciplinary team consultations (MTCs). Especially, 
the lack of participation of all involved disciplines in the MTCs {56%} was seen as a barrier. 
They agreed that the involvement of all disciplines concerning NHL care in MTCs would 
improve NHL care (64%). 
Differences in perceived barriers between the disciplines involved 
Significant differences {P<0.05) in perceived barriers between the four disciplines involved 
in NHL care are found (see Table 3). Pathologists more often perceived barriers according 
to accessibility of the guideline, {57%) its use (52%), and clarity of a local protocol {63%) 
compared to other disciplines; radiation oncologists perceived these barriers in only 14%, 
14% and 0%, correspondingly. Regarding standardized forms, haemato-oncologists less 
often perceived barriers concerning standardized pathology forms (42%) than pathologists 
(84%) and 21% of the haemato-oncologists perceived the lack of integrated forms as a 
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barrier compared to 48% of the radiologists/nuclear medicine physicians. In the 
organizational context, standardized patient information about NHL seems less often 
available for radiation oncologists than haemato-oncologists (classified as barrier in 50% 
versus 15%) and the absence of compulsory training days for NHL was most rated as 
barrier by radiation oncologists {71%). 
Table 2a. Most important perceived barriers that influence NHL care according to patients 
Perceived barriers per domain I Number of 
1 patients • 
.1) Guideline N % 
tnt PTofessionafs 
Patient communication/information 
In my hospital, professionals do not ... 
... provide written information about diagnostics and/or therapy 
... provide information about patient associations 
Emphatic contact 
In my hospital, most professionals do not ... 
... listen carefully to their patient 
... show personal interest in their patient 
... show attention for emotions and coping of the patients' relatives 
_.Patients 
In my hospital.. . 
... patients may not always participate in decision making 
Ctvl Orpnbational ecmtmtt 
Waiting times 
In my hospital. .. 
... time between referral and first diagnostics was >10 weekdays 
... time between first diagnostics and final diagnosis was >15 weekdays 
... treatment could not be started as soon as possible after diagnosis 
... hospital appointments for diagnostics/therapy were not planned on one day 
... my own professional is not available in case of urgent problems 
M Social conteJtt 
Teamwork and personalized care 
In my hospital. .. 
... professionals are not informed about agreements made with other professionals 
... there is no central contact person for making appointments 
... patients often see different professionals for diagnostics and treatment 
Guidance and support 
In my hospital... 
... no help was offered for dealing with emotions and practical problems 
... no psychological help was offered after breaking bad news 
N 
5 
10 
4 
7 
8 
N 
3 
14 
5 
9 
8 
13 
4 
' N 
4 
5 
4 
8 
9 
22 
44 
16 
28 
35 
% 
13 
" 
19 
35 
31 
so 
15 
" 
17 
22 
17 
35 
39 
• Not all questions were answered by all patients. Therefore the results do not always relate to the 
total study population (N=28}. 
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Table 2b. Most important perceived barriers that influence NHL care according to professionals 
Perceived barriers per domain I Number of 
! professional!!~' 
{t) Guideline i N % 
The NHL guideline ... 
... is not really known to me 
... is not easily accessible for me 
... is not extensively read by me 
... is not used as a reference 
... does not give enough room for including patient preferences 
... is not clear enough for my profession 
... is not up-to-date for my profession 
... is hard to update because of lack of consensus 
... should be updated 
... should be available online 
A local NHL protocol ... 
... is not available at our hospital 
... is not clear enough for my profession 
... is not up-to-date for my profession 
... should be available online 
... is not necessary because we use protocols of other hospitals 
flit Pt ofessionals 
Working according to the NHL guideline/protocol 
In our hospital.. . 
... the IPI score is not routinely calculated for NHL 
... indicator lesions are not routinely measured 
... the Cheson response criteria are not routinely used 
Standardized forms 
In our hospital no standardized forms ... 
... for pathology requests are available 
... for pathology reports are available 
... for radiology/nuclear medicine requests are available 
... for radiology/nuclear medicine reports are available 
... no integrated reports are accomplished for radiology and nuclear medicine 
tJV) Oap:nilati amd eonteKt 
Materials and facilities 
In our hospital.. . 
... no standard NHL patient information is available 
... no standard procedure for after care is available 
... no compulsory training days for NHL care are established 
... no specialized oncology nurse is present 
Waiting times 
In our hospital.. . 
... diagnostics can usually not be done in 15 weekdays 
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27 
35 
35 
46 
18 
35 
71 
34 
72 
91 
52 
9 
13 
35 
29 
N 
6 
14 
22 
41 
32 
39 
43 
20 
N 
l4 
13 
9 
34 
15 
9 
24 
32 
32 
42 
16 
32 
66 
31 
66 
83 
47 
15 
22 
63 
58 
" 
15 
21 
40 
70 
56 
59 
65 
32 
22 
15 
32 
24 
16 
Table 2b. Continued. 
Perceived barriers per domain Number of 
---"-- ---- - - --------""""'---------+-'-professionals" 
(V) Social context N % 
Multidisciplinary team consultations ... 
... do not include all professions involved 53 56 
... with all professions involved would improve NHL care 52 64 
• Not all questions are applicable to all five professions or are answered by a I professionals. 
Therefore the results do not always relate to the total study population (N=132). 
b Based on multiple choice questions where more than one answer could be checked . 
Items in Italics are perceived as facilitators 
Discussion 
This is the first study to identify barriers for delivering good quality of care to NHL 
patients. The interviews and survey showed considerable differences in focus between 
patients and professionals involved in NHL care. Patients pointed out more barriers 
regarding patient communication, guidance and waiting t imes, whereas professionals 
focused on guideline related barriers and standardization of forms and procedures. 
Among the professionals from the four disciplines involved in NHL care significant 
differences were encountered in lack of guideline use, standardized forms, patient 
information and compulsory training days. 
In this study, an important barrier pointed out by patients was the need for clear 
information from professionais. Studies in other areas of healthcare have a·iso pointed out 
the lack of information provided by professionals.18' 19 However, the ability of patients to 
recall the information provided might not always be optimal as well.20 Next to good 
communication, emphatic contact is often put forward when experienced care is 
·evaluated . Our results and those of other studies21' 22 show that these two topics are 
important issues of concern for patients. Professionals, on the other hand, did not pay 
special attention to barriers regarding information provision and communication to 
patients. Research shows, however, that emphatic communication can influence patient 
satisfaction, quality of life and even medical outcome. 23' 24 
Interestingly, a barrier frequently mentioned by professionals concerned the lack of an up-
to-date guideline. In general, clinical guidelines aim to promote evidence-based practice 
and improve patient outcomes.25 It is hence necessary to update guidelines on a regular 
basis. The Dutch NHL guideline6 was developed in 2004 and has not been updated since. 
However, several web-based protocols were initiated26 and international evidence-based 
guidelines are available online.5' 7 The use of such protocols is associated with better 
patient outcomes.27' 28 We therefore believe that the implementation of an updated 
national NHL guideline could help to reduce perceived barriers and may result in improved 
quality of NHL care. 
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In several cancer studies guideline adherence was associated with better overall survival 
or progression-free survival.29'30 Our study showed several barriers resulting from not 
working according to guidelines, for example lack of assessing the Cheson therapy 
response criteria (Table 2b). Recently, a national imaging working group developed 
recommendations for the standardization of PET-CT scan requests and reports.31 Another 
important barrier is the lack of well organized MTCs. Guidelines for optimal functioning of 
MTCs have recently been formulated. 32 The dissemination of these recommendations is 
definitely an important step towards improved care. 
With regard to the strengths of this study, a unique setting was created to obtain a broad 
overview of perceived barriers in current NHL care. First of all, professionals of all 
disciplines involved in NHL care were approached to participate in our study. This gave us 
the opportunity to compare barriers perceived between the four disciplines involved. Our 
results indicate differences in perceived barriers among professionals involved in NHL 
care, which is valuable for subsequent research. 
Second, we incorporated the patients' perspective in the study. The inclusion of NHL 
patients in our study is in line with the increasingly important role of patients in managing 
their own hospital care. This study clearly shows the added value of incorporating 
patients' point of view: barriers concerning patient communication and information 
provision were not experienced by professionals, whereas this was a main concern for 
patients. To our knowledge, this is the first study that looks at such a wide-ranging study 
population, including patients as well as professionals from all disciplines involved. 
Third.. identification of the barriers perceived was based on both qualitative and 
quantitative research. Interviews were used to qualitatively explore barriers perceived by 
patients and professionals, after which these results were quantified in a survey. This 
thorough overview is not only applicable on a national level, but might also be valuable 
internationally since recommendations on NHL care in the Dutch guidelines and protocols 
largely conform to international guidelines.4-7' 26 
There are also some limitations in this study that should be addressed. First, we were not 
able to calculate the survey participation rates. LVN and the Dutch Societies do not 
provide home addresses of patients or professionals for study purposes and there is no 
registration for professionals specialized in NHL care. Based on these restrictions, we do 
believe the best possible way to approach participants was utilized. 
Second, the recruitment method used is possibly also responsible for the relatively low 
number of responses and could have introduced underreporting. We think that highly 
motivated persons might participate more often in research than less motivated/involved 
ones. For example, the percentage of professionals that does not really know the NHL 
guideline might be even lower in the non-responder group. Another possible explanation 
for the low number of responses might be that NHL patients are often older patients who 
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may not be familiar with the Internet. Our responders, however, represented NHL 
patients and professionals of all age groups and our total study population was diverse. 
Third, the surveys applied were not validated before use. However, to ensure that they 
truly represent the complete spectrum of NHL care, the surveys were based on the 
barriers identified in the prior interviews. In addition to this, the patient survey was 
deduced from the standardized CQI questionnaire for cancer patients. For this reason 4 
answer possibilities were used in the patient survey, instead of the frequently used 5-
point Likert scale. To the best of our knowledge, no validated questionnaires were 
available that could have been used in our study. 
In conclusion, this study gives a broad overview of barriers that influence NHL practiCe, as 
perceived by patients and professionals. Barriers most mentioned by patients were lack of 
guidance & support, long waiting times and lack of clear communication and emphatic 
contact. Professionals most often stated lack of an up-to-date, online NHL guideline, lack 
of standardized forms for diagnostics and the absence of MTCs with all professionals 
involved. Among the four disciplines involved in NHL care significant differences were 
encountered in guideline use and the lack of standardized forms, patient information and 
compulsory training days. Together with the gaps found in quality of care by Wennekes et 
a/., 12 our results form a solid basis to develop a tailored implementation strategy to 
increase the quality of NHL care and to test this strategy on effectiveness and costs. 
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en Table 3. Differences in perceived barriers between professionals of the disciplines involved in NHL care en 
Perceived barriers per domain Hemato- Pathologists Radiologist$/ Radiation P-value 
oncologists nvclear med. oncologists 
physicians 
(I) GuldeUne N 
" 
N % N 
" 
N 
" The NHL guideline ... 
... is not easily accessible for me 11 24 12 57 10 33 2 14 0.02 
... is not extensively read by me 9 20 11 52 13 43 2 14 0.01 
... is not up-to-date for my profession 34 74 7 35 22 73 9 64 0.01 
... should be updated 32 71 10 50 17 57 13 93 0.04 
A local NHL protocol... 
... is not clear enough for my profession ! 3 13 5 63 1 7 0 0 0.00 
flO Professionals 
Standardized forms 
In our hospital ... 
... no standardized forms for pathology reports are available 16 42 16 84 n.a. n.a. n.a. n.a . 0.00 
... no integrated reports are accomplished for radiology and 8 21 n.a. n.a. 12 48 n.a. n.a. 0.03 
nuclear medicine 
(IV) Organizational context 
Materials and facilities 
In our hospital... 
... no 1standard NHL patient information is available 7 15 n.a. n.a. n.a. n.a. 6 50 i 0.01 
... no compulsory training days for NHL care are established 11 23 5 26 8 31 10 71 I o.o1 
n.a. not applicable to this profession 
en 
-...J 
51. Most important perceived barriers that influence daily NHL care according to patients and professionals (based on the interviews) 
Characteristics per domain: 
Guideline (I) Professionals (II) Patients (Ill) Organizational context (IV) Social context (V) 
(tot.al N•B) (t:()ta1N:o2~)_ _ ___ itgt(!!M::0_~··-- ( tmali\1=15) _(total N=S) 
• Content • Experience & knowledge - Patients want to • Materials & facilities • Communication 
- No up-to-date evidence - Non-specialized professionals postpone diagnostics or - No access to PET-scan in - Lack of communication 
included treat NHL patients therapy" own hospital• between different 
- No unambiguous - Non-centralized hospital care - Lack of national professions• 
recommendat ions about the - Lack of ins ight in other - Patients indicate no need registration and - Working as an individual, 
use of PET /CT-scans professions for extra care or after information system not as a team 
- Lack of separate chapters for - Lack of competence care {programs) 
each profession 
• Availability 
- Poor availability as book 
- No online version accessible 
• Development 
- Time-consuming process 
- Information available 
th rough conferences and 
local protocols 
- Lack of support 
o Working accord ing to protocol 
- Lack of time 
- Lack of constant quality in 
reporting 
• Patient communication 
- Not always capable of 
providing clear information 
- Possible side effects are not 
always mentioned 
• Emphatic contact 
- Difficulties in paying attention 
to feelings of patients and 
Relatives 
Organizational context (IV) 
• Finance 
- Diagnostics are 
Expensive 
• Specialized oncology 
Nurse 
- Lack of time for patients due to - No specialized nurse 
high work load Available 
a Mentioned by both patients and professionals. 
Items in Italics are mentioned by patients only; remaining items are mentioned by professiona ls only. 
• Waiting times 
- Shortage of professionals• 
- Lack of capacity concerning 
materials and facilities 
- Additional diagnostics cost 
a lot of time (revision, 
referral or non-standard 
pathology) 
o Logistics 
- Limited availability of beds 
for NHL patients 
- Lack of standardized 
application forms and 
reports 
- Absence of specified 
protocols 
• Structural multidisciplinary 
team consultations 
- Not all involved 
professions are 
participating 
- Logistic limitations 
- Not clear which patients 
should be discussed 
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Chapter 5 
Development and evaluation of an educational 
e-tool to help patients with non-Hodgkin's 
lymphoma manage their personal care pathway 
J.J.C. Stienen, P.B. Ottevanger, L. Wennekes, H.M. Dekker, 
R.W.M. van der Maazen, C.M.P.W. Mandigers, J.H.J.M. van Krieken, 
N.M.A. Blijlevens, R.P.M.G. Hermens. 
JMIR Research Protocols 2015; 4(1):e6. 
Abstract 
Background: An overload of health-related information is available for patients on 
numerous websites, guidelines and information leaflets. However, the increasing need for 
personalized health-related information is currently unmet. 
Objective: This study evaluates an educational e-tool for patients with non-Hodgkin's 
lymphoma (NHL) designed to meet the needs on personalized and complete health-
related information provision. The e-tool aims to help NHL patients in managing and 
understanding their personal care pathway, by providing patients insight in their own care 
pathway, the possibility to keep a diary and structured health-related information. 
Methods: Together with a multidisciplinary NHL expert panel, we developed an e-tool 
consisting of two sections: 1) a personal section for patients' own care pathway and their 
experiences, and 2) an informative section including information on NHL. We developed 
an ideal NHL care pathway based on the available (inter)national guidelines. The ideal care 
pathway, including dates of first consultation, diagnosis and therapy start, was used to set 
up the personal care pathway. The informative section was developed in collaboration 
with patient association Hematon. 
Fourteen patients and six laymen were asked to evaluate the e-tool. The 24-item 
questionnaire used, discussed issues concerning lay-out (6), user convenience (3), menu 
clarity (3), information clarity (5), and general impression (7). In addition, the panel 
members were asked to give their feedback by e-mail. 
Results: A comprehensive overview of diagnostics, treatments and after-care can be 
established by patients completing the questions of the personal section. The informative 
section consisted of NHL information, regarding NHL in general, diagnostics, therapy, 
after-care and waiting times. 
Six patients and 6 laymen completed the questionnaire. Overall, the feedback was 
positive, with at least 75% satisfaction on each feedback item. Important strengths 
mentioned were the use of a low health literacy level, the opportunity to document the 
personal care pathway and experiences and the clear overview of the information 
provided. The added value of the e-tool in general was pointed out as very useful for 
preparing the consultation with your doctor and for providing all information on one 
website including the opportunity for a personalized care pathway and diary. The majority 
of the revisions concerned wording and clearness. In addition, more explicit information 
on immunotherapy, experimental therapy and psychosocial support was added. 
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Conclusions: We have developed a personal care management e-tool for NHL patients. 
This tool contains a unique way to help patients manage their personal care pathway and 
give them insight in their NHL by providing health-related information and a personal 
diary. This evaluation showed that our e-tool meets patients' needs concerning 
personalized health-related information, which might serve as a good example for other 
oncologic diseases. Future research should be on the possible impact of the e-tool on 
doctor-patient communication during consultations. 
Keywords: e-Health, personalized care, non-Hodgkin's lymphoma, patient education, care 
pathway, consumer health information, empowerment, personal care management. 
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Introduction 
Overview 
In the current digital era, patients are overloaded with health-related information. Many 
patient associations, health care institutes, hospitals, scientific societies, and guideline 
working groups provide their own information through websites and flyers. Unfortunately, 
the increasing call for personalized health-related information is still unmet.1-3 On the one 
hand, this information need includes tools that provide support during interaction with 
caregivers, such as question sheets, decision aids, and option grids.4-6 These tools aim at 
providing information about available (treatment) options and possible risks to make a 
well-informed decision. Decision aids, for example, are shown to be effective with regard 
to improvement of patients' involvement and health-related knowledge.7 
On the other hand, patients ask for more insight into their personal care pathway, 
including diagnostics, therapy, and aftercare, 8 which makes it easier to act as managers of 
their own care. This also points to personalized care, which can be defined as the delivery 
of care that is tailored to an individual patient. Important elements are 1) the delivery of 
care that is responsive to individual preferences, needs, values, and possibilities, and 2) as 
much as possible, patients' engagement in their own care and health. The latter point 
needs a well-informed patient, who has insight into his personal care pathway. In the 
literature, roadmaps or care pathways concerning patient care are mostly directed to 
professionals.9'10 However, making these available for patients could help them in their 
personal care management. 
In addition, reliable health-related information is particularly important for patients, 
where the Internet is an information source of growing importance. A national survey in 
the United States showed that 59% of adults searched online for health-related 
information in 2012.11 In European countries, over 80% of adults used the Internet as the 
main source for health-related information in 2011 and 2012.12' 13 Several quality criteria 
have been developed worldwide to monitor the quality of easily accessible health-related 
information on the lnternet.14 The best-known quality criteria are found in the Health on 
the Net Code of Conduct (HONcode) for websites. 15 Previous research showed that it 
remains difficult to accurately monitor all information posted on the Internet, for example 
online information concerning cancer and other disease-related topics is still of poor 
quality.16-21 
For non-Hodgkin's lymphoma (NHL), a heterogeneous group of over 40 types of malignant 
lymphomas, an abundance of health-related information is available online. Previous 
research showed that patients diagnosed with NHL would like to have access to more 
complete and personalized information on diagnostics, therapy and aftercare.2 In 
response to this, we developed a unique e-tool for NHL patients. This study is, to our 
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knowledge, the first description on the development and evaluation of a personalized care 
pathway for NHL patients that is also linked to the available health-related information 
concerning NHL. 
Aim and objectives 
This paper describes the development and evaluation of a unique, educational e-tool for 
NHL patients, aiming to help patients manage and understand their personal NHL care 
pathway. This is done by providing insight into their personal care pathway based on the 
data patients enter and by providing essential information about NHL care. Additionally, 
patients are given the possibility to register personal experiences in their care pathway, as 
they would in a diary. We hypothesize that having access to all the information available in 
thee-tool, patients will have a better understanding of their disease and will be able to act 
as managers of their own care pathways during interaction with their caregivers. 
Methods 
Setting 
The e-tool described in this paper was developed in the context of the PEARL study, aimed 
at improving hospital care for patients diagnosed with NHL.22 In a previous study, insight 
into current NHL care was acquired by measuring quality indicators at the patient level.23 
Together with the barriers and facilitators found, as perceived by patients and 
professionals/ a tailored improvement strategy was developed. Next to several 
professional-directed tools, an e-tool for patients was included in the tailored strategy. 
This paper describes the development and evaluation of an e-tool for NHL patients. 
E-tool development 
Overview 
We started with the development of a mock-up storyboard, and with the help of a system 
developer this was converted into a distinctive e-tool for NHL patients, tailored to address 
the patients' barriers found in previous research. 2 The barriers included lack of insight into 
the patients' personal care pathway and lack of written information about diagnostics and 
therapy. This is why the e-tool developed consists of two sections: 1) a personal section 
for patients' own NHL care pathway (roadmap) and their experiences with NHL care, and 
2) an informative section including information on NHL. The complete e-tool aims to help 
patients manage the care they receive during their NHL care trajectory. The webmaster of 
the Dutch Lymphoma Patient Association (Hematon, known as LVN before 2014) and an 
expert panel, including a hematologist, radiologist, pathologist, radiation oncologist, 
epidemiologist, and a senior researcher, were closely involved in the e-tool development. 
Quality criteria from the HONcode were taken into account during the development 
process. 
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Personal section of the e-tool 
In this section, users were able to document dates and experiences of first consultation, 
diagnostics, and therapy. The aim was to provide insight into the patients' personal care 
pathway. We developed a general (ideal) NHL care pathway based on the national 
guidelines and recommendations available in the Netherlands. These included, among 
others, the Dutch NHL guidelines, recommendations of the Cooperative Trial Group for 
Hematology Oncology (HOVON) and the Dutch Society of Hematology (NVvH), general 
recommendations for acceptable waiting times, and an NHL guideline based on patients' 
perspectives of Hematon. Internationally available guidelines were consulted when 
applicable. The ideal care pathway, including date of first consultation, date of diagnosis, 
and start date of therapy, was used to set up the format for the personal care pathway 
(roadmap). 
Informative section of the e-too/ 
Users had access to reliable information on NHL and NHL care through this section of the 
e-tool. The aim was to cluster all reliable, online available information and make it 
understandable for all users. Too much or confusing information and a high health-literacy 
level were avoided as much as possible. The Dutch NHL guidelines, NVvH, HOVON, the 
Dutch Cancer Society (KWF), and several NHL-related websites (e.g. Radiotherapie 
Nederland, Chemo and nu, Hematon, and Hematologie Groningen) were used as sources 
of NHL information for the content. These sources are frequently recommended and used 
by professionals, so the content can be considered as authorized by them. We cooperated 
with the webmaster of Hematon to make sure that the information included was 
complete and accurate. The format of the e-tool was based on the NHL care pathway as 
described in the guidelines and on user experiences with other websites. 
E-tool evaluation 
After evaluation of the concept of the text by the expert panel, an external hematologist, 
and the webmaster of Hematon, an assessment was set up to evaluate both sections of 
our e-tool concerning applicability. We recruited NHL patients via Hematon and a 
university hospital in the Netherlands. Patients were eligible when they had, or have had, 
a non-Hodgkin's lymphoma, were over 18 years old, and had access to the Internet. Family 
and friends of 3 members of the project team were asked to participate as laymen. Thee-
tool was evaluated by patients and laymen using a 24-item questionnaire: 19 yes/no 
questions, including space for reasoning, and 5 open-ended questions, including 
improvement suggestions. The questionnaire included questions on layout (6 questions), 
user convenience {3 questions), menu clarity {3 questions), information clarity (5 
questions), and general impression (7 questions), for example, strengths and missing 
information. This method allowed us to obtain as much information as possible to 
76 
improve our e-tool. The expert panel was invited by email to give general feedback on the 
e-tool. 
Results 
E-tool development 
Overview 
We developed an e-tool, consisting of two sections: a personal section and an informative 
section. The content of the sections will be described below, followed by the results of the 
evaluation of the e-tool applicability. The e-tool is available in Dutch 24 for participants of 
the PEARL study and will become publicly available in 2015. The e-tool started with a 
general introduction, which described the aim of the e-tool and gave a short overview of 
the personal and informative sections of the e-tool. Both sections were formatted in 
chronological order (diagnostics, therapy, aftercare), which is in line with the NHL care 
pathway as described in the guidelines and seen in clinical practice. Additionally, 
background information was available concerning the PEARL study, participating hospitals, 
and contact information. 
Personal section of the e-too/ 
This section consisted of questions concerning a patient's personal NHL care pathway, 
which allowed patients to develop a unique overview of all diagnostics, treatments, and 
aftercare/follow-up that they have had. Questions were divided into four items: 
1. Diagnostic examinations, including items such as type and date of the examination, 
executed by whom, and in which hospital. 
2. Diagnosis, including date of first consultation, date of diagnosis, type of NHL, stage of 
the disease, risk profile, date of treatment plan, hospital name, and professional 
name. 
3. Therapy, including type and date of therapy, executed by whom, and in which 
hospital. 
4. Aftercare, including items such as type and date of aftercare, executed by whom, and 
contact information. 
An easy link from the personal section to the informative section was provided next to 
each item. In this way, patients could look up the underlying information belonging to the 
different items. Additionally, it was possible to create a diary, to document their own 
experiences with the different diagnostic examinations or treatments. Information filled 
out in this diary was only visible to the patients themselves. Finally, an overview of the 
personal NHL care pathway was obtained using the answers to the questions. 
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The personal diary, chronologically visualized experiences with NHL care, was provided 
when applicable. An example of the personal NHL care pathway (roadmap) is shown in 
Figure 1. 
.. 
Non"Hodgkin's lymphoma 
Care pathvvay in the hospital 
My pathway 
Ideal 
pathway 
11·08 14·08 15·08 
11·08 
I 
I ~"I} 
St 
I , 
C'ol,l 
'Svt. t<~tt: 
of) 
30·08 04·09 
I I 
31-08 
Radboud urnc Losou• 
Welcome Jozette 
About lhe re-s.e.t~rc.h 
Go to: 
27-G9 
Figure 1. Example of a personal NHL care pathway (personal section e-tool), original in Dutch 
Informative section of the e-too/ 
This section consisted of NHL information from reliable online sources, divided into six 
information items: 
1. NHL in general, including a description of what NHL is, symptoms, and most occurring 
NHLs. 
2. Diagnostic examinations, including items such as blood sample, tissue biopsy, bone 
marrow biopsy/aspirate, PET/CT-scan, and additional examinations. 
3. Diagnosis, including stage, international prognostic index (IPI) score, treatment plan, 
and additional support. 
4. Therapy, including wait-and-see, radiotherapy, chemotherapy, immune therapy, 
stem cell transplantation, and clinical trials. 
5. Aftercare, including response evaluation and monitoring. 
6. Waiting times. 
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External links for more extensive information were added as much as possible, together 
with short educational movies created by KWF or Hematon. An example of the 
informative section is shown in Figure 2. 
~' Non·+lodgkin 's lymphoma 
Care pathway 1n the hospital 
Radboud umc L<>~•"t 
Welcome Jozette 
About the rl's.earch 
Tr€'atment~ Go to: 
On thls page, you can find more information about different types of treatment 
Wait~and-see 
• Radiation therapy 
Radiation therapy is a treatment Where radlatlon Is proj('Cted at the tumor location. This wilt damage the cells at this specific 
location. Not only cancer cells, but also healthy celts wilt he impaired. The impairment wHI slow down cancer cell growth or ewn 
stop it completely. Healthy cells have a mayor advantage< th('y Me better able to rrn::over from this damage than cancer celts 
Common side·effects of radiation therapy are: 
·Fatigue 
• Skin problems (e.g. red skin) 
• In case of radiation of the neck: dry mouth, decreased taste and smell ability 
• In case of radiat1on of the abdomen: nausea, diarrhea 
• In case of radiation around the sexual organs: decreased fertility 
• In case of radiation of the hair/scalp: hair loss 
How radiation therapy exactty works is shown in the short movie below (source: w~,k.wf~ankerbestrljdin~.n_l) 
Figure 2. Example of informative section e-tool, original in Dutch 
E-tool evaluation 
We asked 20 people to participate in our test, including 14 NHL patients and 6 laymen. In 
total, 13 people logged in and 12 returned the questionnaire, which resulted in a 60% 
(12/20) response rate. Little feedback was given by 1 participant by email and he did not 
return the questionnaire. The mean age of the 12 participants (patients and laymen) that 
completed the questionnaire was 56 years (SD 11), with a range of 30-70 years. Of the 
participants, 42% (5/12) were female and 67% (8/12) had a high education level (college 
or university). Additionally, all 6 panel members and the external hematologist provided 
general feedback by email. 
Table 1 includes the results of our e-tool evaluation (applicability) using closed questions 
among NHL patients and laymen. Overall, the evaluation of the e-tool was highly positive. 
Table 1 shows at least 75% (9/12) satisfaction on each section. Concerning layout, all 
responders were satisfied with the clarity of the text, writing style, and clarity of the 
illustrations and short videos. When looking at the user convenience, 11 out of 12 
participants (92%) were satisfied with the format and speed of the e-tool. In relation to 
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menu clarity, all participants found the menu format intuitive and the information needed 
was easy to find. Information clarity, including understandability of the text, was 
evaluated positively as well. Only 2 out of 12 participants (17%) thought too much medical 
terminology was included. 
Table 1. Results of thee-tool evaluation among NHL patients and laymen (closed questions). 
Question Positive response, N (%) 
Layout 
Is the text clear? 
Are you satisfied with letter type and size? 
Are you satisfied with the writing style? 
Is the use of colors attractive to you? 
Are there enough illustrations and short videos to support the text? 
Are the illustrations and short videos clear? 
User convenience 
Is thee-tool easy to use? 
Is the format of the e-tool easy to understand? 
Are you satisfied with the speed of thee-tool? 
Menu clarity 
Does the composition of the menu seem natural? 
Are you satisfied with the navigation through the e-tool? 
Is it easy to find the information you are looking for? 
Information clarity 
Is the information provided on thee-tool understandable? 
Does thee-tool make use of too much medical terminology?" 
Do you understand what NHL is, after reading the information 
provided on thee-tool? 
Do you understand what treatment options are available, after 
reading thee-tool? 
General impression 
Are there any flaws/errors in this e-tool?" 
Would you use this e-tool if made available to you? 
Are there any redundant items in this e-tool?" 
Patients 
I (N=6) 
6 (100) 
3 (50) 
6 (100) 
4 (67) 
5 (83) 
6 (100) 
. 4 {67) 
5 (83) 
6 {100) 
6 (100) 
5 (83) 
6 (100) 
6 (100) 
4 (67) 
6(100) 
6 (100) 
5 (83) 
5 (83) 
6 (100) 
• Percentage of negative responses presented, caused by negative questioning. 
Laymen 
(N=6) 
6 (100) 
6 (100) 
6 (100) 
5 (83) 
5 (83) 
6 (100) 
5 {83) 
6 (100) 
6 (100) 
6 (100) 
5 (83) 
6 (100) 
6 (100) 
6 (100) 
6 {100) 
6 (100) 
5 (83) 
6 (100) 
6 (100) 
Table 2 includes the results of our e-tool evaluation using open-ended questions, and 
shows mainly positive remarks about thee-tool and some improvement points, according 
to NHL patients and laymen. Valuable strengths mentioned by the participants included 
the use of a low health-literacy level, the opportunity to document their personal care 
pathways and experiences (diary), and the clear and helpful overview of the information 
provided. The added value of thee-tool in general was pointed out as very useful for 
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preparing for 'their consultations with their doctors and for providing all information in 
one website, including the opportunity for a personalized care pathway and diary. 
Table 2. Results of thee-tool evaluation among NHL patients and laymen (open-ended questions). 
Question Response 
Information clarity 
What does this e-tool add to the 
information provided by your doctor? 
Gene«~l impression 
What are improvement points f'Of this 
e-tool? 
What are the strengths of this e-tool? 
What did you miss on this e-tool? 
General remarks? 
Makes everything much clearer and understandable. 
Makes it possible to read everything at a quiet moment. 
Provides good preparation for consultation with your doctor. 
Provides a great overview of all necessary information. 
Provides a good overview of your own care pathway. 
Thee-tool is very useful for the patients' relatives. 
Makes it possible to compare with the ideal pathway. 
More expressive color use. 
For patients that forget updat·mg their care pathway, are 
there alerts? 
Better navigation tttrough l'he care pathway. 
Clearer definition of first consult. 
Opportunity to document your personal care pathway. 
Opportunity to document your experiences in a diary. 
Possible to compare with quality criteria (ideal pathway) . 
Low health-literacy level. 
Clear and calm colors. 
Clear overview of medical information and terminology. 
Clear layout and navigation. 
External links to additional information about NHL. 
Overview of information gives the opportunity to translate 
this to yourself. 
Overview of lymph vessels. 
Information about immune therapy and clinical tria.ls. 
Information about psychosocial support. 
l.nforrnation about second opinion. 
Great overview of available NHL information. 
Other websites are fine, but this e-tool provides more 
specific information. 
I already have my own diary, which I will use in the future. 
The tool gives the opportunity to create your own care 
pathway and diary, this has a positive influence on dealing 
with the fact that you are diagnosed with NHL. 
This e-tool can contribute to an optimal doctor-patient 
contact during consultations. 
In general, the e-tool is considered to be a good initiative to help patients manage their 
NHL care. For example, one participant wrote, "I think this tool is excellent and that it will 
be helpful in dealing with the fact that you are diagnosed with NHL. The tool can 
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contribute to an optimal doctor-patient contact." There were no distinct differences in 
feedback between patients and laymen, except that patients provided more comments 
concerning missing items and general remarks. 
Improvement points proposed by the expert panel included addition of a search function 
and contact button, adding items to the personal care pathway section, suggestions for 
links to general cancer websites, and some wording issues (data not shown). 
During the review of the e-tool, all feedback was taken into account. The majority of the 
revisions concerned wording and clarity. With respect to layout, the font size regarding 
explanatory text was enlarged and the color of the submenu was made less bright. 
Regarding user convenience and menu clarity, the navigation at the bottom of each page 
was made clearer. No revisions were made concerning information clarity. In addition, 
more explicit information was included about immune therapy, experimental therapy, and 
psychosocial support. As well, items for the patients' risk profiles and stages of disease 
were added to the personal section. 
Discussion 
Principal results 
In this study, we showed the development and evaluation of a unique e-tool for, and by, 
patients with non-Hodgkin's lymphoma. Based on the evaluation, the e-tool is a feasible 
tool that gives patients insight into their personal care pathway and informs them about 
NHL. The overall positive feedback implies the e-tool's added value of providing 
personalized health information, which is often an unmet need for patients. Taken as a 
whole, this is the first e-tool in the field of oncology that aims at helping patients in their 
personal care management and provides an additional overview of information about 
NHL. 
Comparison with prior work 
Involving patients in the development of health care improvement tools has been an 
upcoming phenomenon in the past several years. Nowadays, the patient's voice is 
incorporated more often in clinical guidelines, quality indicators, and shared decision-
making instruments.8'25' 26 It is important to support patients involved in developing health 
care improvement tools. For example, a wiki has been established for, and tested by, 
patients involved in the development of a guideline on infertilit/7 The shared decision-
making instruments themselves also have a supporting role, as they try to help patients in 
making informed decisions.6' 28-30 However, not all decision aids are directed to patients31'32 
and they usually do not provide insight into the complete personal care pathway. 
Studies focusing on personalized care pathways and assistance with patients' personal 
care management are sparsely described in the literature. Most studies concerning the 
development of patient care pathways or roadmaps concentrate on the education of 
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professionals33' 34 or other health care professionals10• Ryhanen eta/. 35 and Dykes et a/. 36 
developed a tool to educate patients about their care pathway. Dykes et a/. aimed at 
providing education about the anticipated length of stay and treatment plan after acute 
myocardial infarction. Development and evaluation of a breast cancer pathway, an 
Internet-based patient education program, was described by Ryhanen et a/. In line with 
our e-tool, these studies focused on patient education concerning the patient care 
pathway. However, these studies did not include information tailored to the individual 
patient, such as a chronological overview of the personal care pathway or a diary. Atack et 
a/. 37 developed an online patient education system including health-related information 
tailored to the individual patient. Professionals were able to "prescribe" information that 
met the patient's need. However, this system was not focused on the total care pathway 
and was only pilot-tested in 8 patients. Our e-tool is the first that combines the unmet 
needs of patients, including personalized information about the patients' care pathways 
and the possibility to create a diary, together with an overview of all necessary NHL 
information. 
Limitations 
Four limitations were identified with respect to this e-tool. First, this e-tool has been 
developed for NHL patients, a patient category with a more advanced age (incidence of 
NHL increases with age) that might not be active on the Internet. However, the mean age 
of NHL patients included in this study was 61 years (SD 7), and a previous study on 
possible barriers in NHL care also showed inclusion of patients of all ages.2 Furthermore, 
health-related Internet use seems to increase over time in Europe among people of all 
38 
ages. 
Second, the questionnaire used to evaluate the e-tool was not validated, but based on 
evaluation factors derived from the human, organization and technology-fit (HOT-fit) 
framework. 39 We believe that the questionnaire developed included all necessary items to 
extensively evaluate thee-tool. 
Third, the evaluation study only assessed feasibility of the e-tool on a small scale. 
Unfortunately, no information was available about the 7 non-responders, and a relatively 
high percentage of the responders were highly educated, which could have introduced 
some bias. A next step in the implementation is to test the e-tool in daily NHL care and 
evaluate user experiences on a larger scale. This might give insight into the possibilities for 
making the e-tool appropriate on an international level and it might serve as a good 
example for other oncologic diseases. 
Finally, thee-tool is not yet certified by the HONcode. However, all eight items of the code 
of conduct for medical and health websites as described by HON were taken into account 
during the development of the e-tool.40 After testing the e-tool at a larger scale we intend 
to apply for certification. 
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Conclusions 
We have developed a personalized approach using an e-tool for NHL patients. This tool 
contains a unique way to help patients with their care management; it provides insight 
into the personal care pathway and offers general information about NHL. In this 
evaluation study, we report high satisfaction rates and some improvement points for 
future use. We expect that the e-tool will have a positive impact on both patient 
empowerment and doctor-patient communication, since patients are more informed in 
lay language about NHL and their personal care pathway. It is suggested that better-
informed patients are able to ask more specific questions, which makes it possible to 
improve the management of their personal care. Finally, this e-tool may play an important 
role in dealing with NHL, particularly the personal diary option, which has the potential to 
provide psychosocial support for personal experiences in NHL care. The usage and effects 
of the e-tool should be tested and evaluated in future research, which is included as one 
of the purposes of the PEARL study.22 
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Abstract 
Purpose: To test the feasibility and effectiveness of a multifaceted, tailored strategy 
towards improvement of guideline adherence and patient-reported outcomes and 
experiences (PROs and PREs) for non-Hodgkin's lymphoma (NHL) patients compared to a 
standard strategy in a cluster-randomized controlled trial (c-RCT). 
Methods: National NHL guideline adherence was measured by standardized quality 
indicators of optimal care in NHL patients (N=835) managed in 19 Dutch hospitals. 
Hospitals were randomly assigned to either the standard strategy of audit and feedback 
(N=10) or the tailored strategy (N=9), with in addition tools adapted to barriers perceived 
by patients and professionals of current NHL care (e.g. patient e-tool, standardized forms 
for diagnostics and NHL care pathway overview). A before- and after-measurement was 
conducted and the feasibility and effectiveness of both strategies was evaluated by 
extracting data from medical records and questionnaires, including PROs and PREs. 
Results: There was a significant improvement in guideline adherence in both study arms 
for the use of multidisciplinary team consultations (41 -> 49% standard strategy; 41 -> 64% 
tailored strategy). No superior effect on guideline adherence was found for the tailored 
strategy. In line with this, professionals evaluated the feedback report as the best tool to 
improve guideline adherence. 
PROs measuring anxiety and depression, physical well-being and general health status 
showed no differences between the two strategies. However, PREs with NHL care were 
slightly better reported in the tailored strategy. 
Conclusion: This trial demonstrates that feedback resulted in slightly improved guideline 
adherence, but the effectiveness of our tailored strategy was not superior compared to 
the standard strategy. 
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Introduction 
Several national and international clinical practice guidelines have been developed for 
NHL care. 2-6 These clinical practice guidelines aim to summarize recent scientific evidence 
gathered with expert consensus regarding desirable and optimal NHL care. Guidelines 
assist professionals and patients in their decision-making process7 and standardize care, as 
the complexity of diagnosis and treatment of non-Hodgkin's lymphomas (NHLs) continues 
to increase. The current Dutch evidence-based NHL guideline for Dutch professionals 
involved in NHL care has not changed during the past years. 
Previous research showed substantial hospital variation in delivered NHL care and low 
percentages of guideline adherence8-11, indicating suboptimal dissemination and use of 
the guideline. Unfortunately, research on initiatives to improve delivering optimal NHL 
care is scarce. Studies concerning other tumor types showed varying effects of commonly 
used improvement strategies, such as audit and feedback, educational materials and 
reminders. Which strategy, single or multifaceted, accomplishes the most effect regarding 
improvement of guideline adherence and quality of care is not clear. 12-15 However, it is 
generally believed that strategies tailored to current care and the barriers perceived in 
daily practice are generally the most effective.16 We therefore investigated the current 
NHL guideline adherence on patient level and its determinants. 
The barriers for optimal guideline adherence, experienced in daily NHL practice, were 
identified among professionals and patients by conducting interviews and 
questionnaires.17 An improvement strategy tailored to the barriers found and directed at 
both patients and professionals was developed and tested in a randomized clustered trial. 
The objective of the cluster-randomized controlled trial (c-RCT) was to study the feasibility 
and effectiveness of a tailored strategy compared to a standard strategy on NHL guideline 
adherence. We hypothesized that a multifaceted strategy, tailored to the barriers 
perceived and directed to both patients and professionals (tailored strategy), would be 
more effective than a strategy of audit and feedback alone (standard strategy). In 
addition, to get insight into the feasibility of both strategies, the exposure to and 
experiences with the different elements of both strategies were evaluated. 
Methods 
Study design 
A cluster-randomized controlled trial (c-RCT) to perform an effect- and process-evaluation 
on the improvement tools developed to increase guideline adherence. The research ethics 
committee (CMO) of the Radboud university medical center, declared the used study 
protocol18 in accordance with the applicable rules concerning the review of research 
ethics committees and informed consent (registration number 2011/560).Consent of the 
patients for this specific study was not applicable; according to the Dutch law all cancer 
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patients are included in the Netherlands Cancer Registry as maintained by IKNL, unless the 
patient has objected to be registered. The trial is registered with ClinicaiTrial.gov 
(ID.NCT01562509). 
Participants 
Hospitals 
Nineteen Dutch hospitals agreed to participate in this c-RCT, including one university, nine 
teaching, and nine general hospitals. The c-RCT was performed across three regions of the 
Netherlands: nine northern, five eastern, and five southern hospitals. 
Patients 
Newly diagnosed NHL patients were retrospectively selected for data collection regarding 
guideline adherence and quality of care. The Netherlands Cancer Registry (NCR) was used 
to identify potentially eligible patients. For each hospital, a random sample of 25-30 
patients with a mature B-, T- or NK-cell neoplasm was selected for inclusion. Patients 
diagnosed with cutaneous or leukemia-type neoplasms were excluded, as well as patients 
younger than 18 years old. For the before-measurement, patients diagnosed between 1 
October 2010 and 31 December 2011 were included. For the after-measurement and 
process evaluation, patients were eligible if they were diagnosed between 1 November 
2012 and 31 January 2014. 
Randomization 
The hospitals were randomized (based on randomly computer-generated and allocated 
numbers) to avoid contamination of both improvement strategies. After formal consent of 
all hospital representatives, ten centers received the standard strategy and nine centers 
received the tailored strategy. Prior to randomization, the hospitals were stratified 
according to hospital size (small, medium and large). Professionals were not blinded to 
group assignment and received insight into the content of either the standard or tailored 
strategy. 
Improvement strategies 
Standard strategy 
The standard strategy included audit and feedback to the participating hospitals. Audit 
was performed by assessing the baseline guideline adherence using patient records and 
data of the NCR. Feedback was given to all hospitals regarding provided care by means of 
previously validated quality indicators. 11 These indicators for optimal NHL care were 
developed and updated on the basis of evidence-based (inter)national guidelines and 
recommendations, literature and expert-consensus about NHL care. 
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Hospital specific feedback reports were developed and sent once by email to the hospital 
representatives. Feedback was given for each quality indicator (N=20) using a high-low 
chart ranging from 0 to 100% adherence. 
Tailored strategy 
In addition to the audit and feedback report, the tailored strategy included several other 
improvement tools tailored to the current care and the barriers found. The tools were 
directed to patients and professionals (i.e. hematologists/oncologists, pathologists, 
radiation oncologists, radiologists and nuclear physicians), as described in Box 1. The most 
important barrier for patients was lack of patient information and guidance, which was 
used in the development of the patient-directed e-tool (F). Most mentioned barriers by 
professionals included lack of standardized forms for diagnostics, of multidisciplinary team 
consultations (MTCs) and of an up-to-date guideline. These items were depicted in 
professional-directed tools (A-E). 
Outcomes 
Effect evaluation 
The effectiveness of both strategies was measured by means of adherence to the 
previously developed quality indicator set containing 20 indicators for all domains of NHL 
care, including 'diagnostics and staging', 'treatment and follow-up' and 'organization and 
coordination of care'.n In addition, patient-reported outcomes (PROs) and experiences 
with care (PREs) were measured by questionnaires. 
Process evaluation 
The feasibility of both strategies of the c-RCT was investigated to provide insight into the 
processes. The actual exposure to the improvement tools and the experiences of the 
patients and professionals were measured with questionnaires and user data of the e-
tool. 
Data collection 
Regarding patient characteristics and quality indicators, trained registration employees of 
the Netherlands Comprehensive Cancer Organisation {IKNL) collected data from medical 
records, particularly on demographics and tumor-specifics, and quality data about 
diagnosis, treatment of NHL and organization of care. Examples are Ann Arbor stage, 
diagnostic investigations and type of first-line treatment. Data on hospital characteristics, 
such as hospital region, were collected from publicly available information. 
Concerning PROs and PREs, all eligible patients were invited by their physician to 
participate in the study and received a questionnaire between May and September 2014, 
followed by a reminder after 3 weeks. This questionnaire included questions of the FACT-
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Box 1. Improvement tools developed for the tailored strategy 
Professiona·l-directed tools 
A. Audit and feedback meeting. 
Hospital specific performance was discussed during feedback meetings in the hospitals of the 
tailored strategy arm. All professions involved in NHL care were invited via the contact person of 
the hospitals in the tailored strategy arm. The improvement tools below were bundled in an 
improvement document and discussed during the meeting. 
B. List of standardizing options for diagnostic requests and reports. 
Specific tools, directed to all professionals involved and including items that should minimally be 
present in diagnostic requests and reports, were provided to improve documentation concerning 
pathology, radiology and nuclear medicine. For example, reporting the target lesions in number 
and size {in millimeters) in the diagnostic report of the CT scans. In this way, it is more 
straightforward to compare lesions before and after treatment. 
C. Leaflets on multidisciplinary team consultations and pathology panels. 
Multidisciplinary team consultations {MTCs) and pathology panels* were defined and their 
general roles were described to inform professionals. Additionally, a standardized report form 
for MTCs was provided to improve documentation of important NHL items, such as Ann Arbor 
staging and the International Prognostic Index (IPI-)score. 
D. One of the authors (JS) contacted the contact person(s) of each hospital by telephone and e-
mail on a regular basis stimulating them to actively apply the improvement strategy described in 
this Box. 
E. Overview of the NHL care pathway. 
To get insight into the organization of care, a generally applicable NHL care pathway was 
developed. The NHL patient flow and possible barriers, for example concerning waiting times, 
could be visualized using this overview. It also provided information on responsible persons for 
each step in the care pathway and was therefore directed to all professionals involved. 
Patient-directed tool 
F. £-tool for patients. 
An online tool directed to newly diagnosed NHL patients was developed 1 for two purposes. 
Firstly, to inform patients about NHL and accompanying diagnostics, treatment options, waiting 
times and after care. Secondly, to give patients insight into their own care pathway and the 
opportunity to register personal experiences. A folder for informed consent was disseminated to 
patients by physicians and oncology nurses. 
* Pathology panels are defined as regional expert panels of hemato-pathologists to 
improve quality of diagnostics for malignant lymphomas. Pathology panels are to be 
consulted to verify the diagnosis and will inform all pathologists in the region about new 
regulation or interesting casuistry. 
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G7 (physical well-being), HADS (anxiety and depression), EQ-SD (general health status) 
and CQI (quality of care). 
For the process evaluation, patients who consented received additional questions about 
their experiences with the e-tool, for example, about the clarity and the added value of 
this e-tool. In addition, user data of the e-tool were anonymously monitored. To evaluate 
the use of and experiences with all tools, professionals received a questionnaire in 
December 2013, followed by two monthly reminders . Questions were asked about the 
clarity of the text and figures, the relevance for daily practice and possible improvement 
points. 
Sample size 
This study was designed to detect a difference of 20% in guideline adherence between the 
two study arms (40 versus 60%), with a=O.OS (two-sided) and 80% power. This would 
require at least 194 NHL patients. However, the design effect of the clustered format 
should be taken into account as well, with an intraclass correlation coefficient (ICC) of 0.09 
(mean ICC Wennekes et a/.11 and a hospital cluster-correlation of 0.8. Considering the 
design effects of the 19 hospitals, an average of 22 patients per hospital was needed, 
bringing the total to 418 patients per measurement (before- and after-measurement). 
Data analyses 
Descriptive statistics were used to provide insight into the patient and hospital 
characteristics before and after the dissemination of the improvement strategies. Quality 
indicator scores were assessed and defined as the percent age of patients who received 
care as recommended in the guidelines. 
For the effect evaluation, the differences in indicator scores were analyzed, taking into 
account the clustering of the patients within the hospitals. Therefore, multilevel logistic 
regression analyses (random intercept model with all other variables fixed) were 
performed. Per indicator a null-model was built, including covariates for strategy 
(standard/tailored), measurement time (before/after) and its interaction term 
(strategy*measurement). Thus, it was possible to analyze the differences in indicator 
scores corrected for baseline differences between the two strategies. Reliability of the 
data collection was assessed with a duplicate registration of 30 records by two registration 
employees in three hospitals. The reliability of the indicator scores was calculated with a 
Kappa value, a statistical measure for inter-observer agreement corrected for chance.19 
The ICC was calculated for each quality indicator to get insight into the cluster effect of the 
hospitals. ICC values between 0 and 0.40 were found in other secondary care research. 20 
The PROs were calculated following the official rules and differences in PROs and PREs 
were analyzed with multilevel regression analyses, taking into account case-mix factors 
(age, gender and education level) and clustering at hospital level. Multilevel analyses were 
performed using SAS software System for Windows, V9.2 (SAS Institute Inc, Cary, NC, 
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USA). For all other analyses IBM SPSS Statistics for Windows, V20.0 (1MB Corp, Armonk, 
NY, USA) was used. 
For the process evaluation, including the exposure to and experiences with the different 
tools of the improvement strategies, descriptive statistics were performed. 
Results 
Study population 
Figure 1 presents the trial flow diagram for this study. In total, 19 Dutch hospitals were 
included and data were collected for 431 and 430 patients in the before- and after-
measurement, respectively. In total, 26 patients were not eligible for analysis, based on 
final diagnosis, receiving care mainly in another hospital or the unavailability of data, 
leaving 423 patients (431-8) in the before-measurement and 412 patients (430-18) in the 
after-measurement. 
Demographic characteristics of the study population are shown in Table 1. Most 
participants were male (range 53-61%), 38-49% was diagnosed with a diffuse large B-cell 
lymphoma (DLBCL) and the mean age ranged from 65 to 67 years. Some differences were 
seen between the two datasets: less patients with a high Charlson index (P=0.029) and 
normal lactatedehydrogenase (LD) values (P=0.021) were present in the before-
measurement. 
Effect evaluation 
Quality indicators 
Table 2 shows the quality indicator scores for the before- and after-measurement, for 
both the standard and tailored strategy, including identification of differences and taking 
into account case-mix (i.e. gender, Ann Arbor stage, tumor aggressiveness, previous 
malignancies, LD value, Charlson index and hospital region) and clustering. The indicators 
with low improvement potential (2':90%) in the before-measurement showed the same 
high adherence rates in the after-measurement, while the indicators with high 
improvement potential (<90%) showed mixed effects afterwards. 
Significant improvement between the before- and after-measurement was seen in both 
study arms for discussing patients in MTCs. No additional significant effect of the tailored 
strategy was found (delta Ql17, P=0.196), despite the increased adherence of 15%. 
Furthermore, a trend in significant improvement for the tailored strategy alone was seen 
for assessing the international prognostic index {I PI) score (QI5, P=0.069). 
The registration form was adapted after the before-measurement for three quality 
indicators (QI13, Ql14 and Ql16), since the registered data were ambiguous. Therefore, 
only the indicators scores of the after-measurement were compared for these indicators. 
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I 
I 
I 
Standard strategy 
10 hospitals 
4 small; 3 medium; 3 large 
Before-measurement 
221 patients 
After-measurement 
217 patients 
19 Hospitals 
included 
Stratification 
Randomization 
Patient inclusion 
1 October 2010-
31 December 2011 
Patient inclusion 
1 November 2012-
31 January 2014 
-----, 
Tailored strategy 
9 hospitals 
3 small; 3 medium; 3 large 
Before-measurement 
202 patients 
After-measurement 
195 patients 
'- · -- -·----· ----·-·--· ·--- ----~·-~--·-
Figure 1. Trial flow diagram: hospital randomization and included patients. 
Patient-reported outcomes and experiences 
The questionnaires concerning PROs and PREs were sent to 438 patients diagnosed with 
NHL in the 19 participating hospitals. In total, 369 patients (84%) responded, of which 326 
patients (74%} filled out the questionnaire. This included 194 patients in the standard 
strategy and 132 patients in the tailored strategy. The mean age of these patients was 65, 
62% was male and 27% was high educated. 
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No differences in PROs were found between the two strategies regarding physical well-
being, anxiety and depression and general health status. Concerning PREs, a trend was 
seen among 2 out of 19 items. Patients in the tailored strategy seemed slightly more 
positive concerning waiting time for final diagnosis (P=0.019) and talking about their 
feelings with caregivers (P=O.OS8), see Table 3. 
Table 1. Demographics of the standard and tailored strategy arm in 2011 and 2013. 
I Before-measure~t l Characteristics I After-measurement 
l ! . j Standard arm : Tailored arm t Standard arm ! Tailored arm 
I N-=202 ' f N=lSS I N=:t21 ~ IW,2l7 § I N % N .% ! 1.1/ % N % 
Gender --r-
Male 135 61 107 53 127 58 114 59 
Female 86 39 95 47 90 42 81 41 
M ean age (years, SD') 66 13 65 13 67 14 66 12 
Charlson index# :J: 
High risk 105 48 90 45 124 57 97 50 
Low risk 116 52 112 55 93 43 98 50 
rdHL type 
·DLBCL 108 49 86 43 82 38 83 43 
Follicu1ar lymphoma 42 19 36 18 49 23 42 21 
Mantle-cell lymphoma 9 4 14 7 10 5 12 6 
Marginal zone 8-celllymphoma 19 9 27 13 29 13 17 9 
Other classification 43 19 39 19 47 21 41 21 
Tumor type 
Aggressive 139 63 115 57 110 51 115 59 
Indolent 82 37 87 43 107 49 80 41 
Ann Arbor stage 
I or II 64 29 63 32 66 30 66 33 
IU or tV 143 65 125 62 139 64 125 64 
Unknown 7 3 7 3 1 1 3 2 
Not applicable 7 3 7 3 11 5 1 1 
Extra nodal disease A 
Yes 131 59 127 63 134 62 125 64 
No 90 41 74 37 83 38 68 35 
Missing 0 0 1 1 0 0 2 1 
Previcus malignancies 
No {NHL is first malignalllcy} 181 82 171 85 177 82 162 83 
Yes 40 18 31 15 40 18 33 17 
Normal LD value :J: 
Yes 128 58 92 46* 132 61 109 56 
No 77 35 94 47 62 29 71 36 
Missing 16 7 16 7 23 11 15 8 
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Table 1. Continued. 
Characteristics 
Patient's preferences 
Objections 
No objections 
Missing 
Hospital region 
North 
East 
South 
Before-measurement 
Standard arm ~Tailored 
N=221 N=202 
N % N 
15 7 10 
206 93 191 
0 0 1 
125 56 67 
47 22 66 
48 22 69 
#Weighted co-morbidity index combined with age. 
arm 
% 
5 
94 
1 
33* 
33 
34 
*Significant differences (P<0.05) between the tailored and standard arm. 
After-measuremem: 
Standard arm 1 Tailored 
N=217 I N=195 
N % N 
11 5 7 
206 95 188 
0 0 0 
117 54 63 
47 22 72 
53 24 60 
:J: Significant differences (P<0.05) between the before- and after-measurement (total). 
"This term is used if the disease is not in the lymph nodes (extra nodal) or has spread from lymph 
nodes to extra nodal sites. 
Process evaluation 
In total, 137 patients diagnosed with NHL in the tailored strategy hospitals received an 
invitation from their physician or oncology nurse to use our patient-directed improvement 
tool {e-tool). Of these patients, 72 returned the informed consent {63 signed and 9 no-
consent) and 47 patients actually used thee-tool {34% of the invited patients). 
The 63 patients who had access to the e-tool received an additional questionnaire to 
evaluate the e-tool and 33 patients filled it out {52% response). All the patients that 
responded and used the e-tool {N=16) could find the information easily, would 
recommend the information part of the e-tool to other patients and rated the e-tool with 
a 7.5. Half of the patients also used the personal care pathway, which was found to be 
easy in use, was rated with a 7.5, and most of them would recommend this part of thee-
tool to other patients. The most frequent reason that came up for not using the e-tool was 
'no need for additional information'. 
Of the 87 professionals invited to participate, 43 professionals filled out the questionnaire 
{49% response). Professionals from both strategies, who read the feedback report {N=28}, 
rated the report with a 7.0 and reported a clear layout and easily understandable figures. 
Additionally, the report was often rated as having provided new insights concerning 
improvement points. 
In the tailored strategy, the feedback meeting did not add much to the feedback report, 
but it was well received with a 7.0. The other improvement tools were rated between 6.3 
and 7.5, whereas the e-tool and quarterly newsletter had the highest rating. Most 
frequently mentioned reasons for not using the improvement tools were 'not my job 
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arm 
% 
4 
96 
0 
32* 
37 
31 
\.0 Table 2. Indicator scores for quality of delivered NHL care in 2011 and 2013. 00 
Q,uality lndicat~r ! .~ ST %ST %TA %TA 0 Jt , Delta Adj. ; N N Delta ; 2011 N N Dr'Jgnosfs and $t(fgir.g i :2011 2013 2013 e a TA·ST p-value 
Ql1 Diagnosis based on nlstolog,ical examination a<nd an excision or 8{) 193 76 173 ·4 78 176 74 165 -4 i 0 0.889 
wide incision biopsy 
Ql2 Patients staged according to Ann Arbor classification 81 202 84 191 3 81 188 84 177 3 0 0.757 
Ql3 Diagnosis for NHl based on morphology and immune phenotype 96 196 99 189 3A 95 182 97 17'6 2 I -1 0.206 
Ql4 Staging techniques should include CT-scans of neck, thorax, and i 51 220 58 217 7" 43 201 50 194 7 0 0.383 
abdomen, bone marrow aspirate, and bone biopsy 
QlS Assessment of International Prognostic bndex (~;PI) for patients with 45 139 48 108 3 41 111 48 113 7" ; 4 0.153 
aggressive NHL 
Ql6 Assessment of lactate dehydrogenase value 93 221 89 217 -4 92 202 92 195 0 4 0.666 
Ql7 Examination of blood counts 82 221 81 217 -1 82 201 80 195 -2 -1 0.555 
Tnwtment and joffow-up 
QIS Reporting of response to therapy using complete remission, partial 73 166 60 141 -13 73 138 67 129 -6 7 0.890 
remission, stable disease, progression, recurrence 
Ql9 Lesions clocumented in radiology report before therapy 69 179 69 185 0 64 165 65 155 1 1 0.889 
I 1 
; 
Ql10 Lesions documented in radiology report after therapy 60 55 66 47 6 54 59 67 46 12 6 0.933 
Ql11 Evaluation after chemotherapy with CT·scans (or PH}, and for 59 140 55 110 -4 l 65 106 53 105 -12" -8 0.497 
stage IV patients also with a bone marrow aspirate, and bone biopsy I 
Ql12 Patients with DLBCL received chemotherapy with RCHOP I 77 108 71 82 -6 79 86 76 83 -3 3 0.605 
Ql13 Dose of RCHOP was not reduced or rea>Son for reduction was 75 61 
reported¥ 87 54 n.a. , 90 so 79 58 n.a. ·8 0.360 
<.D 
<.D 
Table 2. Continued. 
Quality Indicator %ST N ' OST N Delta %lA % TA N Delta Delta Adj. N 
Organt.mtion f>n<f ' '<XH'O'IMtk>n of cart' 2011 2013 2011 20U .TA·ST p-value 
Ql14 Sending and receiving of unfixed biopsy material¥ 51 170 92 106 n.a. 29 151 71 85 n.a. -21 0.012 
QllS Integrated re,porHng of pathology techniques 92 187 98 187 6* 87 178 92 176 5 ·1 0,309 
Ql16 Pathology report complete¥ 19 196 22 189 n.a. 9 182 14 176 n.a. -8 0.107 
Ql17 Patients discussed in multidisciplinary team consuJtations 41 220 49 217 s• 41 202 64 195 23• 15 0.196 
Ql18 Results of bone marrow pathology known before the start of 
89 174 
treatment 
84 154 ·5 76 143 77 144 1 6 0.204 
Ql19 Diagnostic period of 4 weeks after the first vis·it to the hospital ! 46 220 50 217 4 48 200 49 19'5 1 -3 0.6138 (includ~ng PET) 
Ql20 Start of therapy within 2 weeks after diagnostic period (including i 60 175 61 153 1 54 138 61 142 7 6 0.723 PET) ! 
*Significant difference, based on case-mix and multilevel adjustments (P<O.OS ). 
"Trend in difference, based on case-mix and multilevel adjustments (P<O.lO). 
¥ No adjusted before-after effect calculated, due to changes in quality indicator definitions. Instead, difference between standard and tailored strategy in 
2013 was displayed . 
Abbreviations: ST= standard strategy; TA= tailored strategy. 
responsibility', 'forms insufficient' and 'not enough time'. When asked for the tool with 
the highest impact on improving NHL care, the feedback report was top rated by two-
thirds of the responders, followed by the e-tool. 
Table 3. Differences in experiences with NHL care and self-reported health outcomes 
, N total Standard Tailored 
5 (326} strategy strategy 
Experiences with NHL care 
Time between first diagnostics and final 294 48% 61% 
diagnosis was maximal10 workdays 
I could talk to the caregivers about my feelings 288 90% 96% 
HADS score (9-42) (mean (SO)) 316 8.54 (6.96) 8.58 (7.53) 
HADS anxiety 317 4.56 (4.12J 4.35 (4.03) 
HADS depression 318 4.00 (3.66) 4.23 (4.06) 
FACT-G7 score (0-28) (mean (SD)) 312 19.67 (4.82) 19.93 (4.83) 
EQ-SD score f0-1) (mean t~D)) 305 0.82 (0.20) 0.83 (0.20) 
EQ-SD, VAS scale (mean (SD)) 326 68 (25.3) 71 (21.5) 
*Adjusted for case-mix factors (age, gender and education level) and clustering effect. 
Statistics 
Adj. 
p-value 
0.019 
0.058 
0.838 
0.717 
0.502 
0.811 
0.859 
0.442 
The reliability of the data collected for the indicator scores was good: the average Kappa 
value was 0.8 (range 0.4-1.0; 87% <::0.6}. This indicates an overall good agreement 
between the registration employees. The mean ICC was 0.16 (range 0.0003-0.45}, which 
was calculated for all quality indicators to account for clustering. 
Discussion 
The hypothesized added value of a tailored strategy to improve guideline adherence 
compared to a standard strategy of audit and feedback was not confirmed in this c-RCT. 
This was supported by the feedback report as the best valued improvement tool by 
professionals. Literature also shows 'audit and feedback' as a frequently used strategy to 
commit professionals to improve their healthcare practice.21 PROs did not show any 
differences in anxiety and depression, physical well-being and general health status, 
however, PREs were slightly better for patients in the tailored strategy. Although no 
superior effect of the tailored strategy was shown, the importance of MTCs seems to have 
drawn the attention of professionals. A significant improvement in both study arms was 
noted regarding the use of MTCs to discuss patients, indicating that similar effects can be 
achieved with limited efforts needed in daily NHL care (standard strategy). 
This importance has already been demonstrated for other cancer types, where the effect 
on organization of care22' 23, on clinical decision-making24-28 and clinical outcomes29 has 
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been addressed. In 2013, quality criteria have been evaluated for oncologic MTCs and a 
diversity in the organization of these meetings was found. 30 
The main goal of MTCs is bringing together information to establish the most optimal care 
plan for individual patients. Therefore, multidisciplinary input is inevitable: a full pathology 
report (013/16) based on a reliable representative biopsy (011), all necessary (PET-)CT-
scans (014) including measurement of target lesions (019) and information on prognostic 
factors (015/6/7). Based on this multidisciplinary information, the team decision-making 
process will result in a final diagnosis, stage of the disease (012), and a treatment plan 
(0112) suited for the specific patient. As shown above, a well-organized MTC involves 
many of the quality indicators included in this study, making it a possible key factor for 
improvement studies. Future research should therefore focus on interventions applying to 
the organization of MTCs23 and the existing quality criteria and their influence on quality 
of NHL care. 
A strength of our study is that guideline adherence was measured in a large population 
(N=835) and the quality measures were validated and based on (inter)national evidence-
based guidelines, making the results straightforward to interpret. Furthermore, clinical 
practice was left undisturbed as much as possible, allowing estimation of the actual effect 
in a non-research setting. The tools developed were based on barriers perceived by 
patients and professionals and current guideline adherence, making the developed 
improvement tools tailored to the barriers found in clinical practice. Finally, not only the 
effects of the improvement tools on guideline adherence were evaluated, also patient-
reported outcomes {PROs) and a process evaluation concerning actual exposure to and 
experiences with the tools contributed to an extensive evaluation of the c-RCT. 
There are also some limitations to this study that need to be addressed. First, the findings 
of the study may have been influenced by the low dissemination rate; only a small number 
of patients and professionals actually used the improvement tools. The barriers 
encountered by professionals, such as lack of time and limited willingness to change might 
have been the cause hereof. Importantly, the influence of the same multidisciplinary team 
involved in MTC seems crucial in improvement studies by creating a better 
implementation climate. 31'32 Future research should, therefore, focus at directing 
commitment of the whole multidisciplinary team involved in NHL care, including case 
managers and specialized nurses. A higher participation rate could possibly have resulted 
in an evident effect of the tailored strategy. This is supported by the few patients that 
evaluated the patient-directed tool (e-tool) as good, easy to understand and useful. 
Second, the widespread use of PET-scans for staging and therapy response, recently 
formalized with the introduction of the Lugano classification 201433, challenges the 
application of routinely performed CT-scans (014/10) and biopsies after therapy (0111). 
Third, the PROs and PREs were only measured in the after-measurement, making it 
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difficult to estimate the direct effect of the improvement tools on the patients' outcomes 
and experiences with NHL care. However, studies in patients with other cancer types show 
comparable HADS scores34' 35 and EQ-SD-based utility and VAS scores36' 37 and slightly lower 
FACT-G7 scores38, indicating that our population scores quite similar to other cancer 
patients. 
Fourth, insight into the value of quality indicators in measuring quality of care among 
professionals should be optimized. The most challenging issue is choosing the right quality 
indicators and creating a feasible set that displays the quality of delivered care in outcome 
and process measures, including patients' experiences. Up-to-date guidelines are essential 
in this process, especially since evidence for best-practice rapidly changes with results of 
randomized trials. 
In conclusion, lean feedback about level of professional management of NHL care resulted 
in improved guideline adherence for what is generally considered the most important 
quality factor in cancer patient management: the multidisciplinary team consultation. The 
effectiveness of our tailored strategy showed no superior effects. Our results indicate that 
for future improvement of NHL guideline adherence and the underlying quality of NHL 
care, a relative simple system of continuous audit and feedback of the multidisciplinary 
team is feasible and effective. 
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General discussion 
The PEARL study (imfrovement of pati~nts' hospitAl caB.e for non-hodgkin's ,bymphoma) 
investigated whether hospital care for patients diagnosed with non-Hodgkin's lymphoma 
(NHL) could be improved by introducing a tailored strategy aimed at both patients and 
professionals (hematologists, (radiation)oncologists, radiologists, nuclear physicians, 
pathologists and oncology nurses) . To do so, insight into current NHL care was provided, 
possible barriers that influence NHL care were studied (problem analysis) and a 
multifaceted, tailored strategy based on the problem analysis was developed. This tailored 
strategy was then tested and evaluated in a cluster-randomized controlled trial by 
comparing it with a standard strategy of audit and feedback. 
In this chapter, the main findings of the PEARL study are presented and discussed in the 
light of knowledge acquired in this thesis and existing literature. Furthermore, the 
methods that were used are discussed as well as the implications for future research, 
clinical practice and policy making are provided. 
Main findings 
Current NHL care 
1. In 2007, high improvement potential was found for NHL guideline adherence, 
measured with evidence-based quality indicators regarding NHL care from diagnosis 
to follow-up. Limited improvement in guideline adherence was seen between 2007 
and 2011. The Visible Care program, a national initiative for transparency initiated in 
2008, seemed to have a small positive effect on daily NHL practice. (Chapter 2} 
2. In 2011, room for improvement regarding guideline adherence was present: 
improvement potential was shown for the majority of the quality indicators, 
representing the most important, measurable parts in quality of NHL care {Chapter 2} 
3. At least 20% variation per quality indicator was identified among the 19 participating 
hospitals concerning guideline adherence and quality of NHL care as measured by 
quality indicators. {Chapter 3} 
4. Patient-related characteristics, such as age, extranodal involvement, multidisciplinary 
consultation, tumor type, tumor aggressiveness, LDH level and allocated therapy, 
influenced hospital variation in 14 quality indicators. (Chapter 3} 
5. The hospital-related characteristics hospital region and availability of a PET-scanner 
influenced hospital variation concerning guideline adherence in NHL care in only 3 
quality indicators. {Chapter 3} 
6. Insight into current NHL care and characteristics that influence hospital variation in 
guideline adherence, is useful for the development of tailored improvement 
strategies. (Chapter 2 and 3} 
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Problem analysis 
7. Barriers frequently perceived by patients concerned lack of patient information and 
empathic contact, long waiting times and lack of guidance and support during the 
care process. {Chapter 4) 
8. The most mentioned barriers by professionals included the unavailability of the 
guideline, lack of an up-to-date guideline, standardized forms for diagnostics and 
multidisciplinary team consultations {MTCs). {Chapter 4} 
9. Perceived barriers concerning the guideline and standardized forms significantly 
varied between the disciplines involved: pathologists perceived more often barriers 
than haematologists, radiologists and radiation oncologists, particularly regarding 
accessibility and use of the guideline. (Chapter 4) 
Cluster-randomized controlled trial 
10. Feasibility testing of the educational e-tool, developed to help patients in managing 
and understanding their personal NHL-care pathway, showed that the tool is easy to 
use and understandable. Patients pointed out that the tool was very useful for 
preparing their visit to the doctor and for providing all information on one website. 
(Chapter 5) 
11. Overall, both the tailored strategy of multifaceted tools and the standard strategy of 
audit and feedback showed an improvement regarding adherence to three quality 
indicators: MTCs, staging techniques and time elapsed between last performed 
diagnostics and start of therapy. {Chapter 6} 
12. No superior effect on guideline adherence and quality of NHL care was found for the 
tailored strategy, when compared to the standard strategy. Only for discussing 
patients in MTCs a trend was seen for better adherence. (Chapter 6} 
13. Evaluation of the process of the PEARL study showed that the improvement 
strategies were rated with an average clearness and usability. Professionals rated the 
feedback report as the most useful tool to improve quality of NHL care. (Chapter 6} 
14. Based on the process evaluation, dissemination of the different elements of the 
improvement strategies among all professionals involved and patients diagnosed 
with NHL was insufficient. {Chapter 6} 
15. Patient-reported outcomes and experiences {PROs and PREs) with delivered NHL 
care showed no clear differences between the two strategies: overall, patients found 
themselves in a good health and patients in the tailored strategy tended to be 
slightly more satisfied about the delivered NHL care, particularly regarding waiting 
times, talking about their feelings and aftercare. {Chapter 6} 
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Discussion of the main findings 
The studies performed in the PEARL study, and described in this thesis, taught us that 
assessment of barriers perceived in daily hospital care and objective care assessment by 
means of quality indicators can identify domains of non-Hodgkin's lymphoma care that 
show suboptimal guideline adherence. Improvement strategies tailored to the different 
shortcomings in performance were developed and tested . The applied improvement 
approach confirmed that guideline adherence can be improved, although the obtained 
effects were limited for all domains of non-Hodgkin's lymphoma care as described in the 
guidelines. 
Assessing NHL care 
Defining 'high quality care' 
In improvement research, quality of care is often described as the extent of agreement 
between the desired, evidence-based care and the care as delivered in daily practice, 
which is the definition used in the PEARL study as well. The Institute of Medicine {IOM) 
states that care should be safe, effective, patient-centered, timely, efficient and 
equitable.1'2 These six dimensions represent well the differences in quality of care 
perception among the different stakeholders.3.4 Principle concerns for patients are 
effectiveness and patient-centeredness at the individual level, whereas professionals are 
primarily focus on safe and effective care. Hospital managers are more interested in 
efficient care at hospital level, while health insurers and policy makers look at cost-
effective, and timely care at population level. 5 
These different perspectives should come together, once all stakeholders reach consensus 
about the definition of 'high quality care' and its realization in daily practice. Professionals 
(i.e. doctors) should take the lead in this process, especially in the year of transparency 
{2015) as appointed by Edith Schippers (Dutch Minister of Health). The assigned agendas 
concerning quality, efficiency and transparency of healthcare require all stakeholders to 
work together more extensively. Professionals should realize that the time has come to 
participate actively in this movement. Taking the lead will reduce the chance of losing grip 
on new policy initiatives from health insurers or patient associations concerning high 
quality care (e.g. quality indicators, registries or standards). Furthermore, professionals 
and the other stakeholders need to proceed from the outcome and process perspective to 
a more patient-centered perspective in order to provide insight into healthcare as 
required in the year of transparency. Transparency and quality assessments should be 
considered as opportunities to provide insight into those aspects of current care where 
improvements are needed. In addition, the results of these assessments will provide the 
opportunity to educate and guide professionals towards a more optimal health care. 
Especially the young professionals show willingness to change in daily practice and seem 
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motivated to create a more patient-centered healthcare. However, the different 
stakeholders do have different interests and discussion should be held open between 
stakeholders and society to come to consensus on what really is most important to agree 
upon concerning high quality of care and how this could be accomplished. 
Defining quality indicators for NHL care 
This paragraph discusses the question whether we indeed chose the right quality 
indicators to provide insight into guideline adherence and quality of NHL care. Issues 
concerning the methods used, face validity of the quality indicators, the use of outcome 
measures and the reservations against quality indicators are subsequently described. 
Twenty previously developed evidence-based quality indicators were used to provide 
insight into current NHL care by including representative and measurable elements of 
practice performance for which there is evidence or consensus that they can be used to 
assess the quality of care. The use of a systematic RAND-Delphi method and a national 
expert panel to reach consensus about 'high quality NHL care' during the quality indicator 
development process did not prevent discussion among professionals involved in the 
PEARL study about the applicability of the quality indicators developed. 
In the light of this, the face validity of the quality indicators should be discussed by asking 
the question whether these quality indicators indeed reflect quality of NHL care. In the 
current study, professionals argued that, for example, the performance of a CT scan of the 
neck or assessment of the IPI score are invalid quality measures, since these items have 
commonly no consequences for treatment choices. For patients, however, providing the 
IPI score might be very informative because of its prognostic value and may contribute to 
(the perception of) patient-centered care. It is therefore important for professionals to 
bear in mind the patients' perspective of quality of care. To develop more patient-
centered quality indicators, professionals should involve patients earlier in the 
development phase of quality indicators and focus more on active participation during the 
whole process of improving quality of care. Unfortunately, evidence about the best 
approaches for involving patients in quality indicator development is scarce. 6 The quality 
indicators included in this thesis were for the most part focused on effective and timely 
care, represented in process measures. The possible association of these processes of care 
with outcome measures, such as mortality and progression-free survival, is less clear and 
should be studied more in the future. 
More in general, professionals should take into account that suboptimal quality indicator 
scores are as a signal that delivered care needs closer evaluation, rather than a statement 
that delivered care is insufficient.7 This lack of notion could be one of the underlying 
reasons for professionals to disagree with the developed quality indicators. A relatively 
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easy way to solve suboptimal quality indicator scores might lay in the coordination, 
organization and extent of multidisciplinary collaboration within NHL care. NHL care relies 
on teamwork, which can be improved by closer collaboration and better communication 
among the different professions involved (i.e. hematology, (radiation)oncology, radiology 
and pathology), for example during MTCs. These MTCs will, for example, enhance 
completeness of diagnostics due to more evident discussion between professionals. 
Multidisciplinary discussion of all necessary diagnostic tests is essential to reach consensus 
about the most optimal care plan for individual patients. The quality indicators used in our 
study are important aspects that should be discussed multidisciplinary, such as Ann Arbor 
staging, prognostic factors, target lesions, pathology results and therapy options. In the 
future, separate quality indicators for these items may be measured in a combined quality 
indicator regarding organization and documentation of MTCs. 
Another reason that can intuitively be regarded as contributor to the restraint against 
quality indicators might be that professionals feel their personal functioning is at stake. 
Alarm bells start ringing when quality indicators are developed, since these might be used 
for external purposes, possibly leading to stricter regulations from the Dutch Healthcare 
Inspectorate (IGZ) or health insurers. Professionals should start with internal use of quality 
indicators (at professional and hospital level). In this way, professionals will get more 
feeling with their performances and better understand the reasons for suboptimal 
performance, ideally leading to improvement of care. In a later stage, this could result in 
reliable and valuable information for external use (transparency). Examples of how 
internal feedback on delivered care can be achieved are the development of quality 
indicators, dashboards, care standards, quality registries and, PROs and PREs 
questionnaires, which is also applicable to NHL care. 
Evaluating NHL care before the PEARL study 
Before the start of the randomized trial, NHL care was evaluated; case-mix factors were 
identified and the value of MTCs has been considered, which is discussed below. 
In this thesis, we confirm previous data on suboptimal guideline adherence for delivered 
care to patients diagnosed with NHL8. 12 Low guideline adherence rates, together with 
variations between hospitals, are in daily practice often associated with case-mix factors. 
For example, patients are believed to receive less optimal therapy due to patients' 
preferences, many comorbidities or high age, causing reduced guideline adherence rates. 
In previous studies, however, optimal therapy for elderly was associated with better 
outcomes.13.15 In our data, case-mix factors could partially explain variations between 
hospitals regarding suboptimal guideline adherence (3-35% explained variance), which is 
in line with other cancer studies concerning delivered care. 16.19 Possible other 
explanations to consider include patient preferences, hospital facilities, interdisciplinary 
communication and professionals' willingness to change. Not all case-mix factors seem 
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clinically relevant, which should be taken into account when relating these factors to 
clinical practice. Possible underlying relationships with clinical practice should be explored 
in other populations as well in order to provide more insight in how these case-mix factors 
influence hospital variation. 
As mentioned before, many different professions are involved in NHL diagnostics, therapy 
and follow-up, including hematologists, (radiation-)oncologists, pathologists, nuclear 
physicians and radiologists. MTCs are an important means to discuss an appropriate 
management plan.20-22 Also the fact that NHLs are a heterogeneous group of lymphomas 
makes the availability of multidisciplinary discussions crucial. In our study, more than 50% 
of the patients were not discussed in MTCs, partly due to non-existence of NHL specific 
meetings. Lack of time and ability to organize such meetings could explain this gap23'24, 
which makes it important to create awareness of the value of MTCs. For other cancer 
types, evidence is available that MTCs improve the care management for individual 
patients and quality of cancer care.25-27 In addition, professionals perceive well-organized 
MTCs as having a positive impact on joint decision making, and better inter-professional 
communication and coordination. 28'29 Active dissemination of this evidence-based 
information in refreshment courses and site visits to existing MTCs may help to persuade 
hematologists in organizing NHL specific MTCs. In a later stage, available guidelines for an 
effective MTC can be applied to optimize the implementation process. The guidelines 
include criteria for organization of the MTC, membership, roles and responsibilities of the 
members, the structure of the meeting itself, documentation of the meeting-
recommendations. 30 
Defining barriers of f\lHL care 
We asked ourselves the question whether all barriers perceived by patients and 
professionals were identified in this study. Issues concerning differences between patients 
and professionals and the possible influence of the social context are discussed in this 
paragraph. 
The suboptimal guideline adherence as found in this thesis may be due to several factors 
on patient, professional and hospital level. Even though patient information is easily 
accessible through the Internet and is present in the hospital leaflets, patients often 
perceive a lack of information and good communication with professionals31' 32, which was 
also confirmed in our study. However, these barriers were not put forward by the 
professionals. They mentioned more often organizational conditions, such as lack of an 
up-to-date guideline and of MTCs. Differences in barriers perceived by patients and 
professionals as described in our study are probably not uncommon, but not often 
described as such.33 It is not known from research why these differences exist. Common 
sense tells us, however, that it is more convenient for professionals to focus on 
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organizational barriers, rather than barriers related to their own professional behavior, 
such as communication and information provision. Self-reflection and evaluation of care 
modules have been incorporated in professionals' education during the past years, but 
more in depth attention for these issues should be considered in refreshment courses as 
well. Professionals must become more aware of the patients' perspective concerning 
quality of care and the barriers they perceive. To do so, more extensive communication 
with patients about their experiences, the methods of information provision and shared 
decision-making is essential for professionals. Hospitals should change the organization of 
care into a more patient-centered organization and help professionals in changing their 
individual practice. This takes time, but is essential to make patient-centered hospital care 
a joint goal for the near future. 
The barriers perceived by patients and professionals, as described in this thesis, were used 
to develop tailored improvement tools. However, factors such as active participation of a 
research nurse, commitment and willingness to change of the hematologist, active 
dissemination of the tools to the members of the multidisciplinary team involved in the 
care for NHL patients and persuasion of these members to use the tools were observed, 
but not accurately measured, during the improvement period. Most of these barriers are 
part of the social context in which NHL care is delivered. Unfortunately, the social context 
and the possible influence of professionals' behavior on guideline adherence and 
implementing tools were not examined in this study. It might be interesting to explore 
how the correct behavior is determined in the mono- and multidisciplinary NHL teams and 
if there are differences in willingness to change between hematologists, also in 
comparison with other professionals. Social influences within teams and the presence of 
leadership of hematologists could be identified with elements from several behavioral 
change theories, such as the social influence theory, theory on team effectiveness and 
leadership theory.34-37 These theories can help providing a feasible overview to target the 
social context in which NHL care takes place. In daily practice, professionals should focus 
more at good communication and collaboration among the different professionals 
involved, for which MTCs could be a perfect means. 
Improving NHL care 
Defining improvement tools for NHL care 
After the assessment of NHL care and its barriers, tailored improvement tools were 
developed. In this paragraph, we argue that the most optimal tools are defined by 
discussing the known evidence and explore additional tools for future research. 
From literature we know that many potentially effective implementation tools are 
available, but none is superior in all aspects.38' 39 Moreover, strategies that proved to be 
effective in one study were ineffective in others. Many strategies may be valid and 
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effective, provided that they are adapted to the specific points of guideline adherence 
that need improvement, the target group, the setting and the barriers encountered. 
Multifaceted strategies, i.e. a combination of various interventions, directed to patient, 
professional and organizational level, are probably more effective than single strategies: 
common sense tells us that when education can solve a lack of knowledge among 
professionals, feedback a lack of insight into professional performance and education 
materials a lack of knowledge among patients, a combination of these interventions 
should have the potential to solve all three barriers and should lead to an improvement of 
the quality of care. 
The multifaceted improvement tools as described in this thesis were tailored to the 
barriers perceived and designed to cause a minimum of extra workload for professionals. 
One of the tools applied was 'audit and feedback', which is reported in literature to have a 
small but potentially important effect on improvement in daily practice.40 Our results are 
in line with this, since the feedback report was valued the best improvement tool by 
professionals. Other improvement tools focused on clearer communication between 
professionals by, for example, standardized diagnostic request and report forms. 
Unfortunately, the organizational changes needed for implementation in daily practice 
and the reluctance to change among professionals may have been underestimated, 
potentially causing the relatively small beneficial effect found in this study. Additional 
tools to accomplish these suggested changes must be considered in the future, such as 
opinion leaders promoting evidence-based practice, direct contact with all professionals 
involved to help them to implement changes, a more active role for case-managers and 
incentives for hospitals with high performance scores and for professionals who actively 
participate. The latter one may also positively affect the involvement of professionals in 
the development phase of the improvement tools. Cochrane reviews show, unfortunately, 
an unambiguous effectiveness of the mentioned improvement tools, making further 
research necessary.41,42 Meanwhile, professionals should not wait for new innovations or 
improvement tools. They should act as initiators, actively participate in providing insight 
into NHL care and start developing new hospital-tailored tools in collaboration with the 
multidisciplinary team involved in NHL care. A good way to start might be developing tools 
that will reinforce the social context in the multidisciplinary practice regarding quality of 
care, previously mentioned as unexplored barrier. The positive effect of improving 
leadership and social (team) behavior has been demonstrated for hand hygiene and 
chronic illness care, making it worthwhile to investigate its effect in NHL care.36'43 A first 
step might be assessing the team climate using the Team Climate lnventory.44 
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Evaluating NHL care after the PEARL study 
To evaluate the effect of our study, we focus in this paragraph on the importance of 
collaborating with the different stakeholders involved in NHL care and the value of quality 
registries for high quality of NHL care. 
For the PEARL study, individual hospitals were approached to collaborate in our c-RCT, 
which resulted in 19 hematologists/oncologists (and their hospitals) willing to participate 
in a quality improvement study. Unfortunately, formal collaboration of the Dutch Society 
for Hematology and the Cooperative Trial Group for Hemato-Oncology in adults 
(respectively, NVvH and Hovon) was not realized. To inform the parties about the study 
progress and to acquire some professional support, the Hovon lymphoma working group 
received quarterly updates from the PEARL study. 
We believe that collaboration between all stakeholders involved in NHL care needs 
enhancement to reach a more optimal quality of NHL care. Not only collaboration 
between research teams and societies for medical specialists, but also among patient 
organizations, professionals, hospitals, health insurers and politics. In our study, we 
observed suboptimal communication and collaboration between different professionals 
and disciplines within hospitals, resulting in insufficient dissemination of the improvement 
tools. Future research should therefore focus on more than one contact person of a 
multidisciplinary team and the devotion of an opinion leader is probably necessary to 
motivate professionals to actively participate in improvement research. 
At a national level, a first start in settii1g up collaboratioi1 i1etworks could be providing an 
overview of all national and local initiatives directed to organization and coordination of 
NHL care, including improvement projects. Professionals and researchers should realize 
that collaboration with other (multidisciplinary) groups would probably lead to more 
effective and efficient improvements of quality of care. They must therefore open up to a 
changing culture where people learn from each other, loosing the many 'knowledge 
islands' as they exist today. For healthcare in general, it could be worthwhile to examine 
the opportunities for creating a more transparent research and healthcare system. Expert 
centers for certain types of research should be considered, which is in line with the idea of 
a more centralized hospital care in the Netherlands. In particular, national quality 
registries could be helpful to increase transparency in healthcare systems. 
This thesis made extensively use of data collected by the Netherlands Comprehensive 
Cancer Organisation (IKNL) from the Netherlands Cancer Registry (NCR) and medical 
records. This would not have been feasible for daily practice if professionals themselves 
were responsible for the registration of these items. An upcoming means to help bringing 
high quality of care into practice is the development of quality registries. Societies for 
medical specialists tend to develop their own national registries more frequently, for 
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example for orthopedic implants (LROI), cystectomies, gynecologic surgery, hypospadias 
and cardiovascular diseases. These registries are not directly linked to the electronic 
medical records (data collection from the source), which makes them labor-intensive to 
collect data for. An advanced example of a hematological quality registry is HemoBase, a 
multidisciplinary electronic patient record system, initiated by hematologists, in the 
Northern part of the Netherlands.45 The underlying database makes it possible to monitor 
differences in provided hematological care between hospitals. The participating hospitals 
seem to comply quite well with the database, showing that HemoBase can be a wide-
ranging source for providing insight into quality of NHL care. We believe that political 
issues and individual concerns of professionals, hospitals and regional collaborations seem 
to prevent expanding to a national ground. Another example is PHAROS, a population-
based hematological registry for observational studies, that aims to provide insight into 
the quality and effectiveness of hemato-oncological care in the Netherlands and to 
identify variation in clinical practice.46 For this purpose, the NCR database has been 
extended for several hematological diseases, in collaboration with three IKNL regions 
(Amsterdam, Rotterdam and Zuid), Hovan and the pharmaceutical industry. They 
conducted research mainly focusing on quality of life, trends in incidence and mortality 
and (cost)effectiveness of different therapy options, mainly providing insight into 
outcomes of care. DICA (Dutch Institute for Clinical Auditing) and IKNL are also providing 
services to develop disease-specific registries. The advantage of these registries is that an 
independent organization collects the data in a reliable way, preventing social desirable 
data when professionals score their own performance. On the other hand, hospitals and 
professionals might be reluctant to provide data to 'independent' registries, being afraid 
of losing control about the hospital-specific data. Therefore, good agreements need to be 
made about making the data public for health insurers, inspectorates and politics. 
A particularly important and upcoming issue is involvement of patients in research 
projects concerning healthcare. During this study collaboration was established with the 
patient association Hematon, which was of high value. The input from patients and board 
members was very useful to gain insight into barriers in clinical practice and patients' 
needs, but also their input during the development of the educational e-tool for NHL 
patients was worthwhile. The traditional doctor-patient role might change by tools such as 
this, giving patients more knowledge about their own care pathway and indirectly about 
professional guidelines. E-tools might have the ability to facilitate shared decision making 
for patients, but professionals need a helping hand as well. From patients' perspective, 
interventions such as patient decision aids are promising tools to improve professionals 
adoption of shared decision making in clinical practice.47 
Shared decision making, patient-centeredness and patient empowerment are popular 
issues of debate nowadays, but the implementation in daily practice concerning 
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involvement of patients in the decision making process and guideline and quality indicator 
development is still limited. For NHL patients, a first step into this direction has been made 
by the e-tool developed in the PEARL study. This tool was developed to provide 
information to patients concerning non-Hodgkin lymphomas and insight into their own 
care pathway, with the underlying goal to empower patients. It should be worthwhile to 
further elaborate the e-tool and explore its effect in a larger patient sample, taking into 
account possible improvements needed for informing and instructing NHL patients and 
professionals to use the e-tool. Other initiatives that could be valuable in improving 
patient involvement include the national campaign '3 good questions', initiated by the 
Dutch patient federation (NPCF) and the Federation of medical specialists (FMS)48, and the 
online communication training program 'PatientTIME' (initiated by Nivel)49 • Both projects 
focus at patient involvement and empowerment through better communication, which 
could be valuable in order to increase patient participation in NHL care. 
Methodological considerations 
Insight into current care and potential barriers 
A multidisciplinary, national panel of 14 experts (including pathologists, radiotherapists, 
oncologists and hematologists) previously developed and validated quality indicators 
regarding NHLs. These indicators were used in the PEARL study and were updated if 
necessary, based on recent literature and the expert opinion of a local expert panel 
(consisting of a pathologist, radiotherapist, hematologist, oncologist and radiologist). 
Literature and daily NHL care did not provide reasons to conduct a new consensus round, 
which is why we believe this would not have changed the quality indicator set. However, 
conducting a consensus round could have provided us with new insights into the current 
face validity and public support of the quality indicators. 
One of the strengths of the problem analysis was involving the complete multidisciplinary 
team to determine barriers perceived in daily NHL care concerning guideline adherence 
and providing high quality care. This thesis shows differences among professions regarding 
barriers perceived. Additionally, patients were asked to report barriers perceived in NHL 
hospital care. This combination of different perspectives provided us with a broad 
overview of barriers concerning daily NHL care, based on both qualitative and quantitative 
research (interviews and questionnaires) . However, it occurred to be rather difficult to 
reach potential participants. Patients were contacted via the patient organization 
Hematon and several hematologists, probably causing selection bias and underreporting 
since it is likely that highly motivated patients responded more often to our call. 
Contacting professionals was only possible via general mailings from the societies for 
medical specialists they are involved in, making it more difficult to reach and motivate 
professionals to participate. Also the organization of group interviews with professionals 
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was a challenge, since most professionals did not have much spare time at their agenda. 
Therefore, individual interviews were scheduled with several professionals. The role of 
societies for medical specialists should be more prominent in improvement activities, 
since they can create a broader support for participation of professionals. Unfortunately, 
there is no standardized method to involve these societies, which also could be helpful for 
lowering the workload for the individual professionals. 
Outcomes of care 
Most indicators in this thesis are process indicators, whereas hospitals, healthcare insurers 
and the Dutch Health Care Inspectorate (IGZ) nowadays tend to focus on outcomes like 
morbidity, mortality and progression-free survival. The PEARL study aimed at providing 
insight for professionals into the complete NHL care pathway, including diagnostics and 
staging, treatment and follow-up but also organization and coordination of care. Without 
insight into these process measures, it may be difficult to find out why outcomes show 
suboptimal results. Outcomes such as patient-reported outcomes and experiences were 
included in the after-measurement of the c-RCT to provide insight into the effects of the 
improvement tools tailored to the processes of care. In a few years, when data on 
mortality and progression-free survival will become available for the patients included in 
the PEARL study, the relation between outcome and process indicators can be mapped. 
Research about this relationship (processes and outcomes) for NHL care is scarce, 
however, Nikonova et a/. 50 showed that patient- and disease-related factors are not 
associated with outcomes of DLBCL patients, but do impact diagnostic and treatment 
delays (processes). The latter effect is also seen in our study results. 
Data collection 
Data for the quality indicators were collected retrospectively, making it difficult to 
distinguish between documentation errors and actual inadequate guideline adherence. 
For example, quality indicators as assessment of the IPI score or Ann Arbor stage were 
often difficult to find in medical records. However, this does not always mean they were 
not assessed. Complete documentation is expected to increase with the more 
standardized, electronic medical records, including relatively easy access to the 
documentation of the different professionals involved in NHL care. 
Trained registration employees of IKNL performed data collection from medical records 
and the NCR. Together with the well-structured data collection forms and instruction 
meetings, this expertise resulted in a reliable and consistent dataset. A drawback of the 
system used is that the final cancer diagnosis is registered with a six months delay by IKNL 
(six months after the incidence date). This means that retrospective studies always must 
take into account a considerable delay in final patient selection and data collection from 
the NCR. Joint efforts should be undertaken to facilitate measurement initiatives with the 
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possibility to collect data with only a limited delay in time. For this purpose, real-tirne data 
collection from electronic medical records, including inter-disciplinary and inter-hospital 
data, is necessary. To reach this goal all stakeholders, including professionals, societies for 
medical specialists, health insurers, policy makers and IGZ must put their efforts together. 
In particular, existing systems should be modified into routinely monitoring systems, 
facilitating data collection directly from the electronic medical records. This will increase 
our knowledge about delivered care and care-derived quality indicators. An important 
issue of concern is covering the privacy of the patient data, especially if different data 
system can be linked to one other. Insight into patients' experiences with care cannot be 
mapped with this system. Recently, the NPCF has tested personal health files to give 
patients more insight into their own health (care) on a local level. More efforts should be 
undertaken to facilitate personal health files on a national level in the future. 
Study design 
We performed a multicenter trial aiming at a high power. In total, 19 Dutch hospitals were 
included; all providing data from 10-30 newly diagnosed NHL patients. This large dataset 
offered us the opportunity to make an overview of NHL care in the Netherlands, showing 
which parts of health care scored adequately and which parts showed room for 
improvement. In addition, differences between the three regions that took part in the 
PEARL study were identified. However, the process evaluation showed that the 
improvement tools were used more extensively in one hospital than in the other. It would 
be interesting to explore what the precise exposure of the different tools was in order to 
reveal the actual implementation effect for each tool separatell1 and also to investigate 
why the different hospitals varied in the use of the implementation tools. 
In general, randomized controlled trials with a large study population are considered as 
basic principle for improvement research. In the future, other types of research could be 
considered, for example a case study or include only a few hospitals (N=6) to study the 
feasibility of the improvement tools. Such a rather small study population makes it easier 
to monitor the implementation process and to encourage and support the participating 
professionals in using the improvement tools. While it is more difficult to prove 
differences in low-powered studies, the improvement effects accomplished are expected 
to be larger and easier to attribute to a particular tool. The second step could be a 
randomized controlled trial, where the most optimal and feasible improvement tools can 
be tested in a larger setting. 
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• 
Implications for clinical practice, future research and policy making 
In the above discussion of the main findings presented in this thesis, several implications 
for clinical practice, future research and policy can be formulated. The implications are 
presented separately for the relevant stakeholders involved. 
Implications for clinical practice 
Patients and patient associations 
• Patient associations are advised to take a greater role in the implementation of 
shared decision-making, patients-centered care and patient empowerment. 
e It is important for patients associations to increase their role in reaching consensus 
with all stakeholders about how to define and measure quality of care. 
• Involving patients in guideline and quality indicator development should be a key 
issue for the near future. 
E-tools or decision aids can increase patients' knowledge about the professional 
guidelines and facilitate shared-decision making by empowering patients to 
influence decisions concerning their health (care). 
o Good communication skills to involve patients in their own care seem essential for 
both patients and professionals. Patient organization should consider offering 
communication training for patients to increase their empowerment during 
hospital care. 
.. Patients can be triggers to be more actively involved by Involving them earlier in de 
development phase of guidelines, quality indicators and other quality measures. 
Professionals 
a Professionals must realize that the time has come to actively participate in the 
transparency movement. Transparency and quality assessments should be 
considered as opportunities to provide insight into those aspects of current care 
where improvements are needed, rather than a statement that delivered care is 
insufficient. 
• Participating in quality assessments will provide the ability to educate and guide 
professionals towards a more optimal hospital care. 
• Insight into a more patient-centered and process related perspective will provide 
detailed insight into aspects of care that should be evaluated more closely. 
• Information provision in current practice is not sufficient according to patients. 
Professionals should take the responsibility to improve communication with their 
patients. Specialized oncology nurses and tools as decision aids could help improve 
this care. 
o The degree of multidisciplinary teamwork, of which NHL care mainly consists, must 
be improved by closer collaboration and better communication among the 
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different professions involved (i.e. hematology, oncology, radiology, pathology and 
radiation oncology) . 
., Professionals must become more aware of the patients' perspective concerning 
quality of care and the barriers they perceive. To do so, more extensive 
communication about patients' experiences, information provision and shared 
decision-making is essential. 
• Many professions are involved in NHL diagnostics, therapy and follow-up. MTCs 
should be used as an essential means to discuss the most appropriate management 
plan for individual patients. 
" The social context and the possible influence of professionals' behavior at guideline 
adherence and implementing tools should be explored. Social influences within 
teams and differences in willingness to change could be identified by introducing 
elements of behavioral change theories. 
Professional organizations (societies for medical specialists and hospitals) 
8 The value of MTCs, based on evidence and clinical practice, must be made generally 
known to prevent lack of time and ability to organize such meetings in the future. 
This can be done during refreshments courses or by providing site visits to best 
practices. 
o The organizational changes needed to introduce and successfully implement NHL-
specific MTCs should be facilitated and endorsed by the hospital management (e.g. 
organization and coordination, IT facilities and time management, documentation). 
" Refreshment courses should pay more attention to professionals' self-reflection 
and evaluation of care, rather than incorporating it only in the first few years of the 
professionals' education. 
• Hospitals should promote patient-centered care, which can trigger both patients 
and professionals to apply it more often. 
" Internal feedback on delivered care can be achieved based on quality indicators, 
including the development of dashboards, care standards, quality registries and, 
PROs and PREs questionnaires. 
~ Collaboration between professional organizations and research groups will 
probably lead to more evidence about what good quality of NHL care is and how 
this can be mapped best and most efficiently. 
An overview of all national and local initiatives directed to organization and 
coordination of NHL care should be established, in order to increase collaboration 
between the different professionals and disciplines within and across hospitals 
o Quality registries must be considered as serious new means to help bringing high 
quality of care into practice. The key to reach this goal without increasing the 
registration burden for professionals is developing real-time monitoring systems. 
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Implications for quality of care researchers 
o Obtaining support from professional organizations before the start of a research 
project is of great importance for the willingness to participate among 
professionals. 
" The importance of involving patients in all aspects of quality of care research 
should be acknowledged and brought into practice. More evidence about the best 
approaches to do so must be obtained. 
o Active involvement of the entire multidisciplinary team is essential for capturing all 
aspects of care and its improvement points. 
• All members of the multidisciplinary team should be contacted by the researchers 
in order to optimize active dissemination of the improvement tools. One central 
contact person might not be sufficient for optimal improvement in multidisciplinary 
settings. 
e Providing insight into outcomes of care is often the primarily concern of 
professionals, health insurers and politics. However, insight into the underlying 
processes of care might be just as important, since tailored improvement tools 
often connect to processes of care. 
• Retrospective data collection is an often-used method for quality of care research. 
Documentation errors must be taken into account when using this approach, which 
are difficult to distinguish from inadequate guideline adherence. 
• The study design of choice for this type of research should be reconsidered, since 
case studies might be most informative to test the feasibility of the implementation 
tools. Next, the effectiveness of the most feasible tools can be tested in a 
randomized controlled trial concerning guideline adherence and quality of care 
improvements. 
• In collaboration with professionals, the social context and the possible influence of 
professionals' behavior at guideline adherence and implementing tools must be 
examined in the future. 
" The effect of tools such as opinion leaders promoting evidence-based practice and 
financial incentives for hospitals with high performance scores must be explored 
for NHL care in the future. Also tools more focused on the value of more intense 
multidisciplinary collaborations should be worthwhile to consider. Elements from 
several behavioral change theories could help identifying new leads for further 
improvement of quality of NHL care. 
Implications for policy makers 
• All stakeholders need to deviate from the trusted outcome perspective to a more 
patient-centered and process related perspective in order to provide insight into 
healthcare as required in the year of transparency. 
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o Policy makers, such as health insurers, the ministry of Health and the Healthcare 
inspectorate should take into account that suboptimal quality indicator scores must 
be seen as a signal that delivered care should be evaluated more closely, rather 
than a statement that delivered care is insufficient. 
• Providing insight into guideline adherence and quality of care should start with 
quality indicators for internal use (at professional and hospital level), which can, in 
a later phase, result in reliable and valuable information for external use. 
• The fact that NHLs are a heterogeneous group of lymphomas makes the availability 
of multidisciplinary discussions crucial. It is worthwhile to promote well-organized 
MTCs providing a stable environment for multidisciplinary collaboration between 
the different disciplines involved. In addition, more centralized NHL care, including 
expert centers for subtypes of NHL, should be considered. 
• For healthcare in general, it could be valuable to examine the opportunities for 
creating a more transparent research and healthcare system. Expert centers for 
certain types of research should be considered, which is in line with the idea of a 
more centralized hospital care in the Netherlands. 
" Clear national regulations about the use of data from quality registries should be 
formulated, diminishing the reserve among professionals and hospitals to provide 
data to these registries. 
e Registration of quality data should be performed by independent and certified 
institutes rather than by the professionals themselves, to optimize validity of the 
data and diminish social desirable answers. 
• A more bottom-up approach for obtaining transparency in healthcare will probably 
increase the willingness to participate in the development of quality indicators, 
registries or standards among professionals. 
Final conclusion 
This thesis describes the level of improvement potential for NHL guideline adherence, 
variation in NHL care and its possible determinants, and barriers and facilitators as 
perceived by NHL patients and professionals involved in NHL care. It provided a valid base 
for the development of tailored improvement tools. In a cluster-randomized controlled 
trial, the effect of two improvement strategies on guideline adherence and quality of NHL 
care was tested. All tools were tailored to the barriers perceived by professionals, patients 
and the improvement points from the medical record measurements. We could not 
demonstrate a clear benefit of the multifaceted, tailored strategy for NHL guideline 
adherence and quality of NHL care: only few quality indicators showed better adherence 
rates in both strategies (especially the use of MTCs) and not all quality indicators were 
valued useful for quality improvement in daily practice. Nevertheless, the process 
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evaluation showed promising results on the value of the audit and feedback report and 
patients were positive about the e-tool developed in the PEARL study. 
Finally, this thesis discussed several facets of NHL care, but considerable challenges for 
future research remain. This includes further exploration of collaboration between 
professionals, hospitals and regions, transparency about delivered care, the influence of 
policy makers on daily practice and the value of including patients' perspectives in 
improving quality of care. Also, the growing role of quality registries, the importance of 
collaborating with third parties, including the disadvantage of being dependent from 
them, and the value of bottom-up quality of care research need further investigation. This 
should be taken up by the different stakeholders involved, which may help to evolve 
durable tools for improving guideline adherence and high quality of care. 
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Summary 
Non-Hodgkin's lymphoma {NHL) affects over 300,000 people worldwide each year and is 
listed in the top 10 of most common cancers. In the Netherlands, the incidence of NHL is a 
high as 4000 newly diagnosed patients per year. With an expanding and ageing 
population, these figures are expected to increase. Well organized and carried out 
diagnostics and treatments are essential to help patients in the best possible way. To 
support professionals to do so, several national and international clinical practice 
guidelines have been developed for NHL care. Unfortunately, this does not automatically 
mean that they are all commonly used in daily practice. Previous research showed 
considerably low percentages of guideline adherence and a large hospital variation in NHL 
care, which could be an indication of suboptimal dissemination and usage of the 
guidelines. 
This thesis contains the results of the PEARL study {imfrovement of pati~nts' hospitAl 
caRe for non-hodgkin's !,ymphoma), which is performed to improve hospital care for 
patients diagnosed with NHL. First, insight into current NHL care and barriers of optimal 
NHL care was provided . Based on these insights, improvement strategies directed to a 
more optimal NHL care were developed, tested and evaluated in a cluster-randomized 
controlled trial. 
In Chapter 1 general information about non-Hodgkin's lymphomas is provided, explaining 
more about the incidence, subtypes, diagnosis, treatment, prognosis and survival of NHLs. 
Furthermore, quality of care by means of guidelines and quality indicators is discussed and 
the implementation model used in the PEARL study is explained in detail. Finally, the main 
objectives, as mentioned above, and outline of this thesis are described. 
Current NHL care 
First, insight into the current NHL care is gained from two observational studies. Chapter 2 
outlines trends in guideline adherence and quality of NHL care in the Netherlands 
between 2007 and 2011. A random sample of 771 patients diagnosed with NHL in 26 
Dutch hospitals is examined. Data is collected from medical records and combined into 20 
quality indicators, representing the most important measurable parts in quality of NHL 
care. Additionally, the influence of the national Visible Care program {started in 2008) is 
examined, which included 6 of the 20 quality indicators. For only 3 out of 6 quality 
indicators involved in the national program and none of the other 14 quality indicators 
improved adherence is shown. Improvement potential is still present for 13 quality 
indicators, indicating a limited improvement in quality of NHL care between 2007 and 
2011. The national program seems to have a small positive effect, but has not influenced 
all 20 indicators, illustrating the need for tailored implementation initiatives. 
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In Chapter 3, hospital variation concerning guideline adherence in non-Hodgkin's 
lymphoma is assessed and to what extent this is influenced by patient, tumor, professional 
and hospital related characteristics. The 20 quality indicators are used as a tool to assess 
guideline adherence regarding diagnostics, therapy, follow-up and organization of care, 
retrospectively collected from medical records. Based on data of 423 patients diagnosed 
with NHL, guideline adherence varied considerably between the 19 hospitals: more than 
20% variation is identified in all 20 quality indicators and high variation between the 
hospitals (>50%) is seen in 12 quality indicators. Hospital variation in NHL care is 
associated more than once with the characteristics age, extranodal involvement, 
multidisciplinary consultation, tumor type, tumor aggressiveness, LDH level, therapy used, 
hospital region and availability of a PET-scanner. In total, fifteen characteristics could 
partly explain hospital variation in guideline adherence for NHL care. Particularly age is an 
important determinant: elderly are less likely to receive care as mentioned in the quality 
indicators. 
Problem analysis 
Chapter 4 describes the identification of barriers that influence the delivery of care and 
explored differences between patients' and professionals' experiences, as well as between 
the different disciplines involved. Patients and professionals (i.e. hematologists, radiation 
oncologists, radiologists and pathologists) are interviewed about their experiences with 
NHL care and the barriers are quantified in a web-based survey. Barriers frequently 
perceived by patients concern lack of patient information and emphatic contact, long 
waiting times and lack of guidance and support. Most mentioned barriers by professionals 
concern the unavailability of the guideline, lack of up-to-datedness of it, lack of 
standardized forms for diagnostics and of multidisciplinary team consultations (MTCs). 
Perceived barriers concerning the guideline and standardized forms significantly vary 
between the disciplines involved. The different barriers for high quality of NHL care as 
found between patients and professionals and between the disciplines involved serve as a 
starting point for the cluster-randomized controlled trial. 
Cluster-randomized controlled trial 
Based on the results presented in chapter 2, 3 and 4, tailored tools directed to both 
patients and professionals are developed in order to increase guideline adherence. The 
professional-directed tools include an audit and feedback report and meeting about their 
current care, a list of standardizing options for diagnostic requests and reports, leaflets on 
MTCs and pathology panels, regularly contact with the hospitals' contact persons and an 
overview of the NHL care pathway. The patient-directed tool consists of an educational e-
tool to help patients with non-Hodgkin's lymphoma understand and manage their 
personal care pathway. 
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In chapter 5, the development and evaluation of this e-tool is described. In collaboration 
with a multidisciplinary NHL expert panel and the patient association Hematon, thee-tool 
is developed consisting of two sections: 1) a personal section for patients' own care 
pathway and their experiences (d iary), and 2) an informative section including information 
on NHL in general, diagnostics, therapy, after-care and waiting times. The ideal NHL care 
pathway, based on available (inter) national guidelines, includes dates of first consultation, 
diagnosis and therapy start to set up the personal care pathway. The e-tool is evaluated 
with a questionnaire by 6 patients, 6 laymen and the expert panel, where items as lay-out, 
user convenience, menu clarity, information clarity and general impression are discussed. 
The overall feedback is positive and important strengths mentioned are the use of a low 
health literacy level, the opportunity to document the personal care pathway and the 
clear overview of the information provided. To improve the e-tool, more explicit 
information on immunotherapy, experimental therapy and psychosocial support is added. 
Chapter 6 presents the results of our cluster-randomized controlled trial testing the 
feasibility and effect of two strategies to improve non-Hodgkin's lymphoma guideline 
adherence and quality of hospital care. In addition, the effect on patient-reported 
outcomes and experiences is measured (PROs and PREs) . Hospitals are randomly assigned 
to either the standard strategy of audit and feedback (N=10) or the tailored strategy with 
in addition tools tailored to the barriers perceived by patient s and professionals and 
current NHL care (N=9). Guideline adherence and the strategy effect is measured with a 
before- and after-measurement and the previously developed quality indicators. In total, 
data is extracted from medical files for 835 patients diagnosed with NHL and validated 
questionnaires are used to provide insight into the PROs and PREs. 
There is a significant improvement in guideline adherence in both study arms for the use 
of MTCs (from 41 to 49% in standard strategy and from 41 to 64% in tailored strategy). No 
superior effect on guideline adherence is found for the tailored strategy. In addition, 
professionals evaluated the feedback report as the best tool to improve guideline 
adherence. PROs measuring anxiety and depression, physical well-being and general 
health status show no differences between the two strategies. However, PREs with NHL 
care are slightly better reported in the tailored strategy. In conclusion, this trial 
demonstrates that it is difficult to improve guideline adherence by professionals, however 
both strategies seem feasible and sorted a significant effect. 
Finally, in Chapter 7 the main findings of this thesis are discussed in the light of recent 
literature and implications for future research, clinical practice and policy makers are 
outlined. 
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Samenvatting 
Elk jaar worden wereldwijd meer dan 300.000 mensen geconfronteerd met non-
Hodgkinlymfoom {NHL). Hierdoor is NHL opgenomen in de top 10 van de meest 
voorkomende vormen van kanker. In Nederland is de incidentie hoog: per jaar worden 
ongeveer 4.000 mensen gediagnosticeerd met NHL. Met een alsmaar groeiende en 
vergrijzende bevolking zullen deze cijfers naar verwachting blijven toenemen. Goed 
georganiseerde zorg met de juiste diagnostiek en therapie zijn essentieel om patienten zo 
goed mogelijk te helpen. Om professionals hierin te ondersteunen zijn verschillende 
nationale en internationale richtlijnen ontwikkeld voor de NHL-zorg. Helaas betekent dit 
niet automatisch dat de richtlijnen altijd gevolgd worden in de dagelijkse praktijk. Eerder 
onderzoek toonde dat een aantal aanbevelingen uit de Nederlandse NHL-richtlijn matig 
werden nageleefd en dat er grote variatie in de NHL-zorg tussen ziekenhuizen was, 
mogelijk veroorzaakt door beperkte verspreiding en/of gebruik van de richtlijn. 
Dit proefschrift bevat de resultaten van de PEARL studie (imf_rovement of patif.nts' 
hospilAI caRe for non-hodgkin's ,bymphoma), welke gericht is op het verbeteren van de 
ziekenhuiszorg voor patienten met NHL. Hierbij is inzicht verkregen in de huidige kwaliteit 
van de NHL-zorg en barrieres die optimale zorg in de weg staan. Op basis van deze 
inzichten zijn verbeterstrategieen ontwikkeld, getest en geevalueerd in een cluster-
gerandomiseerd gecontroleerd onderzoek. 
In hoofdstuk 1 is algemene informatie over NHL opgenomen, waarbij een samenvatting 
gegeven wordt over de incidentie, subtypes, diagnose, behandeling, prognose en 
overleving van NHL. Bovendien worden criteria voor optimale kwaliteit van de zorg 
besproken, zoals weerspiegeld in richtlijnen en kwaliteitsindicatoren. Daarnaast wordt het 
gebruikte implementatiemodel nader toegelicht. Tenslotte worden de belangrijkste 
doelstellingen en de opzet van dit proefschrift beschreven. 
Huidige NHL-zorg 
Door middel van twee observationele studies uit dit proefschrift is inzicht verkregen in de 
huidige NHL-zorg. Hoofdstuk 2 schetst trends in richtlijnadherentie (naleven van de 
aanbevelingen) en kwaliteit van de NHL-zorg in Nederland tussen 2007 en 2011, 
gebaseerd op data van 771 patienten met NHL in 26 Nederlandse ziekenhuizen. De 
gegevens zijn verzameld uit medische dossiers en zijn getoetst aan 20 kwaliteits-
indicatoren, welke de belangrijkste meetbare onderdelen in de kwaliteit van de NHL-zorg 
representeren. Bovendien is de invloed van het nationale 'Zichtbare Zorg' programma 
onderzocht (ZiZo). Dit is een initiatief van de overheid om transparantie over de geleverde 
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zorg te verbeteren, gestart in 2008, waarin 6 van de 20 door ons ontwikkelde 
kwaliteitsindicatoren opgenomen zijn. Dit hoofdstuk laat zien dat richtlijnadherentie bij 3 
van de 6 kwaliteitsindicatoren verbeterd is, de overige 14 indicatoren lieten geen 
significante verbeteringen zien . Uiteindelijk is in 2011 verbeterpotentieel zichtbaar voor 
13 kwaliteitsindicatoren, hetgeen wijst op slechts een beperkte verbetering van de 
kwaliteit van de NHL-zorg tussen 2007 en 2011. Het ZiZo programma lijkt een klein positief 
effect te hebben, maar heeft niet op aile 20 indicatoren invloed. De vraag is of dit door 
een op maat gesneden implementatiestrategie verder verbeterd kan worden . 
In hoofdstuk 3 is de variatie tussen ziekenhuizen met betrekking tot naleving van de NHL-
richtlijn bekeken en is onderzocht in hoeverre deze variatie wordt be"invloed door patient-, 
tumor- en professional-gerelateerde kenmerken. De 20 kwaliteitsindicatoren zijn gebruikt 
als een instrument om de richtlijnadherentie te beoordelen met betrekking tot 
diagnostiek, behandeling, follow-up en de organisatie van de zorg. De gegevens voor de 
kwaliteitsindicatoren zijn retrospectief verzameld uit medische dossiers. Op basis van 
gegevens van 423 patienten met NHL is duidelijk geworden dat de richtlijnadherentie 
aanzienlijk varieert tussen de 19 ziekenhuizen: meer dan 20% variatie is zichtbaar in aile 
20 kwaliteitsindicatoren en meer dan 50% variatie is waargenomen bij 12 indicatoren. De 
volgende kenmerken zijn meerdere keren geassocieerd met variatie in richtlijnadherentie 
tussen de ziekenhuizen: leeftijd, extranodale betrokkenheid (weefsel buiten de 
lymfklieren), multidisciplinair overleg, tumortype, agressiviteit van de tumor, LDH niveau 
(een verhoogd gehalte van dit enzym in het bloed kan wijzen op NHL), therapie, regio van 
het ziekenhuis en de beschikbaarheid van een PET-scanner {beeldvormende techniek op 
basis van radioactieve deeltjes). In totaal zijn 15 kenmerken (determinanten) 
ge"identificeerd die de variatie tussen de ziekenhuizen deels kunnen verklaren . Vooral 
leeftijd komt naar voren als een belangrijke determinant: ouderen lijken een kleinere kans 
te hebben om de zorg te ontvangen zoals beschreven in de kwaliteitsindicatoren. 
Probleem analyse 
Hoofdstuk 4 beschrijft het identificeren van barrieres die invloed hebben op het verlenen 
van goede zorg en het exploreren van de verschillen in ervaringen van patienten en 
professionals, alsook van de verschillende disciplines (hematologen, radiotherapeuten, 
nucleair geneeskundigen, radiologen en pathologen) die betrokken zijn bij de NHL-zorg. 
Patienten en professionals zijn ge"interviewd over hun ervaringen met de NHL-zorg en de 
barrieres zijn gekwantificeerd via een online vragenlijst. Patienten brachten barrieres naar 
voren over het gebrek aan patientinformatie en inlevingsvermogen van de professionals, 
lange wachttijden en het gebrek aan begeleiding vanuit professionals. De meest 
genoemde barrieres door professionals waren het niet beschikbaar zijn van de NHL-
richtlijn, het ontbreken van een actuele richtlijn en van gestandaardiseerde formulieren 
voor diagnostiek en multidisciplinaire besprekingen. De barrieres voor het leveren van 
134 
hoge kwaliteit NHL-zorg en de verschillen hierin tussen patienten, professionals en de 
betrokken disciplines dienden als uitgangspunt voor het cluster-gerandomiseerde 
gecontroleerde onderzoek. 
Cluster-gerandomiseerd gecontroleerd onderzoek 
Op basis van de resultaten uit hoofdstuk 2, 3 en 4 zijn op maat gemaakte instrumenten 
(tools) ontwikkeld om richtlijnadherentie te vergroten, gericht op zowel patienten als 
professionals. De op professionals gerichte tools omvatten een audit- en feedbackrapport, 
een bijeenkomst om het rapport te bespreken, een lijst van standaardisatie mogelijkheden 
voor diagnostische aanvragen en rapporten, informatie over de opzet en samenstelling 
van multidisciplinaire besprekingen en pathologie panels, regelmatig contact met de 
contactpersonen in de ziekenhuizen en een overzicht van het NHL-zorgpad. De op 
patienten gerichte tool bestaat uit een educatief online programma (e-tool) voor 
patienten met NHL om hen te helpen inzicht te krijgen in hun persoonlijke zorgpad. 
In hoofdstuk 5 is de ontwikkeling en evaluatie van deze e-tool beschreven. De e-tool is in 
samenwerking met een multidisciplinair NHL expertpanel en de patientenvereniging 
Hematon ontwikkeld en bestaat uit twee delen: 1) een persoonlijk gedeelte voor het eigen 
zorgpad van patienten en hun ervaringen (dagboek), en 2) een informatief gedeelte met 
informatie over NHL in het algemeen en bijbehorende diagnostiek, behandeling, nazorg en 
wachttijden. Het ideale NHL-zorgpad, gebaseerd op beschikbare (inter)nationale 
richtlijnen, is gebruikt om op basis van de datum van eerste consult, diagnose en start 
therapie, het persoonlijke zorgpad vorm te geven. De eerste versie van de e-tool is 
geevalueerd met een vragenlijst onder 6 patienten, 6 leken en het expertpanel, waarin 
vragen over lay-out, gebruiksgemak, duidelijkheid van het menu en de informatie en de 
algemene indruk zijn opgenomen. De algemene feedback was positief en belangrijke 
sterke punten die naar voren kwamen zijn het gebruik van begrijpelijke taal (ook voor 
mensen met lage geletterdheid), de mogelijkheid om het persoonlijke zorgpad op een plek 
te documenteren en het heldere overzicht van de verstrekte informatie. Om de e-tool te 
verbeteren is meer expliciete informatie over immunotherapie, experimentele therapie en 
psychosociale ondersteuning toegevoegd. 
Hoofdstuk 6 laat de resultaten zien van het cluster-gerandomiseerde gecontroleerde 
onderzoek, waarin gekeken is naar de haalbaarheid en effecten van twee strategieen om 
richtlijnadherentie en de kwaliteit van de ziekenhuiszorg random patienten met NHL te 
verbeteren. Bovendien is het effect van de strategieen op patientgerapporteerde 
uitkomsten (PROs) en ervaringen (PREs) gemeten. Ziekenhuizen zijn willekeurig 
toegewezen aan een van beide strategieen: 10 ziekenhuizen aan de standaard strategie 
van audit en feedback en 9 ziekenhuizen aan de op maat gemaakte strategie, welke is 
aangevuld met tools afgestemd op de barrieres ervaren door patienten en professionals 
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en de huidige NHL-zorg. Richtlijnadherentie en het effect van de strategieen is gemeten 
met een v66r- en nameting met behulp van de eerder ontwikkelde kwaliteitsindicatoren. 
In totaal zijn gegevens uit medische dossiers van 835 patienten met NHL gehaald en zijn 
gevalideerde vragenlijsten gebruikt om inzicht te geven in de PROs en PREs. 
Voor het bespreken van patienten in multidisciplinaire besprekingen is een significante 
verbetering in richtlijnadherentie zichtbaar in beide strategieen (van 41% naar 49% in de 
standaard strategie en van 41% naar 64% in de op maat gemaakte strategie). Echter, er is 
geen significant groter effect gevonden van de op maat gemaakte strategie als we kijken 
naar verbeterde richtlijnadherentie. Bovendien beoordeelden professionals het feedback 
rapport (standaard strategie) als de beste tool om richtlijnadherentie te verbeteren. De 
gemeten PROs met betrekking tot angst en depressie, lichamelijk welzijn en de algemene 
gezondheidstoestand lieten geen verschillen zien tussen de 2 strategieen. De PREs 
(ervaringen met de NHL-zorg) zijn iets beter gerapporteerd in de op maat gemaakte 
strategie. Deze studie toont aan dat het moeilijk is om richtlijnadherentie door 
professionals te verbeteren, hoewel beide strategieen haalbaar lijken en een significant 
effect Iaten zien. 
Tenslotte zijn in hoofdstuk 7 de belangrijkste bevindingen van dit proefschrift besproken 
in het Iicht van de recente literatuur en zijn de implicaties voor toekomstig onderzoek, de 
klinische praktijk en beleidsmakers bediscussieerd. 
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lnterventie toolkit 
Deze toolkit is ontwikkeld tijdens de PEARL studie en in zijn originele versie opgenomen als 
bijlage van dit proefschrift. 
Voorwoord 
De interventies opgenomen in dit document zijn gebaseerd op ervaringen van NHL-
patienten en medisch specialisten betrokken bij de NHL-zorg (zowel hematologen, 
oncologen, radiologen, radiotherapeuten, pathologen als nucleair geneeskundigen). Deze 
ervaringen zijn in kaart gebracht middels interviews en een vragenlijstonderzoek. 
Uw ziekenhuis is ingedeeld in de 'uitgebreide interventie'-arm. Naar aanleiding van de 
resultaten van de nulmeting (dossieronderzoek onder 22 NHL-patienten) zal gekeken 
worden welke interventies bij u in het ziekenhuis zullen worden ingezet ter optimalisatie 
van de NHL-zorg zoals op dit moment gegeven in uw ziekenhuis. 
Wij willen u vragen dit document vertrouwelijk te behandelen en niet te verspreiden aan 
derden, zodat de kwaliteit van onze randomized controlled trial gewaarborgd blijft. 
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lnterventie 1: Zorgpad voor NHL patienten 
Uit onze inventarisatie blijkt dat voor patienten met (verdenking op) een NHL het te 
doorlopen zorgpad nog vaak onduidelijk is. Een website met daarop schematisch de 
benodigde informatie hierover zou wei Iicht meer duidelijkheid bieden. 
Het uiteindelijke doel van onze website is om patienten wegwijs te maken in hun eigen 
zorgpad wat betreft NHL, via een soort bewegwijzering op internet. Een aantal punten zal 
op deze website aan bod komen: 
Algemene informatie over NHL, benodigde onderzoeken, therapiemogelijkheden, 
wachttijden en nazorg 
Patienten kunnen hun eigen zorgtraject bijhouden 
Om onze 'meekijkboom voor patienten' goed te implementeren dienen de NHL 
patienten bereikt te worden. Wij hebben hiervoor een folder gemaakt die meegegeven 
dient te worden aan de patient door: 
De oncologie verpleegkundige, nurse practitioner, research verpleegkundige 
Of de specialist zelf 
Ook u, als specialist, kunt inloggen op de website, zodat u weet wat wij uw patienten 
aanbieden. 
Ga naar: www.nhl-info.nl 
Gebruikersnaam: specia listen 
Wachtwoord: welkom 
Voorbeeld website 
."! Non--Hod9~mtymf'oorr. 
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lnterventie 2: Standaardisatie formulieren 
Bij zowel het aanvragen als het verslaan van diagnostische technieken blijkt uit onze 
studie dat hier nag niet altijd aile gewenste informatie aanwezig is. Bijvoorbeeld wat de 
achtergrond van de patient is, in welk traject de patient zich op dit moment bevindt en 
welke conclusies getrokken kunnen worden uit het onderzoek. 
Op de navolgende pagina's zijn voorstellen voor standaard aanvraag- en verslagleggings-
formulieren opgesteld voor: 
a. Pathologie {uitgevoerd PA onderzoek) 
b. Radiologie {CT-scan) 
c. Nucleaire geneeskunde {PET-scan) 
Deze voorstellen zijn gebaseerd op richtlijnen vanuit de Hovan en bestaande formulieren 
uit onder andere het UMC St Radboud. 
Standaardisatie door middel van: 
Aile aanvraagformulieren bevatten de volgende, generieke items: 
o Patientgegevens 
o Aanvragend arts 
o Datum aanvraag 
o Gevraagd onderzoek 
o Gewenste termijn 
o Vraagstelling 
Aile verslagformulieren bevatten de volgende, generieke items: 
o Patientgegevens 
o Verslagleggend arts 
o Datum verslag 
o Uitgevoerd onderzoek 
o Vraagstelling aanvragend arts 
o Conclusie {laatste item van formulier) 
Hieronder volgt een voorstel welke items minimaal benodigd zijn in de verschillende 
aanvraag- en verslagformulieren voor een goede communicatie en documentatie. 
Wij willen u vragen onderstaande formulieren te gebruiken tijdens de PEARL study {okt 
2012-okt 2013). lndien gewenst, kan de onderzoeker sa men met u de formulieren 
afstemmen op de huidige formulieren in uw ziekenhuis. 
139 
tnterventie 2o: Stondoordisotie formulieren pothologie 
Aanvraagformulier pathologie specifiek voor non-Hodgkinlymfomen 
Minimaal benodigde gegevens aanvraag PA onderzoek 
Patientgegevens naam + voorletters, evt. naam echtgenoot, geslacht, 
geboorte datum, UMC-patientennummer, adres, 
postcode en woonplaats, tel.nr patient, huisadres en 
telefoonnummer huisarts, ziektekostenverzekering, 
behandelende afdeling/arts en evt. geboorteplaats 
Aanvragend arts Naam: 
(hoofdbehandelaar) Specialisme: 
Tel.nr: 
Datum aanvraag 
D Diagnostiek D Follow-up 
Gevraagd onderzoek D Histologie D Histologie 
D Cytologie D Cytologie 
D Anders, namelijk ... D Anders, namelijk ... 
D 
Gewenste termijn 
Vraagstelling 
Uitgevoerde ingreep D lncisie biopt D lncisie biopt 
D Excisie biopt D Excisie biopt 
D Dikke naaldbiopt D Dikke naaldbiopt 
D Cristabiopt D Cristabiopt 
Lokatie(s), incl. nodaal/ Lokatie(s), incl. nodaal/ 
extranodaal: extranodaal: 
Datum: Datum: 
Afmetingen biopt: Afmetingen biopt: 
Bekende ziektelokalisaties Zie 'Diagnostiek' 
Pathologisch onderzoek van D Ja, verslag aanwezig D Ja, verslag aanwezig 
elders D Ja, verslag afwezig D Ja, verslag afwezig 
D Nee D Nee 
PA-nummer 
(in te vullen door PA) 
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Verslagleggingsformulier pathologie specifiek voor lymfomen 
Minimaal benodigde gegevens voor verslaglegging PA onderzoek 
Patientgegevens naam + voorletters, evt. naam echtgenoot, geslacht, 
geboorte datum, UMC-patientennummer, adres, 
postcode en woonplaats, tel.nr patient, huisadres en 
telefoonnummer huisarts, ziektekostenverzekering, 
behandelende afdeling/arts en evt. geboorteplaats 
Verslagleggend patholoog Naam: 
Tel.nr: 
Datum verslag 
Uitgevoerd onderzoek 0 Histologisch onderzoek 
0 Cytologisch onderzoek 
0 Vriescoupe 
0 lmmunopathologisch onderzoek 
0 Moleculair klonaliteitsonderzoek 
0 Kwantitatief microscopisch 
0 Electronen microscopie 
0 Anders, namelijk .. . 
Datum : 
Vraagstelling aanvragend arts 
Ontvangen materiaal 0 lncisie biopt 
0 Excisie biopt 
0 Naaldbiopt 
0 Cristabiopt 
Locatie(s), incl. nodaal/extranodaal : 
Datum ingreep: 
0 Ongefixeerd biopt 
0 Gefixeerd biopt 
Weefsel ingevroren? Ja/Nee 
Beschrijving materiaal Macroscopie (uiterlijk, afmetingen): 
Microscopie: 
Conclusie (incl. WHO-classificatie) 
PA-nummer 
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lnterventie 2b: Stondoordisotie formulieren rodiologie 
Aanvraagformulier radiologie specifiek voor non-Hodgkinlymfomen 
LETOP! 
Vanuit de HOVON lmaging-werkgroep zijn aanbevelingen opgeste/d met betrekking tot 
aanvraag en verslaglegging PET-CT scans. Deze aanbevelingen zijn in te zien via 
http:f/www.tijdschri(tvoornucleaireqeneeskunde.nf/files/BESCHOUWING.pdf. 
Hieronder een voorbeeld van een mogelijk aanvraagformulier. 
Minimaal benodigde gegevens voor aanvraag CT-scan 
Patientgegevens naam + voorletters, evt. naam echtgenoot, geslacht, geboorte 
datum, UMC-patientennummer, adres, postcode en woonplaats, 
tel.nr patient, huisadres en telefoonnummer huisarts, 
ziektekostenverzekering, behandelende afdeling/arts en evt. 
geboorteplaats 
Aanvragend arts Naam: 
(hoofdbehandelaar) Specialisme: 
Tel.nr: 
Datum aanvraag 
D Stadiering D Evaluatie therapie 
Gevraagd onderzoek D CT-hals D CT-hals 
D CT-thorax D CT-thorax 
D CT-abdomen D CT-abdomen 
Gewenste termijn 
Vraagstelling 
Uitgevoerde ingreep Vanuit PA verslag 'Uitgevoerde 
ingreep' Zie 'Stadiering' 
Bekende ziektelokalisaties Vanuit PA verslag 'Bekende 
ziektelokalisaties' Zie 'Stadiering' 
Conclusie PA onderzoek 
(type lymfoom) Vanuit PA verslag 'Conclusie' Zie 'Stadiering' 
Thera pie N.v.t. D Chemotherapie 
Of vanuit Diagnose D Radiotherapie 
MDO verslag -----> D Anders, namelijk ... 
Contrast gebruik D Ja D Ja 
Bijv. ivm allergie, nefropathie D Nee, omdat D Nee, omdat 
en/of comorbiditeiten 
Radiologisch onderzoek van D Ja, verslag aanwezig D Ja, verslag aanwezig 
elders D Ja, verslag afwezig D Ja, verslag afwezig 
D Nee D Nee 
Behandeling in studieverband D Ja D Ja 
D Nee D Nee 
CT-nummer 
(in te vullen door radiologie) 
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Verslagleggingsformulier radiologie specifiek voor non-Hodgkinlymfomen 
Minimaal benodigde gegevens voor verslaglegging CT-scan 
Patientgegevens naam + voorletters, evt. naam echtgenoot, geslacht, geboorte 
datum, UMC-patientennummer, ad res, postcode en woonplaats, 
tel.nr patient, huisadres en telefoonnummer huisarts, 
ziel<tekostenverzekering, behandelende afdeling/arts en evt. 
geboorteplaats 
Verslagleggend radioloog Naam: 
Tel.nr: 
Datum verslag 
0 Stadiering 0 Evaluatie therapie 
Uitgevoerd onderzoek 0 CT-hals 0 CT-hals 
0 CT-thorax 0 CT-thorax 
0 CT-abdomen 0 CT-abdomen 
Vraagstelling aanvragend 
arts Vanuit radiologie aanvraag: Vanuit radiologie aanvraag: 
- Vraagstelling - Vraagstelling 
-
Beschrijving target laesies (bij >6 laesies, maxima a I 6 beschrijven) 
# Locatie1 
Afmeting Aspect/ Coupe Afmeting Aspect/ Coupe 
(mm*mm) uitbreiding nr. (mm*mm) uitbreiding nr. 
1 
2 
3 
4 
5 
6 
Som van de laesies 
% verschil baseline vs. follow-up 
Nieuwe laesies na baseline? Ja I Nee 
1 Locaties volgens Hovon: nodaal (nng van Waldeyer, cerv1caal, supraclavlculalr, axllla1r, med1astmaal, h1la1r, 
paraOaortaal, mesenteriaal, iliacaal, inguinaal, milt) en extra-nodaal (centraal zenuwstelsel, huid, lever, long, 
pleuraal (vocht), tractus gastrointestinalis, skelet/beenmerg. 
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0 Stadiering 0 Evaluatie therapie 
Beschrijving non-target lndicatie grootte/hoeveelheid: 
laesies (aile andere Locatie: 
meetbare en niet- Coupe nr/tafelpositie: 
meetbare laesies) 
Relevan·~e 
nevenbevindingen 
Conclusie Minimaal stadium van ziekte Uitspraak over minimale 
res pons 
CT-nummer 
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lnterventie 2c: Standaardisatie formulieren nucleaire geneeskunde 
Aanvraagformulier nucleaire geneeskunde specifiek voor lymfomen 
LETOP! 
Vanuit de HOVON lmaging-werkgroep zijn aanbevelingen opgesteld met betrekking tot 
aanvraag en vers/aglegging PET-CT scans. Deze aanbevelingen zijn in te zien via 
http :jjwww. ti jdsch riftvoorn uc/eaireqeneesku nde. n 1/files/BESCHO UWI NG. pdf. 
Minimaal benodigde gegevens voor aanvraag PET-scan 
Patientgegevens naam + voorletters, evt. naam echtgenoot, geslacht, geboorte 
datum, UMC-patientennummer, ad res, postcode en woonplaats, 
tel.nr patient, huisadres en telefoonnummer huisarts, 
ziektekostenverzekering, behandelende afdeling/arts en evt. 
geboorteplaats 
Aanvragend arts Naam: 
(hoofdbehandelaar) Specialisme: 
Tel.nr: 
Datum aanvraag 
0 Stadiering 0 Evaluatie therapie 
Gevraagd onderzoek 
Gewenste termijn 
Vraagstelling 
Conclusie PA onderzoe!t 
Vanuit PA verslag 'Conclusie' Zie 'Stadiering' 
Uitgevoerde ingreep Vanuit PA verslag 'Uitgevoerde 
ingreep' Zie 'Stadiering' 
Bekende Vanuit PA verslag 'Bekende 
ziektelokalisaties 
ziektelokalisaties' Zie 'Stadiering' 
Thera pie N.v.t. 0 Chemotherapie 
0 Radiotherapie 
0 Anders, namelijk ... 
Vanuit Diagnose MOO verslag 
'Advies' 
Contrast gebruik 0 Ja 0 Ja 
Bijv. ivm allergieen, 0 Nee, omdat 0 Nee, omdat 
nefropathien en/of 
comorbiditeiten 
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0 Stadiering 0 Evaluatie therapie 
Beeldvormend 0 Ja, verslag aanwezig 0 Ja, verslag aanwezig 
onderzoek van elders 0 Ja, verslag afwezig 0 Ja, verslag afwezig 
0 Nee 0 Nee 
Behandeling in 0 Ja 0 Ja 
studieverband 0 Nee 0 Nee 
PET-nummer 
(in te vullen door 
nucl.gnsk) 
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Verslagleggingsformulier nucleaire geneeskunde specifiek voor lymfomen 
Minimaal benodigde gegevens voor verslaglegging PET-scan 
Patientgegevens naam + voorletters, evt. naam echtgenoot, geslacht, geboorte 
datum, UMC-patienten nummer, adres, postcode en woonplaats, 
tel.nr patient, huisadres en telefoonnummer huisarts, 
ziektekostenverzekering, behandelende afdeling/arts en evt. 
geboorteplaats 
Verslagleggend nucleair Naam: 
geneeskundige Tel.nr: 
Datum verslag 
0 Stadiering 0 Evaluatie therapie 
Uitgevoerd onderzoek 
Datum : Datum: 
Vraagstelling Vanuit aanvraag nucl.gnsk: Vanuit aanvraag nucl.gnsk: 
aanvragend arts - Vraagstelling - Vraagstelling 
Beschrijving laesies 
Locatie1 
FOG- Aspect/ Coupe FOG- Aspect/ Coupe 
# 
avide uitbreiding avide uitbreiding nr. nr. 
1 
2 
3 
4 
5 
6 
Verschil baseline vs. follow-up 
Nieuwe laesies na baseline? Ja I Nee 
~ Locat1es volgens Hovon. nodaal (nng van Waldeyer, cerv1caal, supraclav1cula1r, ax1lla1r, 
mediastinaal, hilair, paraOaortaal, mesenteriaal, iliacaal, inguinaal, milt) en extra-nodaal (centraal 
zenuwstelsel, huid, lever, long, pleuraal (vocht), tractus gastrointestinalis, skelet/beenmerg. 
Relevante 
nevenbevindingen 
Conclusie Minimaal stadium van ziekte Uitspraak over minimale 
res pons 
PET-nummer 
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lnterventie 3a: MDO standaardisatie 
Uit onze inventarisatie blijkt dat er nog onduidelijkheid bestaat over de rol van het 
multidisciplinair overleg (MDO) en het PA lymfoompanel. Tot op heden zijn hiervoor geen 
landelijke definities opgesteld en zijn de taken niet altijd duidelijk. Om hier meer duidelijk 
in te scheppen is een voorstel hiervoor opgezet. 
De omschrijvingen kunt u (t.b.v. deze studie) verspreiden in uw ziekenhuis onder de 
betrokken professionals. Hierdoor zal er een hopelijk een beter beeld ontstaan over de 
inhoud en het doel van deze overleggen. 
Omschrijving multidisciplinair overleg (1\.1100) 
Een MDO is een overleg tussen aile disciplines die betrokken zijn bij de behandeling van de 
betreffende groep patienten (in dit geval patienten met een non-Hodgkinlymfoom). Het 
overleg vindt structureel plaats, minimaal 2 keer per maand. 
Tijdens een MDO worden de zorgplannen (incl. afwachtend beleid) besproken van aile 
nieuwe patienten, waarover vervolgens een advies wordt uitgebracht. Patienten waarbij 
de behandeling is afgerond, worden voor vervolgadvies indien nodig besproken tijdens 
een MDO. 
Afgevaardigden van de volgende disciplines dienen (minimaal) aanwezig te zijn bij een 
MDO waar patienten met een non-Hodgkinlymfoom besproken worden: 
Hematoloog/oncoloog (of internist met aandachtsgebied onco/hematologie) 
Patholoog 
Rad iothera peut 
Radioloog 
Nucleair geneeskundige 
Een MDO zorg voor een goede communicatie en samenwerking tussen de verschillende 
disciplines die betrokken zijn bij de zorg voor patienten met een non-Hodgkinlymfoom. 
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i\!aast een generieke omschrijving van het MOO, willen we ook aandacht besteden aan 
de rol van lymfoompanels 
Enkele conclusies uit onderzoek van Prof.dr. JHJM van Krieken naar het nut en de 
noodzaak van lymfoompanels zijn hieronder beschreven. 
1. In Nederland is een volledige dekking door regionale panels voor lymfomen, maar 
er is geen uniforme werkwijze 
2. Aile patienten met een nieuw maligne lymfoom hebben recht op een 
paneldiagnose of een consult van de casus bij een hematopatholoog. 
3. Het leereffect van panels is onvoldoende om na 5 jaar ervaring een panel op te 
heffen. 
4. Er is behoefte aan wekelijkse panels 
5. Telepathologie met videoconferentie is potentieel een goede mogelijkheid om 
reistijd te voorkomen waardoor de frequentie van panelbijeenkomsten omhoog 
kan. lmplementatie en tra ining behoeft nag wei serieuze aandacht 
Om in te gaan op de eerste conclusie, het ontbreken van een uniforme werkwijze, is een 
omschrijving van het lymfoompanel opgesteld . 
Omschrijving lymfoompanel 
Een lymfoompanel is een overleg tussen een aantal in de hematologie gespecialiseerde 
pathologen ter bevordering van de kwaliteit van de diagnostiek voor maligne lymfomen. 
In dit overleg komen ingestudeerde casussen aan bod, opgestuurd ter consultatie door 
pathologen uit de regia. 
Een consult bij het lymfoompanel kan worden aangevraagd wanneer er twijfel bestaat 
over de te stellen diagnose (vo /gens WHO-classificatie) . Hierbij heeft het panel niet de taak 
om aanvullende diagnostiek of een second opinion uit te voeren; het panel geeft een 
diagnose op basis van de reeds uitgevoerde diagnostische onderzoeken . lndien nodig 
wordt een advies voor aanvullende diagnostiek afgegeven . 
Naast de adviserende taak van het lymfoompanel (d.m.v. consulten}, heeft het panel ook 
een educatieve taak: het bespreken van nieuwe regelgeving of interessante casuistiek. 
Hierbij is het belangrijkste doel om de pathologen in de regia op de hoogte te houden van 
de ontwikkelingen in de hematopathologie. Dit kan gedaan worden door middel van een 
nieuwsbrief of het versturen van een verslag van het lymfoompaneloverleg naar aile 
deelnemende ziekenhuizen in de regia. 
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lnterventie 3b: MOO standaardisatie verslaglegging 
In onze studie wordt zichtbaar dat MDO's steeds vaker plaatsvinden. Echter, uit onze 
inventarisatie blijkt dater vaak nog geen gestandaardiseerd verslag wordt gemaakt van dit 
overleg. Bijvoorbeeld wat de achtergrond van de patient is, in welk traject de patient zich 
op dit moment bevindt en welke conclusies getrokken kunnen worden uit het onderzoek. 
Hieronder volgt een voorstel welke items minimaal benodigd zijn in een MDO verslag voor 
een goede communicatie en documentatie. 
Wij willen u vragen onderstaand formulier te gebruiken tijdens de PEARL study (okt 
2012-okt 2013). lndien gewenst, kan de onderzoeker sa men met u het formulier 
afstemmen op het huidige formulier in uw ziekenhuis. 
Verslagleggingsformulier multidisciplinair overleg {MOO) specifiek voor lymfomen 
Dit voorstel is gebaseerd op bestaande formulieren uit verschillende ziekenhuizen. 
Minimaal benodigde gegevens voor verslaglegging van een MDO 
Patientgegevens naam + voorletters, evt. naam echtgenoot, geslacht, geboorte 
datum, UMC-patientennummer, ad res, postcode en woonplaats, 
tel.nr patient, huisadres en telefoonnummer huisarts, 
ziektekostenverzekering, behandelende afdeling/arts en evt. 
geboorteplaats 
Aanmeldend arts Naam: 
(hoofdbehandelaar) Specialisme: 
Tel.nr: 
Datum MOO 
Aanwezige specialisten D lnternist/oncoloog/hematoloog 
D Patholoog 
D Radiotherapeut 
D Radioloog 
D Nucleair geneeskundige 
D Anders, namelijk ... 
D Diagnose MOO D Follow-up MOO 
Huidig probleem 
Vanuit hematoloog Zie 'Diagnose MOO' 
(EPD/status/Hemobase) 
Oncologische 
voorgeschiedenis Vanuit hematoloog Zie 'Diagnose MOO' 
(EPD/status/Hemobase) 
Status praesens, klachten, 
afwijkingen bij lichamelijk Vanuit hematoloog Zie 'Diagnose MOO' 
onderzoek (EPD/status/Hemobase) 
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D Diagnose MOO D Follow-up MOO 
Lab onderzoek 
Vanuit hematoloog Zie 'Diagnose MDO' 
(EPD/status/Hemobase) 
Histologie uit biopsie 
Vanuit PA verslag,in/excisiebiopt: lndien van toepassing vanuit PA 
- Datum aanvraag, datum verslag, in/excisiebiopt: 
verslag - Datum aanvraag, datum 
- Ontvangen materiaal verslag 
- Vraagstelling - Ontvangen materiaal 
- Uitgevoerd PA onderzoek - Vraagstelling 
- Conclusie (WHO classificatie) - Uitgevoerd PA onderzoek 
- PA-nummer - Conclusie (WHO classificatie) 
- PA-nummer 
Aanvullende pathologie 
Vanuit PA verslag, cristabiopt: lndien van toepassing vanuit PA 
- Datum aanvraag, datum verslag, cristabiopt: 
verslag - Datum aanvraag, datum 
- Ontvangen materiaal verslag 
- Vraagstelling - Ontvangen materiaal 
- Uitgevoerd PA onderzoek - Vraagstelling 
- Conclusie (WHO classificatie) - Uitgevoerd PA onderzoek 
- PA-nummer - Conclusie (WHO classificatie) 
- PA-nummer 
Beeldvormend 
onderzoek Vanuit radiologie/nucl.gnsk Vanuit radiologie/nucl.gnsk 
verslag: verslag: 
- Datum aanvraag, datum - Datum aanvraag, datum 
verslag verslag 
- Vraagstelling - Vraagstelling 
- Uitgevoerd onderzoek - Uitgevoerd onderzoek 
- Conclusie (stadium) - Conclusie (responsevaluatie) 
- CT/PET-nummer - CT/PET-nummer 
- Echo/MRI/Palpatie - Echo/MRI/Palpatie 
Ann Arbor stadium 
Zie 'Diagnose MDO' 
IPI score D Leeftijd >60 jaar 
(bij aggressieve D Uitgebreid stadium {III/IV) 
lymfomen) D Extranodale betrokkenheid 
>llokalisatie 
D Performance status >2 
D Serum LDH >normaal 
Totale score (0-5): 
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D Diagnose MOO D Follow-up MOO 
Conclusie 
- IPI risicogroep - Conclusie PA onderzoek 
- Conclusie PA onderzoek - Conclusie beeldvormend 
- Conclusie beeldvormend onderzoek 
onderzoek 
Advies D Aanvullend onderzoek, D Aanvullend onderzoek, 
namelijk ... namelijk ... 
D Therapie, namelijk ... D Therapie, namelijk ... 
D Doorverwijzen naar ... D Nazorg traject starten 
D Anders, namelijk ... D Anders, namelijk ... 
Beargumentatie indien D N.v.t. D N.v.t. 
advies afwijkt van de 
NHL richtlijnen 
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lnterventie 4: lnzicht in logistieke processen 
Bij het verlenen van zo optimaal mogelijke zorg, hoort oak een goede doorstroming van 
de patienten. Helaas komen (lange) wachttijden nag altijd voor in Nederland, maar is de 
oorzaak hiervan vaak niet bekend bij de betreffende ziekenhuizen. Dit kwam oak naar 
voren in onze inventarisatie. 
Een manier om inzicht te verkrijgen in de mogelijke knelpunten op het gebied van 
doorlooptijden is het in kaart brengen van de logistieke processen per diagnostische 
verrichting. Als startpunt daarvoor is het ideale zorgpad voor patienten met een NHL in 
kaart gebracht. 
Door dit zorgpad onder de aandacht te brengen van aile betrokken professionals, wordt 
het traject dat patienten doorlopen voor iedereen duidelijk. 
Tevens is aangegeven wie verantwoordelijk is voor welke stappen in het zorgpad. 
Uiteindelijk zal de behandelend arts eindverantwoordelijk zijn voor het gehele traject. 
lndien in uw ziekenhuis processen anders verlopen, kan het schema eventueel op uw 
situatie aangepast worden (in overleg). 
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i 
Verwijzing door 
huisarts 
' Internist 
Hematoloog 
Oncoloog 
- Anamnese 
• Lichamelijk onderzoek 
· Cristabiopt 
Internist 
Hematoloog ..,.______ 
Oncoloog 
Bespreken 
behandelplan 
... 
Afwachtend beleid 
Internist 
Hematoloog .... 
Oncoloog 
Uitslaggesprek en 
vervolgtraject 
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Verwijzing door 
specialist 
Internist 
Chirurg Patholoog ___.,_ Hematoloog 
- Biopsie • Histologie 
- lmmonohistochemie 
- Aanv. diagnostiek 
MOO ,. 
Vaststellen 
behandelplan 
L___ 
Chemotherapie Radiotherapie J 
MOO .... 
Vaststellen 
vervolgtraject 
Follow-up en nternist 
nazorg Hematoloog 
nco lao 
~ 
· Opname 
· Thuiszorg 
- Hospice 
.I 
Oncoloog 
u::esp:l 
diagnoseN~ 
Radioloog 
..-Nucleair Gnsk t hals, thorax, 
abdomen 
PET(CT) 
Stamceltransplantatie 
lmmunotherapie 
Gentherapie 
.., 
Radioloog 
Nucleair Gnsk 
• CT hals, thorax, 
abdomen 
· PET(CT) 
- Lichamelijk onderzoek 
. Centrale CT hals, 
thorax, abdomen 
• Evt psychosociale zorg 
• Herstel en balans 
- Evt. doorverwijzen 
· Evt psychosociale zorg 
· Palliatieve behandelopties 
Verwijzing 
Oiagnostiek 
Behandehng 1 
Evaluat1e 
-------
Follow-up 
~ ----· 
v1 
Palliatieve 
lase 
Dankwoord 
En dan rest mij nog iedereen te bedanken die, op welke manier dan ook, heeft 
meegeholpen aan de totstandkoming van dit proefschrift. Zonder aile hulp en steun van 
jullie was dit proefschrift nooit geworden zoals het nu is: KLAAR om verdedigd te worden! 
Een aantal mensen wil ik in het bijzonder bedanken. 
Mijn promotoren, Prof. van Krieken en Prof. Blijlevens. Beste Han en Nicole, ondanks jullie 
drukke agenda's wisten jullie de afgelopen jaren tijd vrij te maken voor de PEARL 
werkoverleggen en de stukken die ik jullie ter commentaar toestuurde (soms met wat 
krappe deadlines, dat geef ik toe). lk waardeer jullie kritische blik en betrokkenheid 
enorm. lk wil jullie bedanken voor jullie enthousiaste begeleiding, het vertrouwen dat 
jullie in mij toonden en de nodige klinische input die jullie mijn onderzoek hebben 
gegeven onder het genot van koffie en een koekje (ook al zijn jullie niet zo'n koekjes 
eters ... ©). Jullie vormden een goed promotieteam, bedankt voor de begeleiding! 
Mijn co-promotoren, dr. Ottevanger en dr. Hermens. Beste Nelleke en Rosella, ik ben 
ontzettend blij dat ik jullie promovenda heb mogen zijn. Een beter begeleidingsteam had 
ik me namelijk niet kunnen wensen! Naast de inhoudelijke discussies, toonden jullie altijd 
interesse in mijn persoonlijke situatie, wat ik echt heel erg waardeer. Jullie gaven mij al 
snel een vertrouwd gevoel en dat heeft bijgedragen aan onze mooie samenwerking. Onze 
besprekingen hebben mij altijd gemotiveerd en als ik aan mezelf twijfelde zorgden jullie 
met veel optimisme en complimenten dat ik er weer tegenaan kon. Daarnaast bedankt 
voor het overdragen van jullie kennis, wijze inzichten en intensieve begeleiding. lk vind het 
oprecht jammer dat onze samenwerking er nu op zit! Beste Nelleke, dankjewel voor je 
altijd kritische blik en jouw nuchterheid. Waar ik af en toe in de stress dreigde te raken, 
wist jij me gerust te stellen en samen een oplossing te zoeken. Beste Rosella, wat een 
mooie tijd heb ik gehad bij jou en op de afdeling IQ healthcare. lk wil je niet aileen 
bedanken voor alles wat ik over implementatie en kwaliteit van zorg onderzoek van jou 
geleerd heb, maar ook dat je altijd klaarstond voor mij. AI was je in Leuven, op vakantie of 
zat je thuis met een voet in het gips, altijd maakte je tijd voor mij! Bedankt voor a lies! 
Beste Lianne, Saskia, Richard en Heleen. Jullie maakten de PEARL projectgroep compleet! 
lk wil jullie bedanken voor jullie inspirerende ideeen en kritische blik op mijn artikelen. 
Lianne, bedankt dat jij altijd bereid was om mijn vragen te beantwoorden over jouw 
onderzoek, ook toen je niet meer bij IQ healthcare werkzaam was. 
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Heel hartelijk dank aan aile ziekenhuizen, artsen, verpleegkundigen en patienten die 
hebben meegeholpen bij de uitvoering van de PEARL studie. Zonder jullie medewerking, 
ervaringen en kritische vragen hadden we dit onderzoek nooit kunnen uitvoeren. Bedankt! 
Ook de IKNL registratiemedewerkers en hun teamleiders betrokken bij de PEARL studie, 
wil ik enorm bedanken voor hun inzet en geduld bij het verzamelen van data uit de 
patientendossiers. 
Dan de collega's van IQ healthcare, wat heb ik een leerzame en bovenal leuke tijd gehad 
de afgelopen 5,5 jaar! Marielle Ouwens, in 2009 nam jij mij aan als wetenschappelijk 
onderzoeker voor jouw nieuwe sectie IQ development. Bedankt dat je mij zo nauw 
betrokken hebt bij het opzetten van deze sectie, hiervan heb ik veel geleerd. Daarnaast 
heb jij mij gestimuleerd om een promotietraject in te gaan, ik ben dankbaar dat je mij 
hierin wegwijs hebt gemaakt en mij bij Rosella hebt aangedragen als mogelijke 
promovenda. 
In de bijna 6 jaar heb ik veel IQ collega's gehad, te veel om iedereen persoonlijk te 
noemen. lk wil jullie allemaal bedanken voor de gezelligheid, inhoudelijke discussies, 
leermomenten, steun en inspiratie in de afgelopen jaren, o.a. tijdens de lunches, 
kennisgroepen en de intervisie, maar uiteraard ook de filmavonden, borrels, biermenu bij 
Cafe de Fiets, bowlingavonden en etentjes waren altijd erg gezellig. lk mis de spontane 
middagjes in de Aesculaaf en het frietje bij De Harmonie echt wei! Rixt, het heeft ons heel 
wat geld gekost, maar ik vond het ontzettend gezellig om met jou de stad in te gaan voor 
onze {voor sommige collega's onbegrijpbare) gezamenlijke shopverslaving. 
Jasper {vRP) en Marleen, mijn {laatste) kamergenoten bij IQ. Bedankt voor aile gezelligheid 
en het dulden van mijn hardop nadenken of in mezelf praten ©. Marleen, ik vond het leuk 
dat we samen naar onze bruiloften hebben toegeleefd, ook al was Jasper hier iets minder 
enthousiast over©. Jasper, bedankt voor al jouw raad en daad, ik weet dat ik bij jou altijd 
terecht kan met vragen en ik vind het ontzettend leuk dat jij mijn paranimf wilt zijn. 
Juliette, Frederike, Janine, Dennis, Jolanda en lrah, jullie ondersteuning is van ontelbare 
waarde geweest. Zonder jullie was het nooit gelukt om dit onderzoek op tijd en naar 
voldoening af te ronden. Dank voor jullie inzet en hulp, ook bij de last-minute vragen! 
Reinier en Eddy, ik wil jullie bedanken voor de begeleiding die jullie mij geboden hebben 
bij het doen van complexere statistische analyses en kosteneffectiviteitanalyses. lk heb 
veel van jullie geleerd, dank hiervoor. 
Oud-PhD-councilleden, naast de inhoudelijke activiteiten die we samen hebben 
georganiseerd, heb ik een erg leuke en gezellige tijd gehad met jullie! 
Collega's van de Nederlandse Vereniging voor Urologie {NVU}, bedankt voor jullie 
interesse in {de voortgang van) mijn promotieonderzoek, jullie hulp en meeleven de 
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afgelopen maanden en de flexibiliteit die mogelijk was voor het regelen van alles random 
mijn promotie. 
Liselore en Sanne, oud-collega's van IQ, hoewel we al een hele tijd geen collega's meer 
zijn, spreken we nog regelmatig met elkaar af. lk hoop dat we nog vaak gezellig bij elkaar 
op de koffie komen en uren kunnen kletsen over a lies wat we meemaken. 
Lieve vrienden van de basisschool, middelbare school, universiteit, zeilvereniging en 
vrienden vanuit Jasper, wat ben ik gezegend met zoveellieve, leuke mensen om mij heen! 
Bedankt voor aile interesse die jullie altijd in mij en mijn promotieonderzoek toonden en 
daarnaast voor de leuke dingen die zorgden voor de nodige parties ontspanning en 
plezier! 
Ankie, Nicole, Marel en Angelle, we zien elkaar niet zo heel vaak, maar met jullie blijft het 
na ruim 20( !) jaar vriendschap nog altijd even gezellig. 
lnge, Irene, Sabine, Jasper (vM) en Marilou, ook onze vriendschap gaat al heel wat jaren 
mee, waarin we heel wat ups & downs hebben meegemaakt, met als meest recente ups 
het Down the Rabbit Hole festival, familievriendenweekendjes met bowlen en 
gourmetten, en niet te vergeten onze nieuwe hobby: escape rooms! 
Kim, Lotte, Rachel en Emmy, jullie begrijpen als geen ander wat promoveren inhoudt. lk 
ben blij dat we elkaar hebben leren kennen tijdens onze studie en dat we nog regelmatig 
bij elkaar komen voor weekendjes weg, spellenavondjes of een speciaalbiertje. Lotte, ik 
vind het heel bijzonder dat jij mij tijdens mijn promotie wilt bijstaan als paranimf! 
Marjolein, Andrea, Marit, Marianne en Agnetha, met jullie ben ik altijd even helemaal 
weg. Op het Gaastmeer of de Amer, even lekker uitwaaien op de zeilboot en 's avonds 
spelletjes doen is heerlijk ontspannend en doet mij aile drukte even vergeten. 
Vriendengroep vanuit Jasper, bedankt dat jullie mij met open armen hebben ontvangen in 
2010. BBQ's, oud & nieuw en verjaardagen, het is altijd even gezellig. Een speciaal 
woordje voor Pieter, ik wil je enorm bedanken voor het ontwerpen van de cover van dit 
proefschrift. Het is precies geworden zoals ik in gedachte had! 
Lieve vrienden, ik hoop dat we ook de rest van onze Ievens tijd blijven maken voor elkaar 
en nog ontelbaar veelleuke dingen samen gaan meemaken! 
Dan mijn paranimfen, ook al zijn ze al eerder genoemd ... Jasper (vRP) en Lotte, wat ben ik 
blij en vereerd dat jullie vandaag naast mij staan! Jasper, we hebben behoorlijk wat tijd 
sa men doorgebracht als IQ-kamergenoten, waarbij ik je wil bedanken voor jouw nuchtere 
blik op dingen (zowel werk als daarbuiten), jouw gewoonte om overal een antwoord op te 
zoeken (ik heb de vraag nog niet gesteld of je hebt het al opgezocht) en jouw kennis over 
vanalles en nog wat! Bedankt voor de leuke tijd bij IQ! 
Lotte, tijdens de studie hebben we veel samen ondernomen, niet aileen samen in de 
collegebanken, ook samen koken, stappen of gewoon kletsen! lk weet dat ik op je kan 
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rekenen, je bent net zo'n perfectionist als ikzelf en je denkt ook overal aan, alles wat een 
goede paranimf nodig heeft. 
Lieve (schoon)familie: mama, Dennis, Andre, Robbin, Jo, Jeannette, Jasper, Hugo en Joyce. 
lk wil jullie bedanken voor de oprechte interesse die jullie de afgelopen jaren hebben 
getoond in mijn onderzoek en voor jullie hulp met bijvoorbeeld het schrijven van 
begrijpelijke teksten voor patienten . lk heb genoten van de vele gezellige momenten 
samen, in de vorm van etentjes, dagjes uit, winkelen of gewoon een kopje thee thuis. 
Hopelijk kunnen we dit nog vele jaren blijven doen sa men. 
Lieve mama en Dennis, ik ben enorm trots dat ik jullie dochter/zus ben! AI ruim 30 jaar 
lang staan jullie onvoorwaardelijk voor mij klaar en hebben jullie mij (samen met papa) 
gemaakt tot wat ik nu ben. Papa kijkt zeker weten trots op zijn drie musketiers neer, kon 
hij dit nog maar samen met ons meemaken. Bedankt dat jullie geduld met mij hadden 
wanneer dit nodig was en dat jullie mij blijven herinneren om in mezelf te geloven. 
Afgelopen jaar heb ik niet altijd evenveel tijd voor jullie gehad, maar nu heb ik weer tijd 
genoeg om samen leuke dingen te gaan doen! 
Allerliefste Jasper, wat ben ik ontzettend blij dat ik jou heb leren kennen! lk prijs me elke 
dag gelukkig dat ik jouw vrouw mag zijn. Je was mijn steun en toeverlaat de afgelopen 
jaren en nam de vele avond/weekenduren die ik aan dit proefschrift heb gewerkt voor lief. 
Jij zorgde ervoor dat zoveel mogelijk andere klussen gedaan werden en dat ik niet vergat 
om af en toe te ontspannen. Bedankt voor de keren dat je mijn overvolle hoofd weer op 
orde hebt gebracht en een glimlach om mij gezicht wist te toveren! Lieve Jasper, ik hou 
van je en Iaten we, na deze drukke periode, nu vooral de tijd gaan nemen om te genieten 
van elkaar, ons nieuwe huis en aile ontzettend lieve en gezellige mensen om ons heen! 
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